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 i 
Abstract 
Mycobacterium tuberculosis is an obligate human pathogen and is the primary 
causative agent of tuberculosis. New Zealand has a relatively low incidence of 
tuberculosis disease, however, Māori (the indigenous people of New Zealand) and 
Pacific People are disproportionally affected. Molecular typing shows that 
approximately two-thirds of M. tuberculosis isolates from New Zealand-born 
patients can be assigned to clusters of related strains. The largest M. tuberculosis 
cluster in New Zealand is known as the ‘Rangipo’ cluster and is predominantly 
found in Māori. This strain has been the source of several tuberculosis outbreaks 
over the last 30 years and anecdotal evidence suggests it may be particularly 
virulent. Two other large clusters, known as the ‘Southern Cross’ and ‘Otara’ 
clusters, most commonly occur in Pacific People.  
Here, whole genome sequencing, phylogenetics and structural biology were used to 
investigate evolutionary origins and functional consequences of genomic diversity 
in New Zealand M. tuberculosis clusters, with a particular focus on the Rangipo 
strain. Analysis of Rangipo strain non-synonymous single nucleotide 
polymorphisms (nsSNPs) identified bacterial genetic factors that may contribute to 
the high transmissibility of this strain. The F420-dependent oxidoreductase Rv2893 
harbours a Rangipo-specific G72S mutation encoded by a nsSNP. H37Rv and 
Rangipo Rv2893 structures were solved and show the effect of this G72S mutation. 
Binding of the F420 cofactor was confirmed and characterised. SNP analyses also 
guided the optimisation of a diagnostic assay for rapid Rangipo strain classification 
at low cost and with high discriminatory power. Phylogenetic analyses revealed the 
Rangipo and Otara clusters belong to a larger M. tuberculosis clade of 
French/European origin that is also prevalent in indigenous populations in Canada. 
Molecular dating indicates dispersal of this clade to the South Pacific was driven 
by expanding European trade networks in the early 19th century and identifies host 
factors that have contributed to the dispersal and expansion of the Rangipo and 
Otara strains.  
Overall, these results show that relatively recent changes in host ecology have likely 
played a crucial role in driving the success of the Rangipo strain in New Zealand 
and point to bacterial genetic factors that may influence its virulence and thereby 
also contribute to its prevalence. 
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Chapter One  
1 
1 Chapter One 
Introduction 
1.1 Tuberculosis: The disease  
Tuberculosis is primarily a pulmonary disease but can also affect almost every 
organ of the body. Tuberculosis disease in humans is most commonly caused by 
the bacterial species Mycobacterium tuberculosis, an obligate human pathogen. 
Infection occurs when a person inhales airborne bacteria aerosolised by an infected 
individual. Inhaled bacilli are engulfed by alveolar macrophages in the lung and a 
host immune response is triggered involving immune cell recruitment to the site of 
infection, and an immune structure called a granuloma is formed. The granuloma is 
a compact aggregation of immune cells and serves as a host protective response to 
wall off and eradicate the infection (reviewed in Ramakrishnan 2012). However, in 
some individuals, eradication and containment fails and infection progresses to 
active disease. Active tuberculosis occurs when the granuloma structure undergoes 
caseous necrosis and breaks down, causing localised tissue damage and lung 
cavitation. This allows bacilli to be released into the airways and infected 
individuals may transmit the disease to others by coughing or through saliva. 
Symptoms of the disease include a persistent cough, night sweats, fever and fatigue, 
and left untreated has around a 70% mortality rate (Tiemersma et al. 2011).  
The result of M. tuberculosis infection is highly variable and comprises a spectrum 
of responses ranging from clearance, to subclinical latent infection, to the 
development of active disease (Young et al. 2009). The course of the disease is also 
variable and comprises of a range of clinical presentations, including pulmonary 
disease and extrapulmonary forms such as lymph node tuberculosis and miliary 
tuberculosis (widespread dissemination via the blood stream). The outcome of 
exposure and infection is determined by a complex interplay between the host and 
pathogen. The virulence of the infecting strain, size of the bacterial inoculum, host 
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clinical characteristics, and social/environmental factors all contribute to the 
outcome of infection (Lönnroth et al. 2009; Salgame et al. 2015) (Figure 1.1). For 
the majority of individuals infected with M. tuberculosis, clinical symptoms do not 
develop and they are not a risk for spreading the disease. Approximately 5-10% of 
infected individuals however will progress to active disease in their lifetime, with 
the majority doing so in the first two years of infection (Salgame et al. 2015). As 
active pulmonary tuberculosis is required for transmission to occur, progression to 
active disease and transmission are related in tuberculosis. 
 
 
Figure 1.1. Risk factors for tuberculosis infection and progression to active disease. 
 
 
1.2 Mycobacterium tuberculosis: The pathogen 
M. tuberculosis is a slow growing mycobacterial species with a generation time of 
around 16-24 hrs. It is a gram-positive acid-fast aerobe and unlike other gram-
positive bacteria, it has a thick and highly complex lipid-rich cell wall (reviewed in 
Brennan 2003; Cook et al. 2009). This provides a hydrophobic permeability barrier 
that plays an important role in intrinsic antimicrobial resistance (Smith et al. 2012) 
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and the array of lipids and glycolipids are also thought to be important for bacterial 
pathogenicity (Neyrolles and Guilhot 2011).  
M. tuberculosis is a highly specialised pathogen and the mechanisms underlying its 
virulence are complex and multifaceted. M. tuberculosis virulence involves the 
ability of the bacilli to survive extracellularly until a new host is found and then to 
invade, survive and multiply within host macrophages upon infection. Two central 
features of M. tuberculosis virulence are; (1) its ability to cause active disease 
leading to cavitation and the expulsion of bacilli allowing transmission, and (2) its 
capability to persist in a subclinical latent state whilst maintaining the potential to 
reactivate even decades after infection. In order to achieve this, the pathogen has 
developed sophisticated strategies and acquired virulence factors to enable it to 
survive in challenging environments, counteract host antimicrobial responses, 
persist in a non-replicative state, and facilitate the progression to active disease.  
M. tuberculosis lacks classical virulence factors, such as toxins, that are typical of 
other bacterial pathogens. In M. tuberculosis, a virulence factor can generally be 
considered as a gene whose loss leads to a decrease in pathogenicity but does not 
impair bacterial growth under standard in vitro conditions (Forrellad et al. 2013). 
Sassetti and Rubin (2003) have identified 194 genes that are essential for growth of 
M. tuberculosis in mice and represent essential virulence determinants, and dozens 
of additional virulence factors have been identified in experimental studies of 
individual genes and using comparative approaches. The manually curated 
virulence factor database PATRIC_VF (Wattam et al. 2014) currently lists over 450 
virulence factors for the laboratory reference strain H37Rv. Identifying and 
understanding the role of virulence factors in M. tuberculosis is essential for the 
development of new drugs and vaccines to combat this important disease. 
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1.3 Evolution and genetic diversity of the M. tuberculosis 
complex 
1.3.1 The M. tuberculosis complex 
M. tuberculosis is a member of a group of closely related mycobacteria known as 
the M. tuberculosis complex (MTBC). The MTBC comprises seven human adapted 
lineages, the animal adapted strains, and the smooth tubercle bacilli Mycobacterium 
canettii (Figure 1.2). The human adapted lineages, lineages 1-7 (L1-L7), belong 
to the species M. tuberculosis sensu stricto (L1–L4 and L7) and Mycobacterium 
africanum (L5 and L6). Among these, L2, L3 and L4 are often referred to as the 
“modern” lineages and the remaining lineages as the “ancient” lineages (Brosch et 
al. 2002). The human adapted lineages show a strong phylogeographical structure, 
as further discussed further in Section 1.3.3. L4, the ‘Euro-American’ lineage, is 
the most widely globally dispersed of the human-adapted lineages. This lineage 
comprises ten separate sublineages (Figure 1.2), which have differing 
phylogeographic distributions (Stucki et al. 2016b). Within the animal adapted 
strains, different ecotypes are adapted to particular mammalian host species and 
have distinct species designations. For example, Mycobacterium bovis and 
Mycobacterium pinnipedii usually infect cattle and seals, respectively. The last 
member of the MTBC, M. canettii, is found only on the Horn of Africa and is 
assumed to be an opportunistic pathogen with an environmental reservoir (Koeck 
et al. 2011). In this thesis, the term MTBC is used to refer to all members of the 
MTBC excluding M. canettii. 
Over a century after M. tuberculosis was originally isolated by Robert Koch in 
1882, the first whole genome sequence of a M. tuberculosis strain (the laboratory 
reference strain, H37Rv) was determined, revealing a GC rich genome of 4.4 Mb, 
containing ~4,000 protein coding genes (Cole et al. 1998b). Since this time, the 
complete genome sequence of M. africanum (Zhu et al. 2015), M. bovis (Garnier et 
al. 2003), M. canettii (Supply et al. 2013), and numerous additional strains of 
M. tuberculosis have been determined.  
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Figure 1.2. Phylogeny of the MTBC. The MTBC comprises seven human adapted lineages 
(L1-L7) and the animal adapted strains. L4 splits into ten major sublineages as shown. 
Phylogenetic placement of the TbD1 deletion that differentiates between the “modern” (L2, 
L3, and L4) and ancient lineages (all other lineages) is shown. (Adapted from Stucki et al. 
(2016b)). 
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1.3.2 Emergence of the M. tuberculosis complex 
M. tuberculosis was originally thought to have arisen in humans as a result of a 
zoonosis linked to animal domestication ~10,000 years ago. Molecular data 
however, has revealed that the animal adapted strains are nested within the diversity 
of extant human adapted lineages and have a reduced genome compared to 
M. tuberculosis, refuting the hypothesis that M. tuberculosis evolved from M. bovis 
(Brosch et al. 2002; Hershberg et al. 2008). The ancestor of the MTBC is generally 
now hypothesised to have evolved from a pool of environmental smooth tubercle 
bacilli similar to M. canettii (Supply et al. 2013). The acquisition of new genes by 
horizontal gene transfer as well as genomic decay appear to have played a crucial 
role in the early evolution and transition to a pathogenic lifestyle in the ancestor of 
the MTBC (Veyrier et al. 2009; Veyrier et al. 2011). Despite its important role in 
the early evolution of the pathogen, members of MTBC do not undergo horizontal 
gene transfer, and have a strongly clonal population structure (Baker et al. 2004; 
Hirsh et al. 2004; Supply et al. 2003). 
Africa is the only continent where all extant MTBC lineages occur and the earliest 
branching clades are restricted to Africa, suggesting an African origin of the MTBC 
and subsequent dispersal throughout the world via human migrations (Comas et al. 
2013; Hershberg et al. 2008; Wirth et al. 2008). The date at which the MTBC 
emerged remains much debated. Archaeological evidence suggests that 
tuberculosis is an ancient disease. The oldest biomolecular evidence for the MTBC 
comes from a bison bone from Wyoming dated to 17,000 years before the present 
(Rothschild et al. 2001), and infection with an MTBC strain dating back 9,000 years 
has been reported in Israel (Hershkovitz et al. 2008), however, the authenticity of 
this finding has been questioned (Wilbur et al. 2009). The ‘out-of-Africa’ 
hypothesis suggests the most recent common ancestor (MRCA) of the MTBC 
existed ~70,000 years ago and that the MTBC accompanied migrations of modern 
humans out of Africa (Comas et al. 2013). Conversely, two separate ancient DNA 
studies both estimated the MRCA existed fewer than 6,000 years ago (Bos et al. 
2014; Kay et al. 2015). If the MRCA of the extant members of the MTBC is indeed 
younger than previously thought, this does not necessarily represent the time the 
disease first emerged as wholescale clonal replacement could have displaced 
ancient strain diversity.  
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1.3.3 Phylogeography of the M. tuberculosis complex 
The geographical distribution of the human adapted lineages of the MTBC differ 
markedly and show a strong phylogeographical structure (Gagneux et al. 2006a; 
Gagneux and Small 2007; Hershberg et al. 2008). The most widely globally 
dispersed lineages are L4 and L2 (which includes the “Beijing” family). 
Conversely, L7 is almost exclusively found in Ethiopia (Firdessa et al. 2013) and 
the M. africanum lineages (L5 and L6) are largely restricted to West Africa (De 
Jong et al. 2010). The phylogeographical distribution of the human adapted lineages 
is suggestive of co-evolution and adaptation of particular lineages to sympatric 
human host populations (Baker et al. 2004; Brudey et al. 2006; Comas et al. 2013; 
Gagneux et al. 2006a; Hershberg et al. 2008; Hirsh et al. 2004; Wirth et al. 2008). 
Adaptation of MTBC lineages to sympatric host human populations is supported 
by epidemiological studies in human populations whereby association of bacterial 
lineages with their sympatric host populations persist even in cosmopolitan 
environments where there is presumed mixing of human populations and bacterial 
strains (Gagneux et al. 2006a; Hirsh et al. 2004; Reed et al. 2009). Variation in host 
immunity is thought to play a role in this, a hypothesis supported by the finding that 
HIV infection, which causes immunodeficiency, disrupts the sympatric host-
pathogen relationship (Fenner et al. 2013).  
Comparison of the MTBC phylogeny with that of the main human mitochondrial 
haplogroups reveals congruence between the tree topologies, consistent with the 
MTBC diverging and evolving in parallel with its human host (Comas et al. 2013). 
In contrast, a similar analysis of the global phylogeographic structure of human 
Y-chromosome data did not identify strong signatures of co-divergence between 
M. tuberculosis and human populations (Pepperell et al. 2013). The more recent 
origin proposed for the MTBC (Bos et al. 2014; Kay et al. 2015) also precludes the 
possibly of co-evolution between humans and the MTBC and further, raises the 
question as to how the pathogen dispersed to achieve its current global distribution 
in this relatively recent timeframe. In a recent study, O’Neill et al. (2017) (preprint) 
sought to address this question using migration and demographic analyses. The 
authors connect major human events with global dispersal of the MTBC and present 
an historical context for a relatively recent evolutionary history of the MTBC based 
on mutation rates derived from ancient DNA analyses (O’Neill et al. 2017). 
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Regardless of the age of the MTBC, the association of different phylogenetic 
lineages of the MTBC with different host populations can still be hypothesised to 
reflect possible adaptation to specific human populations. Furthermore, the MTBC 
lineages appear to differ in their range of host specificity; some are suggested to 
behave as generalists able to persist in a range of human host populations, whilst 
others appear to be more specialist and infect only a small range of host populations 
(Brites and Gagneux 2015). This phenomenon is also observed amongst the ten 
major sublineages of the L4 lineage, which vary from being widely globally 
distributed to geographically restricted (Stucki et al. 2016b).  
 
1.3.4 Genetic variation within the M. tuberculosis complex 
Although the MTBC organisms are low in genomic diversity compared to other 
bacteria (Frothingham et al. 1994), they are genetically more diverse than 
traditionally assumed. There is increasing evidence that suggests this genomic 
variation can have phenotypic, clinical and epidemiological consequences (Section 
1.4.1, reviewed in Coscolla (2017)). Members of the MTBC differ in their content 
of single nucleotide polymorphisms (SNPs), small insertions and deletions (indels) 
and large genomic deletions.  
SNPs are one of the most common forms of genetic variation. The majority of these 
occur in coding regions, which comprise slightly over 90% of the M. tuberculosis 
genome (Cole et al. 1998a; Fleischmann et al. 2002). On average, M. tuberculosis 
clinical genomes harbour a SNP approximately every 3000 base pairs and two 
human adapted members of the MTBC differ by an average of around 1200 SNPs 
(Coscolla and Gagneux 2014). Analysis of the whole genome sequences of 1,601 
MTBC isolates from around the world identified over 90,000 SNPs, of which 
almost 7,000 were strain specific (Coll et al. 2014). Strains belonging to L4 were 
found to contain 15-962 SNPs relative to the H37Rv reference genome, with an 
average of 746 per genome (Coll et al. 2014). A large proportion of SNPs occur as 
singletons (i.e. are only found in a single strain), a phenomenon suggested to be 
attributable to background selection (Pepperell et al. 2013). Due to their low 
frequency, such variants are better referred to as single nucleotide mutations rather 
than SNPs. 
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1.4 Consequences of genetic variation in M. tuberculosis   
1.4.1 Impact on infection and disease outcome 
It was previously thought that genetic variability between M. tuberculosis strains 
was not of clinical significance. However, increasing evidence now suggests that 
bacterial genetic background can have important clinical and epidemiological 
consequences. Numerous animal and in vitro studies of M. tuberculosis virulence 
have provided evidence of strain dependent differences in immunogenic and 
pathogenic properties of M. tuberculosis (Aguilar et al. 2010; Dormans et al. 2004; 
Lopez et al. 2003; Marquina-Castillo et al. 2009; Portevin et al. 2011; Theus et al. 
2005). Evidence also suggests strain genotype can influence disease epidemiology 
and transmissibility (Anderson et al. 2013; De Jong et al. 2008; Kato-Maeda et al. 
2010; Yang et al. 2012), the efficacy of BCG vaccination (Lopez et al. 2003; 
Tsenova et al. 2007), and the emergence of drug resistance (Drobniewski et al. 
2005; Ford et al. 2013).  
Strains belonging to the “modern” lineages typically have more virulent phenotypes 
in animal and in vitro models and are generally more transmissible than other strains 
(reviewed in Coscolla 2017; Coscolla and Gagneux 2014). For example, modern 
lineage strains are reported to replicate faster in vitro and in aerosol infected mice 
(Reiling et al. 2013), induce lower early inflammatory responses (Portevin et al. 
2011), and are more likely to progress to active disease when compared to ancient 
lineage strains (De Jong et al. 2008). Whole genome sequencing (WGS) provides 
a powerful tool to study M. tuberculosis transmission (Section 1.6). Recent WGS 
studies have shown elevated transmission and a higher proportion of disease due to 
recent transmission for L2 compared with L1 (Guerra-Assunção et al. 2015; Holt 
et al. 2018). The L2/Beijing family is also commonly associated with drug 
resistance, and it is suggested that the genetic background of these strains is better 
suited to tolerate the fitness costs of drug resistance conferring mutations (Borrell 
and Gagneux 2009).  
Strain dependent differences in virulence phenotypes and transmissibility have also 
been reported at the sublineage level (Aguilar et al. 2010; Anderson et al. 2013; 
Kato-Maeda et al. 2010; Kato-Maeda et al. 2012). For example, differences in the 
transmissibility of Beijing strains have been associated with virulence phenotypes 
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in a mouse model; mice infected with highly transmitted strains were shown to have 
higher mortality, more extensive tissue damage, and differential cytokine 
expression (Aguilar et al. 2010). The association of virulence phenotypes with 
transmission also supports an elementary role for increased virulence in enhanced 
transmission.  
 
1.4.2 Molecular determinants of virulence   
While it is becoming evident there are important differences in virulence 
phenotypes between different lineages of M. tuberculosis, the molecular 
mechanisms underlying strain dependent variation in virulence remain unclear. 
Thousands of single nucleotide changes have been identified in clinical 
M. tuberculosis isolates and have potential phenotypic consequences. Around 
two-thirds of SNPs in M. tuberculosis are non-synonymous (nsSNPs), meaning 
they change the amino acid sequence of encoded proteins. Non-synonymous 
changes can result in amino acid substitutions, frame shifts, or premature stop 
codon insertion, potentially altering protein structure and function, which in turn 
has the potential to affect clinical and epidemiological characteristics of the disease. 
Rose et al. (2013) have estimated that around 44% of SNPs may impact protein 
function, although it remains to be determined whether this variation has biological 
and/or clinical consequences. Determining the functional consequences of SNPs at 
the molecular, biochemical and biological level, is important to ultimately elucidate 
the role this variation plays in the outcome of infection and disease. 
The most well characterised effects of single nucleotide changes on bacterial fitness 
(and amongst the most consequential) are those involved in the development of 
drug resistance. As the MTBC does not undergo horizontal gene transfer, drug 
resistance in M. tuberculosis is primarily caused by single nucleotide mutations. 
Other SNPs that mitigate the fitness costs associated with drug resistance, termed 
‘compensatory mutations’, have also been well documented (Casali et al. 2014; 
Comas et al. 2012; De Vos et al. 2013). Furthermore, strain genetic background 
also influences the fitness costs associated with the acquisition of drug resistance 
mutations (Gagneux et al. 2006b).  
Chapter One  
11 
However, the majority of single nucleotide variants in the MTBC are not associated 
with drug resistance. Hence, this presents the obvious question: what effects do the 
remainder of these have on bacterial phenotype? Elucidating the effect of SNPs on 
protein function is an important step towards understanding the practical 
consequences of genomic variation in the MTBC and also can shed new light on 
M. tuberculosis biology. Systematic biochemical in vitro and in vivo analysis of the 
catalogue of M. tuberculosis SNP diversity is simply not practical. Comparative 
approaches and in silico prediction of functional effects provide a means to identify 
SNPs that may affect protein function, presenting candidates for further study. 
Recent genomic analysis of outbreak strains in Denmark and New Zealand have 
identified SNPs in virulence factors that may contribute to the success of these 
strains (Folkvardsen et al. 2018; Gautam et al. 2017), however this is yet to be 
experimentally validated. Holt et al. (2018) have recently identified a threonine to 
alanine SNP at position two (T2A) in EsxW that is under positive selection and is 
suggested to be a possible contributor to enhanced transmission of Beijing family 
strains (Holt et al. 2018). This SNP was shown to lead to a slightly increased affinity 
and stability of the EsxW/EsxV heterodimer (Holt et al. 2018), which is thought to 
be involved in ESX-5 substrate selection - a crucial virulence determinant for 
M. tuberculosis. SNPs that alter transcriptional regulation also have the potential to 
alter bacterial phenotype. SNPs affecting promoter activity and transcription start 
sites and nsSNPs in transcriptional regulators, have been associated with lineage 
specific differences in transcription profiles (Rose et al. 2013).  
Understanding the complex relationship between bacterial genotype, virulence and 
clinical outcomes, is important for the development of improved vaccines, 
treatment regimens and public health measures. Characterising the effects of strain 
specific variation at the molecular level is an essential step towards understanding 
how genomic variation in the MTBC affects bacterial phenotype and its clinical and 
epidemiological outcomes. Studying genotype-phenotype associations also require 
robust methods to genotype isolates and is discussed in the following section.  
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1.5 Genotyping M. tuberculosis 
Molecular typing of M. tuberculosis is important both in public health and research 
settings. Genotypic information can be used to discriminate between reactivation 
and re-infection, link index cases and contacts, and to track the spread of strains 
throughout the population. Strain lineage can also influence important clinical and 
epidemiological aspects of the disease (Section 1.4.1). The ability to distinguish 
genotype for M. tuberculosis with high confidence is therefore important for 
tuberculosis control efforts and to study genotype-phenotype associations. 
Genotyping data can also be used to investigate phylogenetic relationships within 
the MTBC to understand the population structure and evolution of the pathogen and 
provide insights as to how it has achieved its current global distribution.  
 
1.5.1 Traditional molecular typing methods 
Traditional molecular typing methods for M. tuberculosis involve the analysis of 
repetitive genetic elements using restriction fragment length polymorphism (RFLP) 
and/or polymerase chain reaction (PCR) based approaches. The three main typing 
methods used in epidemiological investigations are IS6110-RFLP, mycobacterial 
interspersed repetitive unit variable number tandem repeat analysis (MIRU-VNTR) 
and spoligotyping (Figure 1.3). 
IS6110-RFLP is based on differences in the copy number and genomic locations of 
the IS6110 insertion element, which is exclusively found in the MTBC (van 
Embden et al. 1993) (Figure 1.3B). This method was the first “gold standard” for 
molecular typing of the MTBC and has been used in hundreds of studies around the 
globe. This approach however has limited resolution for strains with low numbers 
of IS6110 repeats (Cowan et al. 2002), is laborious, and relies on having large 
amounts of high-quality DNA requiring long culturing times. Spoligotyping and 
MIRU-VNTR typing are PCR based genotyping techniques developed to overcome 
some of the limitations of IS6110-RFLP. Spoligotyping patterns are defined by the 
presence or absence of 43 unique spacer sequences located in the direct repeat (DR) 
region of the M. tuberculosis genome (Kamerbeek et al. 1997) (Figure 1.3C). This 
approach provides typing information at the sublineage level, however, its ability 
to determine epidemiological links between tuberculosis cases is limited. 
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MIRU-VNTR typing classifies strains based on the number of repeats at different 
VNTR loci in the M. tuberculosis genome (Figure 1.3D). MIRU-VNTR typing 
using 15 or 24 loci has a similar overall discriminatory power to IS6110-RFLP 
when used alone or in combination with spoligotyping (reviewed in Merker et al. 
2017). Both spoligotyping and MIRU-VNTR typing patterns can be readily 
compared to hundreds of other patterns from around the globe using the 
SITVITWEB (Demay et al. 2012) and MIRU-VNTRplus (Weniger et al. 2010) 
databases. They also require only small amounts of DNA, and therefore have 
turnaround times significantly faster than IS6110-RFLP. As a result of these 
benefits, MIRU-VNTR alone, or combined with spoligotyping, replaced 
IS6110-RFLP as the gold standard for tuberculosis genotyping until quite recently. 
These methods are in the process of being superseded by WGS as advances in next 
generation sequencing technologies and reduced costs are making this more 
practical (Section 1.6). 
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Figure 1.3. Schematic showing the principles of traditional molecular typing methods. (A) 
M. tuberculosis genome showing IS6110 elements (dark blue) and PvuII cleavage sites 
(light blue arrows); MIRU-VNTR loci with different numbers of repeats scattered around 
the genome (green boxes); and the direct repeat (DR) locus (yellow). (B) IS6110-RFLP 
typing. M. tuberculosis genomes differ in the locations and number of IS6110 elements 
they possess. The whole genome is digested with PvuII and then separated by gel 
electrophoresis. Hybridisation of fragments with an IS6110 specific DNA probe produces 
the characteristic banding pattern for each isolate. (C) Spoligotyping. The DR region is 
amplified by PCR and products are hybridised to spacer-specific oligonucleotide probes. 
The presence (black square) or absence (white square/blank) of 43 unique spacers located 
between direct repeats at the DR locus determines the spoligotyping pattern. (D) 
MIRU-VNTR typing. The number of repeats present at each MIRU-VNTR locus 
determines the MIRU-VNTR genotype. Specific primers amplify each locus and amplicon 
sizes are determined by gel electrophoresis. Standardised sets of 12, 15 or 24 different loci 
are used for genotyping.  
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1.5.2 Large sequence polymorphisms and single nucleotide polymorphisms 
The molecular markers used for MIRU-VNTR and spoligotyping are prone to 
convergent evolution and have limited discriminatory power, limiting their use in 
phylogenetic studies. Although not typically used clinically, genotyping methods 
based on the analysis of genomic deletions (commonly also referred to as large 
sequence polymorphisms (LSPs), or regions of difference (RDs)), have been used 
as more robust markers for phylogenetic analysis of the MTBC. LSPs can be used 
to assign strains to the major lineages and sublineages of the MTBC (Figure 1.4A) 
and have provided valuable insights into the global phylogeographic distribution 
and evolution of the pathogen (Comas and Gagneux 2009; Gagneux et al. 2006a; 
Hershberg et al. 2008). 
SNPs provide useful epidemiological and phylogenetic information and can also 
have important functional consequences (Section 1.4.2). SNPs show very low levels 
of homoplasy (~1%) (i.e. do not frequently undergo convergent evolution) and thus 
represent robust markers for phylogenetic analysis (Comas et al. 2009; Homolka et 
al. 2012). Phylogenetic trees constructed using SNP data are congruent with the 
main lineages identified by LSPs and better resolve phylogenetic relationships, 
identifying previously un-discriminated lineages (Coll et al. 2014; Homolka et al. 
2012) (Figure 1.4B). Accordingly, several SNP classification schemes describing 
sets of phylogenetically informative marker SNPs for the assignment of strains to 
the main lineages and sublineages have been reported (Coll et al. 2014; Filliol et al. 
2006; Homolka et al. 2012). The most comprehensive of these to date describes a 
set of 62 marker SNPs, allowing assignment to the all the main lineages and 
sublineages with high confidence and classifies a greater number of lineages than 
previously published alternatives (Coll et al. 2014). SNPs also offer practical 
advantages as genetic markers due to their suitability for the development of rapid 
and relatively inexpensive high throughput assays to genotype clinical isolates. For 
example, Stucki et al. (2012) have developed two rapid SNP-typing methods to 
classify isolates into the main MTBC lineages with high confidence and 
comparably little cost. Analysis of genome-wide SNPs using WGS provides the 
ultimate resolution for strain typing, epidemiological and phylogenetic analysis, 
further discussed in the following section. 
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Figure 1.4. Phylogeny of the MTBC based on LSPs and SNPs. (A) Schematic phylogeny 
of the main MTBC lineages based on LSPs. Specific lineage defining regions of difference 
are indicated on branches, lineage colours correspond the colouring in (B). RDs as in 
Gagneux et al. (2006a) and Brosch et al. (2002), additional LSPs enabling further 
classification of the animal adapted strains and M. tuberculosis lineage 2 are not shown. 
(B) Bayesian phylogeny inferred from genome-wide SNPs of 261 genomes, including three 
M. pinnipedii strains from 1000-year-old Peruvian mummies (orange) (Adapted from Bos 
et al. (2014)). 
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1.6 Whole genome sequencing of M. tuberculosis   
WGS is now considered the new gold standard for strain genotyping and 
phylogenetic analysis, providing the ultimate resolution to discriminate between 
closely related clones. Due to advances in next generation technology and reduced 
costs, WGS is likely to become routine in typing laboratories (at least in low 
incidence countries) and hundreds of genomes from different M. tuberculosis 
strains from around the globe have now been sequenced. This is providing valuable 
insights into the transmission, emergence of drug resistance, evolution and global 
dispersal of the pathogen. 
WGS provides a powerful approach to study tuberculosis transmission and 
outbreaks in high resolution. Genomic network analysis provides detailed insights 
into M. tuberculosis transmission dynamics, enabling inference of transmission 
pathways, detection of sub-clusters and micro-epidemics, identification of “super 
spreaders”, and has the potential to predict undiagnosed cases, potentially leading 
to earlier identification and treatment of infectious cases and their contacts (Gardy 
et al. 2011; Guerra-Assunção et al. 2015; Roetzer et al. 2013; Stucki et al. 2015; 
Walker et al. 2013b). Important to the determination of SNP thresholds for 
distinguishing linked and unlinked M. tuberculosis cases is the short-term mutation 
rate, which has been estimated at 0.3–0.5 SNPs per year (Bryant et al. 2013b; 
Roetzer et al. 2013; Walker et al. 2013a). Most isolates from epidemiologically 
linked patients differ by five of fewer SNPs (Perez-Lago et al. 2014; Walker et al. 
2013a). Walker et al. (2013a) have proposed a threshold of five or fewer SNPs 
between isolates as suggestive of epidemiological linkage and more than 12 SNPs 
to rule out recent transmission.  
Molecular dating provides another layer of information, enabling evolutionary 
timelines to be reconstructed characterising the dynamics of outbreaks and dating 
key events, such as the emergence of drug resistance and expansion of successful 
clones (Bjorn-Mortensen et al. 2016; Eldholm et al. 2015; Eldholm et al. 2016). 
Such high-resolution studies combining molecular-dating with spatial and/or 
epidemiological data have only recently been made possible due to increased 
accessibility and affordability of WGS, and offer a powerful way to study pathogen 
evolution in space and time. 
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In addition to studying inter-patient diversity, WGS can provide valuable insights 
into intra-patient variation and micro-evolutionary processes (Perez-Lago et al. 
2014; Trauner et al. 2017) and differentiate relapse and re-infection cases with 
greater resolution than traditional typing methods (Bryant et al. 2013a; Guerra-
Assunção et al. 2014). WGS also offers great promise as a tool to rapidly identify 
drug resistance mutations, potentially reducing the time taken to diagnose drug 
resistance from weeks to days (Koser et al. 2013; Pankhurst et al. 2016).  
 
 
1.7 Tuberculosis in New Zealand 
The research presented in this thesis is based on the genomic analysis of prevalent 
M. tuberculosis strains found in New Zealand. New Zealand is considered a low 
incidence country, having an annual tuberculosis notification rate of around 6.5 
cases per 100,000 population, which translates to approximately 300 cases per year 
(ESR 2018). Tuberculosis is a notifiable disease in New Zealand under the 
Tuberculosis Act 1948 and is one of several communicable diseases (including 
meningococcal disease and acute rheumatic fever) that are a major source of 
socioeconomic and ethnic inequalities in New Zealand (Baker et al. 2012). 
 
1.7.1 The New Zealand population 
Aotearoa New Zealand has a population of approximately 4.9 million people and is 
the largest island nation in the Polynesian region of Oceania (national population 
estimate as at June 2018, StatsNZ (2018)). The majority of the population live on 
the two main islands, the North Island (Te Ika a Maui) and the South Island (Te Wai 
Pounamu) (Figure 1.5). Māori are the indigenous people of New Zealand and New 
Zealand is also home to the largest diaspora communities of indigenous Pacific 
People globally (Spickard et al. 2002). The European ethnic group is the dominant 
ethnic group and 74% of people identify with at least one European ethnicity (2013 
National Census, StatsNZ (2013)). The other major ethnic groups are Māori (15%), 
Asian (12%), Pacific People (7%) and Middle Eastern/Latin American/African 
(MELAA) (1%) (it is important to note that some people identify with more than 
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one ethnic group). Nearly two-thirds of people who identify with at least one Pacific 
ethnicity were born in New Zealand.  
 
 
Figure 1.5. Map of New Zealand showing the main islands and geographical regions. 
 
 
 Tuberculosis incidence in New Zealand  
Unless otherwise indicated, all of the following statistics are from the 2015 annual 
surveillance report of tuberculosis in New Zealand released by The Institute of 
Environmental Science and Research (ESR) (ESR 2018). Statistics pre-dating this 
are either provided in the 2015 report, or extracted from older reports (Bissielo et 
al. 2012; ESR 2015a; 2015b; Lim and Heffernan 2013). 
From 1990 to 2003, New Zealand tuberculosis notification rates fluctuated between 
8.5–11.6 per 100,000. Between 2003 and 2007, rates decreased to 6.7/100,000 and 
have remained relatively stable since. In 2015 there were 294 notified cases of 
tuberculosis, resulting in a rate of 6.4 per 100,000 population (6.4/100,000). The 
majority of notifications were for new cases (97.3%, 286/294) and most were 
laboratory confirmed (88.8%, 261/294). The New Zealand 2015 notification rate is 
lower than the corresponding rate reported for the United Kingdom (10.5/100,000) 
(England 2016), but higher than for the United States (3.0/100,000) (CDC 2017), 
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Canada (4.6/100,000) (Gallant et al. 2017) and Australia (5.2/100,000) (NNDSS 
2015). 
There are several demographic differences in tuberculosis notifications in New 
Zealand, including age, ethnicity and place of birth. The majority of new cases 
occur in patients over 14 years of age (96.9%, 277/286), and the highest rate is 
observed in the 15–39 age group (9.5/100,000). Higher rates of tuberculosis occur 
in socioeconomically deprived areas and this trend is most apparent among New 
Zealand-born cases. Regional differences in notification rates are also apparent. The 
Auckland and Counties Manukau district health boards (DHBs) have the highest 
rates at 12.7/100,00 and 12.3/100,000, respectively, while in other DHBs rates 
range from zero (i.e. no cases) to 7.0/100,000. Rates vary markedly with ethnicity 
and over the last five years the Asian ethnic group has consistently had the highest 
notification rate (Figure 1.6A). In 2015, the highest notification rates were observed 
for the Asian ethnic group (34.3/100,000), followed by Pacific Peoples 
(20.2/100,000), MELAA (15.7/100,00), Māori (3.2/100,000) and European or 
Other ethnic groups (0.6/100,000).  
 
 
Figure 1.6. New Zealand tuberculosis notification rates by ethnicity (2011-2015). Annual 
notification rates of new cases for different ethnic groups and the overall national rate are 
shown. It is important to note that although rates are relatively high for the MELAA 
(Middle Eastern/Latin American/African) group, the absolute number of cases in this group 
are low (8-16 cases annually). (Source: ESR (2018)).  
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For the five years from 2011–2015, slightly over three-quarters of all notified cases 
(75.5–82.9%) were born outside of New Zealand, and around half of these occurred 
within the first six years of arrival in New Zealand. The proportion of tuberculosis 
patients born in the Pacific Islands has recently increased from 13.2% in 2014, to 
21.5% in 2015. Among New Zealand-born cases in 2015, 44.9% occurred in Māori, 
24.5% in Pacific People, 22.4% in the European or Other group, and 8.2% in the 
Asian ethnic group. 
New Zealand has a relatively low rate of drug resistant tuberculosis and only one 
case of extensively drug-resistant tuberculosis has been identified (this was in an 
immigrant from Myanmar in 2010 (Goh et al. 2011)). Drug susceptibility testing to 
isoniazid, rifampicin, ethambutol, streptomycin and pyrazinamide is routinely 
performed. In 2015, 89.7% (218/243) of tested isolates were fully drug susceptible 
and two cases of multi-drug-resistant tuberculosis were identified (0.8% of cases). 
Drug resistance is higher among non-New Zealand-born than New Zealand-born 
cases (11.6% compared to 2.8% of isolates, respectively) and only two multi-drug 
resistant tuberculosis cases have been identified in New Zealand-born patients in 
the ten years from 2004 to 2015.  
 
 Molecular typing in New Zealand 
Universal typing of tuberculosis isolates was introduced in New Zealand 2002. 
Prior to 2009, IS6110-RFLP was the primary typing method, after which 
MIRU-VNTR became the primary method with secondary typing by IS6110-RFLP. 
Since 2011 typing has been undertaken by MIRU-VNTR analysis alone. At present, 
all molecular typing is carried out by the national tuberculosis reference laboratory, 
LabPLUS (Auckland, N.Z.). Primary typing is performed by MIRU-VNTR 12-loci 
analysis, and secondary typing by MIRU-VNTR 24-loci when an isolate shares its 
12-loci pattern with previously typed isolate (Lim and Heffernan 2013).  
Over one-third of MIRU-VNTR typed M. tuberculosis isolates in New Zealand 
have non-unique molecular typing results and are able to be assigned to ‘clusters’ 
(groups of strains with identical typing patterns) (ESR 2018). Genotypic clustering 
of M. tuberculosis isolates is typically interpreted to indicate recent transmission, 
although clustering can also represent reactivation of latent infection with endemic 
strains (Nguyen et al. 2004). A higher proportion of cases with non-unique 
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molecular types occur in the Māori (74.1%), and Pacific People (80.1%) ethnic 
groups, compared to all other groups (European or Other 32.5%, Asian 24.3%, 
MELAA 12.8%) (Figure 1.7). Cases born in the Pacific Islands have the highest 
proportion of non-unique molecular types for any region of birth (72.1%), although 
overall, overseas born cases have a lower proportion of non-unique molecular types 
(40.3%) compared to New Zealand-born patients (61.4%).  
Although the majority of tuberculosis clusters in New Zealand are small (<5 cases), 
there are a small number of large clusters, some of which have been a source of 
tuberculosis infection for over two decades. The largest cluster in New Zealand 
based on identical or highly similar MIRU-VNTR typing patterns is most prevalent 
in Māori and is known as the ‘Rangipo’ cluster (Section 1.1.3). Two other major 
clusters, called the ‘Southern Cross’ and ‘Otara’ clusters, are most common in 
Pacific People. Since 2002, the Rangipo cluster has been responsible for at least 
165 tuberculosis cases, the Southern Cross cluster 152 cases, and the Otara cluster 
32 cases (V Playle, LabPLUS, personal communication). 
 
 
 
Figure 1.7. Proportion of clustered tuberculosis cases in New Zealand (2011-2015). 
Percentage of non-unique (i.e. clustered) and unique MIRU-VNTR typing profiles for 
different ethnic groups and the overall national proportion are shown. (Source: ESR 
(2018)). 
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 The Rangipo cluster  
The Rangipo cluster is the largest New Zealand M. tuberculosis cluster identified 
by related MIRU-VNTR typing patterns. This cluster has been a cause of ongoing 
outbreaks for around 30 years (Calder 2013; Colangeli et al. 2014; De Zoysa et al. 
2001; McElnay et al. 2004). Approximately 12% of clustered cases in New Zealand 
belong to the Rangipo cluster and it is associated with more DHBs than any other 
cluster (Sexton et al. 2008). The majority of Rangipo strain cases occur in Māori 
(88%, 81/92 201), and it accounts for around one-quarter of tuberculosis cases in 
this population (J Sherwood, ESR, personal communication).  
The Rangipo strain is most notably associated with a large outbreak in the late 1990s 
linked to the Rangipo prison (De Zoysa et al. 2001). During a three and half year 
period, this outbreak resulted in at least 61 cases of active tuberculosis and 119 
cases of latent tuberculosis throughout the North Island (De Zoysa et al. 2001). It 
has since become known as the Rangipo strain, although cases caused by this strain 
have been recognised from the early 1990s, pre-dating the prison outbreak 
(N Karalus, Waikato Hospital, personal communication). In a subsequent 2002 
Hawke’s Bay outbreak, 19 new cases of active tuberculosis and 42 cases of latent 
disease were diagnosed, including contacts only casually connected to the index 
case (McElnay et al. 2004). Such large outbreaks present a serious challenge to 
tuberculosis control efforts in New Zealand and stretch local public health and 
clinical services. Recently, an outbreak of the Rangipo strain involving six cases 
occurred in a small Waikato town in 2017/2018, showing the strain continues to 
spread and cause disease in New Zealand (R Hoskins, Waikato Hospital, personal 
communication). 
Although no virulence testing has yet been undertaken, anecdotal evidence suggests 
this strain may be highly transmissible and previous outbreaks demonstrate high 
infectivity of index cases, infection of casual contacts, and the generation of large 
numbers of secondary cases (Calder 2013; De Zoysa et al. 2001; McElnay et al. 
2004). Host social/environmental factors are also likely important contributors to 
the success of the Rangipo strain. For example, prison incarceration and/or gang 
affiliations were a feature of several cases in previous Rangipo outbreaks (De Zoysa 
et al. 2001; McElnay et al. 2004).  
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A clear understanding of the bacterial and host factors that underlie the success of 
this prevalent strain are imperative to improve public health measures and develop 
effective strategies to halt its further spread. Prompt identification of Rangipo strain 
cases is also important for this. To address this, WGS-data has been used in our lab 
to guide the development of a rapid SNP-based Rangipo strain-specific diagnostic 
assay (Ruthe 2015). WGS offers a promising route to shed light on transmission 
and bacterial genetic factors that may contribute to the success of the Rangipo strain 
and other prominent clusters in New Zealand. WGS of Rangipo isolates has 
revealed very little SNP diversity among isolates (0–19 SNP differences between 
isolates), consistent with relatively recent transmission (Colangeli et al. 2014; 
Gautam et al. 2017). A number of nsSNPs in virulence associated genes in Rangipo 
strains have been identified (Colangeli et al. 2014; Gautam et al. 2017; Ruthe 2015), 
providing valuable insight into the genomic context of the Rangipo cluster, 
although questions still remain concerning the functional consequences of common 
Rangipo genetic variants. Important evolutionary and social questions surrounding 
the origins and expansion of the Rangipo strain are yet to be addressed and are 
necessary to understand how this strain has become established as an important 
cause of tuberculosis in New Zealand. 
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1.8 Objectives 
In my doctoral research I have used WGS data, phylogenetics and structural biology 
to examine the evolutionary origins and functional consequences of genetic 
variation in the New Zealand M. tuberculosis Rangipo strain and other prominent 
local strains. The overall aim of this research was to enhance our understanding of 
factors contributing to the success of the Rangipo strain in New Zealand. The 
specific objectives addressed in this thesis are outlined below. 
 
Objective one:  Identify SNPs specific to the Rangipo strain. 
Objective two: Examine the consequences of genomic variation specific to the 
Rangipo strain at the molecular level using protein 
crystallography and biochemical approaches. 
Objective three: Characterise the phylogenetic relationships and genetic 
variation within and between the Rangipo, Southern Cross and 
Otara clusters.   
Objective four: Examine the evolutionary history of the Rangipo strain and 
identify its historical origin. 
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2 Chapter Two 
Rangipo SNP-based analyses 
2.1 Introduction 
Colangeli et al. (2014) have sequenced the whole genomes of ten New Zealand 
Rangipo strain Mycobacterium tuberculosis clinical isolates spanning a 19-year 
period from 1991 to 2011, using the Applied Biosystems Inc. (ABI) SOLiD 
platform. These data were used to estimate M. tuberculosis mutation rates during 
latency and active disease (Colangeli et al. 2014) and for additional single 
nucleotide polymorphisms (SNP) analyses undertaken in this laboratory (Ruthe 
2015). Isolates included five cases from a single source outbreak and five cases with 
no known epidemiological links to the outbreak (Figure 2.1). The ten isolates were 
found to carry little genetic variation, differing from each other by only 1–14 SNPs, 
and neighbour-joining trees also showed close phylogenetic relationships between 
the isolates (Colangeli et al. 2014). A detailed phylogeny in the context of other 
New Zealand or global M. tuberculosis isolates and full lineage classification was 
not performed. SNP differences between recently transmitted isolate pairs and 
reactivation cases estimated an approximately ten-fold slower mutation rate for 
latent M. tuberculosis compared with active disease (5.5 x 10-10 and 7.3 x 10-11 
substitutions/site/generation, respectively (assuming a 20 hr generation time, 
µ(20hr))) (Colangeli et al. 2014). This was in contrast to the situation reported in 
rhesus macaques, whereby mutation rates estimated for latent and active disease 
were very similar (2.0 x 10-10 and 2.2 x 10-10 substitutions/site/generation, µ(20hr)). 
The rate reported by Colangeli et al. 2014 translates to a mean rate of ~1.4 x 10-7 
substitutions/site/year (my own calculations) which is similar to other short-term 
mutation rate estimates estimated from clinical M. tuberculosis isolates (Eldholm 
et al. 2015; Eldholm et al. 2016; Ford et al. 2013; Pepperell et al. 2013; Roetzer et 
al. 2013; Walker et al. 2013a).  
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Figure 2.1. M. tuberculosis Rangipo strain isolates sequenced by Colangeli et al. (2014). 
Chronological representation of epidemiological relationships among ten Rangipo isolates 
(1991–2011) sequenced on the ABI SOLiD platform. Each square represents a case at time 
of diagnosis, case “X” (grey box) and is assumed to be the index case for several other 
cases in the cluster. X was not available for sequencing. Broken lines represent known 
epidemiological links between cases. Isolates “C” and “R” were taken from the same 
individual 17 years apart and were shown to be the result of reinfection. Case “T” was the 
parent of “A”, however SNP analysis indicated this was not a direct transmission (Colangeli 
et al. 2014). Modified from Colangeli et al. (2014).  
 
 
Colangeli et al. (2014) identified a total of 747 SNPs between the reference strain 
H37Rv and the ten Rangipo isolates, and 247 high quality SNPs were shared 
amongst all Rangipo isolates. Ali Ruthe completed her PhD in this laboratory in 
2015 and performed further analyses on the 247 common Rangipo SNPs (Ruthe 
2015). Ruthe (2015) cross-checked all 247 SNPs against 38 M. tuberculosis 
complex (MTBC) genomes in public databases and Mycobacterium canettii to 
determine if other strains carry the same variants. Ninety-nine SNPs were not 
identified in any other strains and were classified as ‘Rangipo specific’ SNPs 
(RS-SNPs). Three putative RS-SNPs (1380G>A in Rv1821/secA; 691G>A in 
Rv2504c/scoA; and 334A>G in Rv3119/moaE1) were used to develop a rapid 
cost-effective diagnostic assay using multiplex polymerase chain reaction 
(PCR)-restriction fragment length polymorphism (RFLP), allowing classification 
of strains as Rangipo or non-Rangipo (Ruthe 2015). This assay was found to 
quickly and accurately distinguish Rangipo strain cases using DNA extracted from 
cultured isolates with higher discriminatory power than conventional MIRU-VNTR 
typing (Ruthe 2015). Region of difference PCR analysis identified the Rangipo 
strain as belonging to the L4/Euro-American lineage of the MTBC but the L4 
sublineage remained unassigned (Ruthe 2015).  
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2.1.1 Objectives 
Since the original analysis of Rangipo strain SNP data was performed (Colangeli et 
al. 2014; Ruthe 2015) the number of M. tuberculosis strains available in public 
databases for comparison has increased enormously. The primary objective of this 
work was to reclassify the 247 Rangipo SNPs and identify candidates of interest for 
structural and biochemical investigation. It was also important to assign the 
Rangipo strain to an L4 sublineage and re-evaluate the previous Rangipo 
PCR-RFLP diagnostic (Ruthe 2015) in light of an updated SNP analysis.  
While more thorough phylogenetic and variant analyses were performed once 
Illumina sequencing of New Zealand cluster isolates was completed (Chapter Four), 
the analyses described in this chapter are included as they were pivotal to the 
direction of much of the work undertaken as part of this thesis. 
 
 
2.1 Methods 
2.1.1 Previous Rangipo strain outbreaks 
Contact tracing results for three large Rangipo strain outbreaks have previously 
been reported (Calder 2013; De Zoysa et al. 2001; McElnay et al. 2004). The 
number of cases identified with active and latent tuberculosis were analysed for 
each outbreak. The proportion of total screened contacts with active and latent 
tuberculosis was calculated and compared to average estimates of tuberculosis 
prevalence in contacts reported in a large meta-analysis of 108 studies in 
high-income and 95 studies in low- to middle-income settings (Fox et al. 2013). 
 
2.1.2 M. tuberculosis genomic DNA  
Genomic DNA (gDNA) from clinical New Zealand M. tuberculosis cluster isolates 
was available from previous work in this laboratory (Ruthe 2015). DNA had been 
either extracted by Roberto Colangeli (University of Medicine and Dentistry of 
New Jersey, U.S.A.) as in Colangeli et al. (2014), or provided as crude clinical 
isolate extracts from LabPLUS (Auckland, N.Z.). LabPLUS samples included 
Chapter Two  
29 
gDNA from Rangipo, Otara and Southern Cross cluster isolates, and additional 
smaller New Zealand clusters identified by related MIRU-VNTR typing patterns 
(NZ_041, NZ_069, NZ_037, NZ_094) (Appendix A.1). Additional gDNA samples, 
including samples from various MTBC lineages and L4 sublineages, were provided 
by either LabPLUS or our collaborator Htin Aung (University of Otago, N.Z.). 
DNA was quantified using a NanoDrop 2000 spectrophotometer (Thermo 
Scientific, U.S.A.) by measuring absorbance at 260 nm. The ratio of absorbance at 
260 nm to 280 nm provides an indication of sample purity and a 260/280 ratio of 
~1.8 was considered ideal indicating a DNA sample free from protein, RNA, phenol 
or other contaminants. Working M. tuberculosis genomic DNA samples were 
prepared by diluting a small amount of stock DNA solution with TE buffer (10 mM 
Tris-HCL, 1 mM EDTA, pH 8.0) to a concentration of approximately 10 ng.µl-1. 
 
2.1.3 Identification of putative Rangipo specific SNPs 
Ten Rangipo genomes (Figure 2.1) were previously sequenced by collaborators 
Roberto Colangeli and David Alland at the University of Medicine and Dentistry 
of New Jersey (U.S.A.). Isolates from 2002 onwards were typed by IS6110-RFLP 
and six isolates (A, C, F, N, O) by MIRU-VNTR 24-locus typing, and share the 
same molecular typing patterns (IS6110-RFLP, 13/008RP; MIRU-VNTR, 
233325153324-341444223362) (Ruthe 2015). Isolates were sequenced on an ABI 
SOLiD 5500XL instrument (Applied Biosystems Inc., U.S.A.) as described in 
Colangeli et al. (2014). Briefly, each isolate was sub-cultured and two individual 
colonies from each original culture were sequenced. SNPs relative to H37Rv were 
called using the CLC genomics workbench and SNPs supported by <80% of reads 
were discarded (Colangeli et al. 2014). 247 high quality SNPs present in all 20 
genomes were identified.  
A list of all 247 SNP positions with the base change and associated gene was 
provided in excel format. In this thesis, SNPs are named with the prefix “Rv” 
followed by the position in the H37Rv reference genome (NC_000962.3) and the 
reference base and nucleotide change as described in Fenner et al. (2013). For 
example, the 1380G>A in the Rv1821/secA gene is named Rv2067836GA as it 
changes the H37Rv nucleotide at position 2067836 from G to A. To identify SNPs 
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specific to the Rangipo strain, the position of each SNP was cross checked against 
1084 global M. tuberculosis genomes in the GMTV database to determine if the 
same variant is present in other isolates (http://mTB.dobzhanskycenter.org) 
(Chernyaeva et al. 2014). Putative non-synonymous RS-SNPs (RS-nsSNPs) 
identified from this comparison were further checked by submitting protein 
sequences containing Rangipo variants to Protein BLASTP (BLASTP) and 
searching against the non-redundant protein sequence database 
(https://blast.ncbi.nlm.nih.gov) (Altschul et al. 1990).  
 
2.1.3.1 In silico SNP functional assessment 
Functional categories of genes harbouring RS-SNPs were assigned using the 
Tuberculist database (Lew et al. 2011). To identify SNPs that may impact on protein 
function the program SNAP2 was used (Screening for Non-Acceptable 
Polymorphisms) (Hecht et al. 2015). The H37Rv reference sequence of  
proteins harbouring RS-nsSNPs were input into the SNAP2 webserver 
(https://rostlab.org/services/snap2web/), the residue of interest was searched, and 
the result extracted for the variant amino acid corresponding to the SNP of interest.  
 
2.1.4 Validation of SNPs by Sanger sequencing 
2.1.4.1 Primers 
Sanger sequencing was used to confirm the presence of RS-nsSNPs. Geneious R8 
(Biomatters, N.Z.) and Primer3 (http://primer3.ut.ee) were used to design primers 
to amplify short genomic regions (168–387 bp) spanning SNPs of interest 
(Appendix A.3). Primer specificity was checked in Primer-BLAST (Ayres et al. 
2012). Primers were ordered from Integrated DNA Technologies, Inc. (U.S.A.) and 
resuspended in 100 µM TE buffer (10 mM Tris-HCL, 1 mM EDTA, pH 8.0). 
Working stock solutions were prepared at 10 µM in MQ water. 
 
2.1.4.2 Polymerase Chain Reaction 
PCR was performed in 20 µl reactions containing 0.5 units (U) HOT FIREPol® 
DNA polymerase (Solis BioDyne, Estonia), the supplied B1 buffer at 1X 
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concentration, 2.0 mM MgCl2, 250 µM dNTPs and 0.3 µM of each primer. 
Approximately 10 ng of gDNA from Rangipo isolate “A” was used as the PCR 
template and all reactions were run alongside a negative control. A touchdown PCR 
protocol was employed to reduce the potential for non-specific priming.  
Thermal cycling conditions used for amplification were as follows: 
95 °C 15:00 (min:sec) 
95 °C  0:20 
68 °C  0:20  x 5 -1 °C per cycle 
72 °C  0:20 
95 °C  0:20 
63 °C  0:20   x 30  
72 °C  0:20 
72 °C  1:00  
5 µl of each PCR product was run on an agarose gel (Section 2.1.4.3) to check for 
a single band of the correct size. PCR products were then ExoISAP treated (Section 
2.1.4.4) to remove any remaining primers and free dNTPs before sequencing. 
 
2.1.4.3 Agarose Gel Electrophoresis 
DNA fragments were separated by agarose gel electrophoresis. Samples were 
mixed with 5X DNA loading dye (25% (v/v) glycerol, 0.2% (w/v) bromophenol 
blue) and separated on 1–2% (w/v) agarose TAE (40 mM TRIS-acetate, 2 mM 
EDTA) gels made with SYBR safeTM DNA gel stain (Invitrogen, U.S.A.) and run 
in TAE running buffer. Gels were visualised by blue light and band sizes were 
determined by visual comparison against a 1 Kb Plus DNA ladder (Thermo Fisher 
Scientific, U.S.A.). 
 
2.1.4.4 ExoISAP treatment and Sanger sequencing of PCR products 
20 U Exonuclease I (Thermo Fisher Scientific, U.S.A.) and 1 U rAPid Alkaline 
Phosphatase (Roche, Switzerland) were gently mixed with 5 µl of PCR reaction and 
incubated for 30 min at 37 °C, followed by inactivation at 80 °C for 15 min. 
ExoISAP treated PCR products were sent to the Massey Genome Service 
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(Palmerston North, New Zealand) for sequencing on an ABI3730 DNA Analyzer 
(Applied Biosystems Inc., U.S.A.). 
 
2.1.5 Sublineage classification 
2.1.5.1 MIRU based sublineage classification  
The MIRU-VNTRplus database website (http://www.miru-vntrplus.org) (Allix-
Beguec et al. 2008) was used perform MIRU-based lineage assignment for the New 
Zealand clusters based on MIRU-VNTR 24-locus typing patterns (Appendix A.1). 
The “Identification by similarity search” tool was used with the default categorical 
weighting of 1 and strict distance cut off of 0.17 to classify lineage based on the 
best match with reference strains in the database. “Identification by phylogenetic 
tree” was performed using the UPGMA method to classify any strains without 
matches and as further verification of the classification. 
 
2.1.5.2 S lineage PCR-RFLP assay 
The S lineage, also known as ‘S-type’, is a sublineage of the L4/Euro-American 
lineage. Published S lineage marker SNPs are listed in Table 2.1. A PCR-RFLP 
assay was developed to type for the S-type marker SNP from Homolka et al. (2012) 
(Section 2.2.3.1). The S-type clade identified in Homolka et al. (2012) is congruent 
with the L4.4.1.1 sublineage described in Coll et al. (2014). 
 
Table 2.1. Phylogenetically informative S lineage marker SNPs. 
 SNP aa change Locus Reference 
S-type  Rv648992CG synonymous Rv0557/mgtA Homolka et al. (2012) 
L4.4.1.1/S Rv355181GA synonymous Rv0291/mycP3 Coll et al. (2014) 
 
PCR-RFLP enables SNPs to be easily and cheaply detected if one of the variant 
bases create a recognition sequence for cleavage by a restriction enzyme. WatCut 
(http://watcut.uwaterloo.ca/template.php) was used to screen both the S-type and 
the L4.4.1.1/S marker SNPs (Table 2.1) to identify restriction enzymes that would 
recognise only one of the variant bases. The BstNI restriction enzyme was identified 
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as a suitable restriction enzyme for the detection of the S-type SNP (Homolka et al. 
2012) as it is expected to cut non-S samples [CC^WGG] but not samples carrying 
the S-type marker SNP [CGWGG]. Primers were designed to amplify a 343 bp 
product containing this marker SNP and include an additional BstNI cut site to act 
as an internal digestion control (Table 2.2). Expected fragments sizes for S lineage 
isolates following BstNI digestion are 138 and 205 bp; and for non-S, 138, 151 and 
54 bp (Table 2.2). PCR was performed using the same thermal cycling parameters 
as in Section 2.1.4.2 and 5 µl of product was run on an agarose gel to check for 
amplification. The remaining PCR product was then digested in a total 25 µl 
reaction volume with 3 U BstNI (New England Biolabs, U.S.A.), NEBuffer 3.1 and 
MQ water. Digestion reactions were incubated at 60 °C for 1 hr in a PCR machine 
and fragments were separated by gel electrophoresis on a 2% gel (Section 2.1.4.3).  
 
Table 2.2. S lineage PCR-RFLP assay. PCR primers for the amplification of the  
S-type Rangipo marker SNP (Rv648992CG) from Homolka et al. (2012) and expected 
fragments following restriction enzyme digestion with BstNI. 
Primer name Primer sequence  (5' to 3') 
Product 
size (bp) 
Digested fragments (bp) 
S lineage Non-S 
Rv0557(L153V)_fwd CTGCTTGGCTACGGTGGACT 
343 138, 205 138, 151, 54 
Rv0557(L153V)_rev GAGCAAGCCGACCCACAAAG 
 
 
2.1.6 DS6Quebec deletion PCR assays 
The DS6Quebec deletion removes an ~11.4 kb region (positions 1987457 to 1998849) 
replacing it with an IS6110 element, and is characteristic of the DS6Quebec strain 
family endemic in Canada (Nguyen et al. 2004). A multiplex PCR assay was 
designed to screen isolates for the presence or absence this deletion using three 
primers (Table 2.3). A pair of external primers bind upstream and downstream of 
the DS6Quebec deletion. If the isolate has the deletion, a large 1836 bp PCR product 
spanning the deletion and its associated IS6110 element is amplified. An internal 
primer binds within the DS6Quebec region to pair with the external upstream primer 
to amplify a small 250 bp product if the region is present as in H37Rv (the external 
primer pair will not produce a product as the genomic distance between them is too 
large (11.9 kb)). 
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A DS6Quebec-IS6110 insertion-specific PCR using primers described in Nguyen et 
al. (2004) was then performed on isolates testing positive for the deletion to verify 
the location is exactly the same as in the Canadian DS6Quebec family. Internal IS6110 
primers were used with primers that span the deletion junction so that amplification 
will only occur if the deletion/IS6110 insertion occurred at exactly the same site. 
 
Table 2.3. DS6Quebec deletion assays. Primer sequences and expected PCR products for the 
multiplex PCR to screen for the deletion (1), and DS6Quebec-IS6110 insertion-specific 
verification of the DS6Quebec deletion (2 and 3). NA = no amplification. 
 
Primer name/ 
target region Primer sequence (5' to 3') 
Position 
in H37Rv1 
Product (bp) 
DS6Quebec  H37Rv 
1 DS6 5¢ upstream TCAGGCACCGTGACATATTCG 1987278 
1836 250  DS6 5¢ internal TCTTAGCCAATAGACTGCCGC 1987527 
 DS6 3¢ downstream CGCAGTAACTATCGCTGACCTAT 1999149 
22 IS6110 3¢ junction AAGCCCCGGCCGCGGCTGGATGAAC 1987438 
161 NA 
 IS6110 3¢ internal TTCAACCATCGCCGCCTCT N/A 
32 IS6110 5¢ internal GGTACCTCCTCGATGAACC N/A 
99 NA 
 IS6110 5¢ junction AGCCAGCCAACCCCGGCCCTTGAAC 1998868 
1  Position of 5¢ end of primer in the H37Rv reference genome. 
2  Primer sequences from Nguyen et al. (2004). Note that due to the direction of the 
IS6110 element, the IS6110 3′ primers amplify the 5′ flank of the deletion and the 
IS6110 5′ primers amplify the 3′ flank. 
 
PCR reactions were prepared as per Section 2.1.4.2. Touchdown PCR was used to 
reduce the potential for non-specific priming for all PCR reactions. Thermal cycling 
conditions used for the DS6Quebec multiplex PCR were as follows: 
95 °C 15:00 (min:sec) 
95 °C  0:20 
68 °C  0:20  x 5  -1 °C per cycle 
72 °C  2:00 
95 °C  0:20 
63 °C  0:20   x 30  
72 °C  2:00 
72 °C  3:00  
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Thermal cycling parameters used for DS6Quebec-IS6110 insertion-specific PCRs:  
95 °C 15:00 (min:sec) 
95 °C  0:20 
70 °C  0:20  x 5  -1 °C per cycle 
72 °C  0:20 
95 °C  0:20 
65 °C  0:20   x 30  
72 °C  0:20 
72 °C  3:00  
PCR products were analysed by agarose gel electrophoresis (Section 2.1.4.3). 
Sanger sequencing of PCR products as in Section 2.1.4.4 to confirm the correct 
genomic regions had been amplified and as additional confirmation of the deletion. 
 
2.1.7 Contig mapping and analysis 
SNP analyses identified SNPs shared between the Rangipo strain and Canadian 
SUMu strain isolates (Section 2.2.2). Genomic contigs for 12 Canadian SUMu 
M. tuberculosis isolates (SUMu001–SUMu012) were downloaded as fasta files 
from the Broad Institute (TB Natural Mutation Rate Sequencing Project, Broad 
Institute of Harvard and MIT, http://www.broadinstitute.org/). Contigs were 
mapped to the H37Rv reference genome (NC_000962.3) in Geneious R8 
(Biomatters, N.Z.) using default settings. Variant positions of interest and the 
DS6Quebec deletion region (positions 1987457 to 1998849) were manually 
examined. 
 
2.1.8 Rangipo diagnostic assay 
A Rangipo specific SNP-based multiplex PCR-RFLP diagnostic assay has 
previously been developed in this laboratory (Ruthe 2015). Based on the updated 
analyses performed in this work, the Rangipo diagnostic was revised to type for a 
single RS-SNP, Rv2067836GA in the Rv1821/secA2 gene. 
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2.1.8.1 Rangipo PCR-RFLP assay 
The Sau3AI restriction enzyme and its isoschizomer MboI were previously 
identified as suitable restriction enzymes for the detection of the Rangipo 
Rv1821/secA2 SNP as they are expected to cut non-Rangipo samples [^GATC], but 
not samples carrying the Rangipo SNP [AATC] (Ruthe 2015). A new forward 
primer was designed to be used with the original reverse primer to incorporate an 
additional Sau3AI/MboI cut site to act as in internal digestion control. Primers were 
designed and prepared as in Section 2.1.4.1. Primers are expected to amplify a 
455 bp PCR product spanning the SNP and restriction enzyme digestion of this 
product is expected to produce 386 and 69 bp fragments for Rangipo strain isolates, 
and 215, 171 and 69 bp fragments for non-Rangipo (Table 2.4). 
 
Table 2.4. Rangipo specific PCR-RFLP diagnostic assay. PCR primers for the 
amplification of the Rv1821/secA2 Rangipo marker SNP (Rv2067836GA) and expected 
fragments following restriction enzyme digestion with Sau3AI or its isoschizomer MboI. 
Primer name Primer sequence (5' to 3') Product size (bp) 
Digested fragments (bp) 
Rangipo  Non- Rangipo 
Rv1821 Fwd new GAGGCCAAGGAAGGTATCGAGAC 
455 386, 69   215, 171, 69  
Rv1821 Rev1 CGCCCGGCCATTTGAGTTGA 
1  Reverse primer from Ruthe (2015). 
 
PCR reactions were carried out in 20 µL volumes with 1 U HOT FIREPol® DNA 
Polymerase (Solis BioDyne, Estonia), supplied buffer B1 at 1X concentration, 
2.0 mM MgCl2, 250 µM dNTPs and 0.3 µM of each primer. Approximately 10 ng 
of M. tuberculosis template gDNA of was added to each reaction tube and all 
reactions were run alongside a no template negative control. 
The following thermal cycling conditions were used for amplification: 
95 °C 15:00 (min:sec) 
95 °C  0:20 
55 °C  0:20  x 30  
72 °C  0:30 
72 °C  1:00  
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PCR products were digested with MboI in order to distinguish between Rangipo 
and non-Rangipo isolates. 1 µl MboI (New England Biolabs, U.S.A.), NEB buffer 
4.1 at 1X final concentration, and MQ H2O were added to the PCR reaction to a 
final volume of 50 µl. This was incubated at 37 °C for 1 hr in a PCR machine, 
followed by 65 °C for 20 min. Digested products were separated on 1.5% agarose 
gels (Section 2.1.4.3). 
 
2.1.8.2 Sputum samples 
Clinical sputum specimens were provided by the Waikato Hospital (Hamilton, 
N.Z.) to assay with the Rangipo PCR-RFLP diagnostic. Samples had been 
decontaminated using the BD BBL MycoPrep Kit (BD, U.S.A.), heat inactivated at 
95 °C for 20 min and then spun down at 4,500 rpm for 10 minutes by hospital 
laboratory staff. PCR was performed using 0.5 µl of the supernatant as template and 
products were digested as in Section 2.1.8.2. 
 
2.1.9 Ethical Considerations 
Ethical approval is not required for sequencing and DNA analysis of New Zealand 
clinical M. tuberculosis bacterial isolates. Ethical approval was not required for 
Rangipo diagnosis from sputum samples as this was a public health investigation 
seeking to improve the turnaround time for pathogen strain typing and samples were 
used solely for the purpose they were collected for (diagnosis and strain typing of 
mycobacterial pulmonary infection), and destroyed immediately after. No 
identifiable health information was provided to researchers. 
 
 
2.2 Results  
2.2.1 Previous Rangipo strain outbreaks 
Contact tracing summary data was available for three large Rangipo strain 
outbreaks that occurred between 1996 and 2012 (Calder 2013; De Zoysa et al. 2001; 
McElnay et al. 2004). Collectively these outbreaks resulted in at least 94 cases of 
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active tuberculosis, of which 68 where identified through contact tracing (additional 
cases were notified to public health services) and 253 cases of latent infection. In 
total, 4.6% (68/1482) of traced contacts were diagnosed with active tuberculosis 
(95% CI, 4.0–5.0%). This is over three times higher than the estimated average 
prevalence of active tuberculosis in traced contacts in high-income settings (1.4%; 
95% CI, 1.1–1.8%) and 1.5 times higher than for low- and middle-income settings 
(3.1%; 95% CI, 2.2–4.4%) (Fox et al. 2013). Furthermore, this excludes additional 
cases identified by notification to public health services. The prevalence of latent 
infection in traced contacts was 17.1% (253/1482) (95% CI, 11.7–33.5%), which is 
lower than the estimated average for low- to middle-income settings (51.5%; 95% 
CI, 47.1–55.8%) and lower but within the 95% CI for high-income settings (28.1%; 
95% CI, 24.2–32.4%) (Fox et al. 2013). In each Rangipo strain outbreak, the 
proportion of infected contacts with active disease exceeded the 5–10% expected 
to progress to active disease, and overall 21.2% of infected individuals (68/321) 
were diagnosed with active tuberculosis (95% CI, 11.7–33.5%). 
 
Table 2.5. Contact tracing of previous Rangipo strain outbreaks. Percentage of traced 
contacts is shown in brackets. 
 North Island 
1996-20001 
Hawkes Bay 
20022 
Hawkes Bay 
20123 Total 
Traced contacts 733 397 352 1482 
Active tuberculosis 35 (4.8%) 19 (4.8%) 14 (4.0%) 68 (4.6%) 
Latent tuberculosis 119 (16.2%) 40 (10.1%) 94 (26.7%) 253 (17.1%) 
Total infected  154 (21.0%) 59 (14.9%) 108 (30.70%) 321 (21.7%) 
Infected contacts 
with active disease 22.7% 32.2% 13.0% 21.2% 
Contact types Community and prison contacts 
Household,  
close associates,  
and co-workers 
Household, and 
shearing gang 
workers 
 
1  De Zoysa et al. (2001) 
2  McElnay et al. (2004) 
3  Calder (2013) 
 
2.2.2  Rangipo SNPs 
Two hundred and forty-seven SNPs common to the Rangipo cluster were 
previously identified in ten Rangipo genomes sequenced on the ABI SOLiD 
platform (Colangeli et al. 2014). I then checked all 247 SNP positions by searching 
the GMTV database for the presence of the same variation in >1000 MTBC 
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genomes (accessed March 2015). Eleven of the 247 SNPs were found not to be 
SNPs relative to H37Rv (Table 2.6, Appendix A.2). Of the 236 remaining positions, 
210 SNPs were present in at least one other strain and 26 were not present in any 
other isolates, and thus represent putative RS-SNPs. Nearly two-thirds of all SNPs 
were non-synonymous SNPs (nsSNPs) (150/236, 63.5%), consistent with that 
typically reported for M. tuberculosis (Fleischmann et al. 2002; Hershberg et al. 
2008; Rose et al. 2013). A similar proportion of nsSNPs were observed for the 
RS-SNP subset (16/26, 61.5%). 
 
Table 2.6. Classification of 247 common Rangipo SNPs. SNPs classified as Rangipo 
specific were not present in >1000 M. tuberculosis isolates in the GMTV database. 
Classification sSNPs nsSNPs Total 
Not a SNP relative to H37Rv – – (11) 
Present in at least one other strain 76 134 210 
Rangipo specific SNP (RS-SNPs) 10 16 26 
Total 86 150 236 
 
Amino acid sequences of the 16 proteins with RS-nsSNPs were submitted to 
BLAST to search other M. tuberculosis proteins for the same amino acid changes. 
This identified two amino acid changes (Rv0071 R67L and Rv1860/apa T146N) 
shared by the Rangipo strain and three M. tuberculosis isolates from Canada – 
SUMu002, SUMu004 and SUMu005.  
The Canadian SUMu genomes carrying the Rv0071 and Rv1860 variants are from 
three of 12 M. tuberculosis isolates from Aboriginal communities in Western 
Canada sequenced using Roche 454 whole genome shotgun methodology 
(Pepperell et al. 2013). All 12 SUMu genomes are publicly available as contigs 
(raw fastq were files not available). These were downloaded and mapped to the 
H37Rv reference genome in Geneious R8 and all 26 putative RS-SNP positions 
were manually examined. SNPs in Rv0071 and Rv1860 were found to match those 
in the Rangipo strain, and two additional synonymous Rangipo SNPs; 
Rv1088676CT in Rv0976c and Rv2491388CT in Rv2221c/glnE, were also present. 
These four SNPs were all found in the SUMu002, SUMu004 and SUMu005 
genomes, but not in any other Canadian SUMu genomes.  
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Excluding these four SNPs, a final list of 22 RS-SNPs was produced (Appendix 
A.2). Fourteen of these were non-synonymous and thus have potential effects on 
protein function and bacterial fitness (Table 2.7).  
 
Table 2.7. Non-synonymous Rangipo specific SNPs. 
SNP Locus  aa change Gene product 
Rv3253CG Rv0002/dnaN P401R DNA polymerase III beta sliding clamp subunit dnaN 
Rv489437CT Rv0405/pks6 S1236L Probable membrane bound polyketide synthase Pks6 
Rv550620GT Rv0458 D316Y Probable aldehyde dehydrogenase 
Rv1289731TC Rv1161/narG Y802H Respiratory nitrate reductase alpha chain NarG 
Rv1836099TG Rv1631/coaE Y363D Dephospho-CoA kinase CoaE  
Rv2807374GC Rv2492 G33R Hypothetical protein 
Rv3202633GA Rv2893 G72S Possible oxidoreductase 
Rv3283879TC Rv2941/fadD28 V182A Long-chain-fatty-acid-AMP ligase FadD28  
Rv3366098GA Rv3007c P118L Possible oxidoreductase 
Rv3561770AG Rv3193c L468S Probable conserved transmembrane protein  
Rv3895925GA Rv3479 A36T Possible transmembrane protein 
Rv3980075CA Rv3540c/ltp2 E195D Probable lipid transfer protein or keto acyl-CoA thiolase ltp2 
Rv4085870GA Rv3646c/topA T463M DNA topoisomerase I topA 
Rv4377908CT Rv3894c/eccC2 G849S EESX-2 type VII secretion system protein eccC2 
 
The final RS-SNP list excluded two SNPs previously used as diagnostic markers; 
Rv2819180CT in Rv2504c/scoA and Rv3485475AG in Rv3119/moaE1 (Ruthe 
2015), as these were identified in other isolates in the GMTV database. The third 
diagnostic marker SNP Rv2067836GA in Rv1821/secA2, was not identified in any 
other isolates and remains classified as an RS-SNP. This was further validated by 
comparison against 220 M. tuberculosis L4.4 genomes in Chapter Four (Section 
4.3.2.2).  
One RS-nsSNP (Rv489437CT in Rv0405/pks6) and one SUMu shared SNP 
(Rv79685GT in Rv0071) have previously been validated in the Rangipo strain 
(Ruthe 2015). In this work, the remaining 13 RS-nsSNPs were confirmed by Sanger 
sequencing (Section 2.1.4). 
  
Chapter Two  
41 
2.2.2.1 Gene functional categories 
Functional categories for genes carrying all 236 Rangipo SNPs were assigned using 
the Tuberculist database (Lew et al. 2011). Of the SNPs common to the Rangipo 
strain, genes in cell wall and cell processes were the most highly represented 
accounting for 27.5% of all SNPs (65/236), and 30.0% of nsSNPs (45/150) (Table 
2.8). This was followed by the intermediary metabolism and respiration category, 
which accounted for 21.2% of all SNPs (50/236) and 20.7% of nsSNPs (31/150). 
Genes in the intermediary metabolism and respiration category were the most 
highly represented among the RS-SNPs accounting for 31.8% of all RS-SNPs 
(7/22) and 35.7% of RS-nsSNPs (5/14); followed by cell wall and cell processes, 
22.7% of all RS-SNPs (5/22), and 21.4% of RS-nsSNPs (3/14). The proportion of 
genes involved in lipid metabolism and in intermediary metabolism and respiration 
were enriched ~1.7-fold in the RS-nsSNP subset compared to the full set of nsSNPs. 
These two functional categories collectively accounted for 57.1% (8/14) of variant 
genes unique to the Rangipo strain; an approximate two-fold enrichment relative to 
their overall proportion of 28% in the M. tuberculosis genome (Camus et al. 2002) 
(Table 2.8). Genes involved in lipid metabolism were particularly over represented. 
This category accounting for 12.0% of common Rangipo nsSNPs (18/150) and  
21.4% RS-nsSNPs (3/14), a two- and 3.5-fold enrichment, respectively, compared 
an overall proportion of just 6% in the M. tuberculosis H37Rv genome. 
Although no RS-SNPs were identified in genes classified in the virulence, 
detoxification, adaptation functional category, four RS-nsSNPs occurred in genes 
encoding virulence factors listed in the PATRIC_VF and/or the VFDB databases: 
Rv0405/pks6, Rv1161/narG, Rv3540c/ltp2, and Rv2941/fadD28. 
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Table 2.8. Functional categories of genes harbouring Rangipo SNPs. 
 Common Rangipo SNPs  Rangipo specific SNPs 
H37Rv1 
Gene Functional Category sSNPs nsSNPs All SNPs  sSNPs nsSNPs All SNPs 
Cell wall and cell processes 20 (23.3%) 45 (30.0%) 65 (27.5%)  2 (25.0%) 3 (21.4%) 5 (22.7%) 18% 
Conserved hypotheticals 16 (18.6%) 24 (16.0%) 40 (16.9%)  2 (25.0%) 1 (7.1%) 3 (13.6%) 26% 
Information pathways 7 (8.1%) 17 (11.3%) 24 (10.2%)  1 (12.5%) 2 (14.3%) 3 (13.6%) 6% 
Insertion seqs and phages2 2 (2.3%) 1 (0.7%) 3 (1.3%)  0 0 0 4% 
Intermediary metabolism and respiration 19 (22.1%) 31 (20.7%) 50 (21.2%)  2 (25.0%) 5 (35.7%) 7 (31.8%) 22% 
Lipid metabolism 10 (11.6%) 18 (12.0%) 28 (11.9%)  1 (12.5%) 3 (21.4%) 4 (18.2%) 6% 
Regulatory proteins 7 (8.1%) 9 (6.0%) 16 (6.8%)  0 0 0 5% 
Virulence, detoxification, adaptation 5 (5.8%) 5 (3.3%) 10 (4.2%)  0 0 0 2% 
Total 86  150  236  8 14 22 (89%) 
1  Percentage of genes in each functional category in the H37Rv reference genome as reported in Camus et al. (2002) 
2  This gene category is underrepresented as the majority were excluded from SNP calling analyses due to the difficulties with mapping repetitive regions  
of the genome. 
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2.2.2.2 SNP functional effect prediction 
SNAP2 is a freely available machine learning based classifier trained to distinguish 
between effect and neutral amino acid variations (Hecht et al. 2015). It considers a 
variety of sequence and variant features, including automatically generated multiple 
sequence alignments (which provide the most important signal), structural features, 
and annotations if available, to predict whether or not a single amino variant 
changes molecular function. For each residue and possible substitution, the program 
calculates an output score ranging from -100 (strong neutral) to +100 (strong 
effect), reflecting the likelihood that a specific mutation alters protein function, as 
well as the expected accuracy of the prediction.  
All 14 RS-nsSNPs were analysed with SNAP2 to identify those with predicted 
functional effects. Eight SNPs were predicted to have an effect, including those in 
the virulence-associated proteins Rv0405/pks6 and Rv1161/narG (Table 2.9). 
Around two-thirds of SNPs predicted to have functional consequences were found 
in genes involved in intermediary metabolism and respiration (Rv0458, 
Rv1161/narG, Rv1631/coaE, Rv2893 and Rv3007c). This gene functional category 
was also over represented among RS-nsSNPs compared with the proportion of 
genes in category in the M. tuberculosis genome (Section 2.2.2.2). The remaining 
three SNPs predicted to have an effect were found in genes involved in cell wall 
and cell processes (Rv3894c/eccC2), conserved hypotheticals (Rv2492), and in 
lipid metabolism (Rv0405/pks6).  
The highest ranked SNP in terms of predicted effect, Y363D in Rv1631/CoaE, was 
further examined in silico (Section 2.2.2.3). The Rv2893 G72S SNP was also 
further examined (Section 2.2.2.4) and is the subject of biochemical and structural 
investigation in Chapter Three. 
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Table 2.9. SNAP2 functional effect predictions for RS-nsSNPs. SNAP2 output is shown in 
the predicted effect, score and expected accuracy columns. Known virulence factor genes 
are listed in bold type. SNPs are ranked according to effect prediction score.  
Locus SNP Predicted Effect Score 
Expected 
Accuracy 
Gene Functional 
Category 
Rv1631/coaE Y363D effect 87 91% 
Intermediary 
metabolism and 
respiration 
Rv1161/narG Y802H effect 80 91% 
Intermediary 
metabolism and 
respiration 
Rv2492 G33R effect 79 85% Conserved hypotheticals 
Rv3007c P118L effect 59 75% 
Intermediary 
metabolism and 
respiration 
Rv0405/pks6 S1236L effect 46 71% Lipid metabolism 
Rv2893 G72S effect 28 63% 
Intermediary 
metabolism and 
respiration 
Rv3894c/eccC2 G849S effect 20 63% Cell wall and cell processes 
Rv0458 D316Y effect 14 59% 
Intermediary 
metabolism and 
respiration 
Rv3646c/topA T463M neutral -5 53% Information pathways 
Rv3193c L468S neutral -17 57% Cell wall and cell processes 
Rv0002/dnaN P401R neutral -26 61% Information pathways 
Rv3540c/ltp2 E195D neutral -67 82% Lipid metabolism 
Rv2941/fadD28 V182A neutral -77 87% Lipid metabolism 
Rv3479 A36T neutral -80 87% Cell wall and cell processes 
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2.2.2.3 Rv1631/coaE Y363D SNP 
The Y363D SNP in Rv1631/coaE was predicted as the most significant SNP in 
SNAP2 analyses (Section 2.2.2.2). Examination of M. tuberculosis CoaE domain 
architecture in PFAM shows it is comprised of an N-terminal catalytic 
dephosphocoenzyme A kinase (CoaE) domain and a C-terminal GrpB domain 
(Figure 2.2A). The Y363D SNP is located in the GrpB domain 45 residues from the 
C-terminus. The GrpB PFAM HMM logo reveals that the Y363D SNP changes one 
of four highly conserved residues comprised of two tyrosines and two lysines 
(Y-K-Y-K) near the C-terminal end of the domain (Figure 2.2B).  
 
 
Figure 2.2. Domain structure of M. tuberculosis CoaE and position of the Y363D 
RS-nsSNP. (A) PFAM domain architecture shows Y363D is located in the GrpB domain 
45 bp from the C-terminal end of the protein. (B) The PFAM HMM logo for the GrpB 
domain shows four highly conserved Y-K-Y-K residues at the C-terminal end of this 
domain. Y363D changes the first of these conserved sites and is highlighted by a red box.  
 
The GrpB domain family is suggested to belong to the nucleotidyltransferase 
superfamily (Kuchta et al. 2009). This is a large and diverse family of proteins, 
nearly all of which catalyse the transfer of a nucleotide to an acceptor hydroxyl 
group (Kuchta et al. 2009). There are no structures available for M. tuberculosis 
CoaE and the only crystal structure of a GrpB domain is that of conserved protein 
GrpB of unknown function from Enterococcus faecalis (PDB ID: 2NRK). 2NRK 
shares 24% identity with the GrpB domain of M. tuberculosis CoaE, including the 
four conserved Y-K-Y-K residues and two sites identified as catalytic residues on 
the basis of structural homology (Asp52 and His99) (Kuchta et al. 2009) (Figure 
2.3A). The Rangipo Y363D SNP position corresponds to Tyr131 in the 2NRK 
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structure. Examination of 2NRK shows the conversed Y-K-Y-K residues are 
positioned adjacent to one another on two neighbouring alpha helixes forming a 
highly conserved motif (Figure 2.3). The highly conserved nature and chemical 
properties of the Y-K-Y-K motif and its position across from the active site Asp52 
and His99 residues suggests this motif might be important for substrate binding in 
the GrpB protein family. However, in M. tuberculosis CoaE the only currently 
assigned function of the GrpB domain is in the proper protein folding of the enzyme 
and the last 50 residues at the C-terminus (including the Y363D SNP and all four 
conserved Y-K-Y-K residues) are dispensable for proper folding and full catalytic 
activity in vitro (Walia et al. 2009). Therefore this SNP may be less likely to affect 
CoaE activity than expected based on the prediction from SNAP2.  
 
 
Figure 2.3. The conserved protein GrpB from E. faecalis (2NRK). The position of 
conserved Y-K-Y-K residues are indicated. The position of the Y363D RS-SNP 
corresponds to residue Tyr131 in 2NRK. (A) Sequence alignment and secondary structure 
elements of the M. tuberculosis CoaE GrpB domain and 2NRK. A black arrow indicates 
the position of Y363D. Catalytic residues Asp52 and His99 are highlighted in grey and the 
conserved Y-K-Y-K residues in orange. Secondary structure elements (alpha helixes red, 
beta sheets blue) were predicted using JPred4. (B) The 2NRK structure showing the 
position of the Y-K-Y-K motif and catalytic residues.  
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2.2.2.4 Rv2893 G72S SNP 
Rv2893 is predicted to be a F420-dependent oxidoreductase and belongs to the 
luciferase like hydride transferase (LLHT) family of enzymes (previously known 
as luciferase like monooxygenases) (Selengut and Haft 2010). A PDB protein 
sequence search was performed to identify deposited structures with sequence 
similarity to Rv2893 (accessed 2015). Four of the top five unique protein hits were 
for F420-dependent LLHTs; F420-dependent glucose-6-phosphate dehydrogenase 
from M. tuberculosis (mtbFGD, PDB ID: 3B4Y and 3C8N) (Bashiri et al. 2008), 
methylenetetrahydromethanopterin reductase from Methanosarcina barkeri  
(bMer, 1Z69) (Aufhammer et al. 2005), Mer from Methanobacterium 
thermoautotrophicum (tMer, 1F07), and Mer from Methanopyrus kandleri (kMer, 
1EZW) (Shima et al. 2000). These share 21-32% protein sequence identity with 
Rv2893. All remaining proteins identified were non-F420-dependent LLHTs.  
A sequence alignment of Rv2893 with mtbFGD, bMer, tMer, kMer and 
MSMEG_2516 (the Mycobacterium smegmatis homologue of Rv2893) shows 
Rv2893 has the conserved glycine in position 179 that enables binding of the 
phosphate group of F420 without steric hindrance (Aufhammer et al. 2004), 
consistent with it being an F420-dependent protein (Figure 2.4). Rv2893 also retains 
the conserved active site histidine (His48) and a second histidine occupies the site 
of the catalytic glutamate (His109) (His40 and Glu109 in mtbFGD (Oyugi et al. 
2016)). The Rangipo G72S SNP site corresponds to Gly71 in mtbFGD and is 
conserved in the alignment. In mtbFGD, Gly71 is positioned two residues from 
Ser73 and Val74, which are connected by a rare non-prolyl cis-peptide bond 
(Bashiri et al. 2008). Examination of the mtbFGD structure shows Gly71 is 
positioned at the end of a beta sheet next to the base of the non-prolyl cis-peptide 
bond (Figure 2.5). This cis-peptide bond is found in other F420-LLHTs and is 
important for F420 binding and catalysis. It creates a bulge that packs against the 
Re-face of F420 that helps induce a butterfly bend in the ring system of F420, 
increasing the reactivity of the C5 atom (which is oxidised or reduced in the 
reaction) (Aufhammer et al. 2004; Aufhammer et al. 2005; Bashiri et al. 2008; 
Shima et al. 2000). The location of the G72S mutation near at the base of this bulge 
could have important consequences for F420-binding and catalysis via influence on 
the bulge and its interaction with F420.  
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Figure 2.4. Multiple sequence alignment of F420-dependent of bacterial LLHT family 
proteins. Sequences are shown for M. tuberculosis Rv2893, the M. smegmatis orthologue 
MSMEG_2516, and three F420-dependent LLHTs identified by sequence similarity 
searches in the PDB (mtbFGD, kMER, tMer and bMER). Catalytic resides (mtbFGD His40 
and Glu109) and the conserved glycine that differentiates F420 -binding LLHTs are marked 
with red boxes and asterisks. The Rangipo specific G72S mutation is marked by a blue box 
and asterisk. Only the first 196 residues of Rv2893 are shown. 
 
 
Figure 2.5. Corresponding position of the Rangipo G72S SNP site in M. tuberculosis FGD 
(3B47). The non-prolyl cis-peptide bond linking Ser73 and Val74 is indicated and Gly71, 
(position of the Rangipo SNP), is shown in red and labelled. F420 is coloured yellow. 
  
Chapter Two  
49 
2.2.3  Lineage classification 
MIRU-VNTR-based lineage assignment was performed using the 
MIRU-VNTRplus database. This classified the Rangipo, Otara and NZ_094 
clusters as belonging to the S lineage, Southern Cross and NZ_037 as LAM, and 
NZ_041 and NZ_069 as H37Rv-like. 
 
2.2.3.1 S lineage classification PCR-RFLP assay 
The S lineage, or ‘S-type’, was originally classified based on traditional molecular 
typing methods and is equivalent to the L4.4.1.1/S sublineage described in a recent 
high-resolution SNP phylogeny (Coll et al. 2014). L4.4.1.1/S belongs to the L4.4 
sublineage of the L4/Euro-American lineage and L4.4 comprises three clades; 
L4.4.1.1/S, L4.4.1.2 and L4.4.2. L4.4 is reported to account for 10% of global L4 
isolates and is the most common L4 sublineage in New Zealand, accounting for 
43% of L4 cases (Stucki et al. 2016b).  
To confirm the assignment of the Rangipo, Otara and NZ_094 clusters to the S 
lineage and to provide a fast and affordable method to identify other S lineage 
isolates, a SNP-based RFLP-PCR assay was designed. WatCut identified that the 
S-type marker SNP Rv648992CG described by Homolka et al. (2012) is selectively 
recognised using the restriction enzyme BstNI. A 343 bp product spanning the 
S-type Rv648992CG marker SNP was amplified by PCR and digested with BstNI. 
Sanger sequencing of the PCR product confirmed the correct 343 bp fragment had 
been amplified and the presence of the marker SNP in the Rangipo strain. Digestion 
with BstNI gave the expected fragments of 205 and 138 bp for S-type, and 138, 151 
and 54 bp for non-S-type, allowing classification of isolates as S lineage or non-S 
(Figure 2.6A,B). Due to size similarity, the 138 and 151 bp fragments for non-S 
isolates migrated as a single band on the gel. This assay was used to screen New 
Zealand M. tuberculosis cluster isolates (Figure 2.6C). The Rangipo, Otara and the 
NZ_094 clusters were all classified as belonging to the S lineage and Southern 
Cross and the remaining clusters as non-S, consistent with MIRU-VNTR based 
lineage assignment. 
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Figure 2.6. S lineage PCR-RFLP assay. (A) Schematic showing positions the BstNI 
recognition sequences (arrows) and expected fragment sizes. (B) Agarose gel showing 
uncut PCR products and digested fragments for non-S (H37Rv) and S lineage (Rangipo A) 
isolates. (C) S lineage typing of New Zealand M. tuberculosis cluster isolates. 
MIRU-VNTR cluster ID is shown above the lane number (lanes 1-3, NZ_041; 4-6, 
NZ_069; 7-12, Rangipo; 13-15, Otara; 16-18, Southern Cross; 19-21, NZ_037; 22-24, H, 
reference strain H37Rv; N, PCR negative control).  
 
 
2.2.4 DS6Quebec deletion 
BLAST searches identified two SNPs shared only with Rangipo and three 
M. tuberculosis SUMu genomes from Aboriginal communities in Canada (Section 
2.2.1). The most common M. tuberculosis lineage in Western Canadian Aboriginal 
populations and in French Canadian populations in Quebec is the DS6Quebec strain 
family (Pepperell et al. 2011). Spoligotyping patterns of DS6Quebec isolates show 
that this strain family belongs to the S lineage (Nguyen et al. 2003). The DS6Quebec 
family is characterised by the presence of a large genomic deletion called the 
DS6Quebec deletion. This removes ~11.4 kb between positions 1987457 and 
1998849, replacing it with an IS6110 element (Nguyen et al. 2004) (Figure 2.7). A 
similar but evolutionarily independent ~12 kb deletion (positions 1986636 to 
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1998621) known as the RD152 deletion is also found in the hypervirulent 
Beijing/W strain (Tsolaki et al. 2005). 
 
 
Figure 2.7. Schematic of the DS6Quebec and RD152 deletions. Genomic regions present in 
H37Rv that are deleted by the DS6Quebec deletion and the RD152 deletion in the Beijing/W 
strain are shown in blue and green, respectively.  
 
All 12 M. tuberculosis SUMu genomes were examined for the presence of S lineage 
marker SNPs (Table 2.1) and evidence of the DS6Quebec deletion, as indicated by 
absence of coverage over the region. Eight of these genomes, including the three 
sharing SNPs with the Rangipo strain, had the DS6Quebec deletion and belong to the 
S lineage. The remaining four genomes were non-S lineage and did not have the 
DS6Quebec deletion. The identification of Rangipo SNPs shared with a subset of 
S lineage/DS6Quebec SUMu isolates suggested that the Rangipo strain might have a 
close phylogenetic relationship with the Canadian DS6Quebec lineage and harbour 
the DS6Quebec deletion. 
PCR assays were used to screen Rangipo and other New Zealand M. tuberculosis 
cluster isolates for the DS6Quebec deletion (Figure 2.8). A multiplex PCR was used 
to first identify isolates with deletions in the DS6 region using forward and reverse 
primers external to the deletion together with an internal reverse primer (Figure 
2.8A,C,D). If an isolate has the DS6Quebec deletion, a large 1836 bp product is 
amplified from the external primers. If the region is not deleted, a short 250 bp 
product is amplified from the external upstream and the internal primer, and the 
external primers will not amplify as the genomic distance between them is too large 
(11.9 kb). Two separate DS6Quebec-IS6110 insertion-specific PCRs as described in 
Nguyen et al. (2004) where then performed (Figure 2.8B,C,E). These use external 
deletion flanking primers that include 5 bp of the end of the IS6110 sequence and 
20 bp of the sequence flanking the deletion, so that amplification will only occur if 
IS6110 insertion has occurred at exactly the same site (Figure 2.8B,E). 
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Figure 2.8. DS6Quebec deletion PCR assays. (A) DS6Quebec multiplex PCR. Expected PCR 
product indicating deletion of the DS6Quebec region is shown in blue and in red if the region 
is not deleted. Primer binding sites are indicated by black triangles. Not to scale. (B) 
DS6Quebec-IS6110 insertion-specific verification of the DS6Quebec deletion. Note that due to 
the direction of the IS6110 insertion, the IS6110 3′ primers amplify the 5′ flank of the 
deletion and the IS6110 5′ primers amplify the 3′ flank. (C) Schematic showing theoretical 
PCR products for the DS6Quebec multiplex (M) and DS6Quebec IS6110 insertion-specific 
PCRs (3′ and 5′) for strains harbouring the DS6Quebec deletion and for H37Rv. (D) DS6Quebec 
multiplex PCR amplification products. A, Rangipo A; 10, Rangipo 10; H, H37Rv; N, PCR 
negative control. (E) DS6Quebec-IS6110 insertion-specific PCR amplification products. The 
absence of a PCR product for Rangipo A in the multiplex PCR is likely due to DNA 
degradation preventing amplification of the large 1836 bp product. 
Chapter Two  
53 
Sanger sequencing confirmed the correct products had been amplified and the 
presence of the DS6Quebec deletion in the Rangipo strain. Rangipo isolate A 
produced bands of the correct sizes for both insertion-specific PCRs but failed to 
amplify in the multiplex PCR (Figure 2.8D,E). This is likely due to DNA 
degradation preventing amplification of the large 1836 bp product as LabPLUS 
Rangipo samples amplified in the large multiplex PCR product as expected for 
isolates carrying the deletion (Figure 2.8D, Figure 2.9A). 
New Zealand M. tuberculosis cluster isolates were screened with the multiplex 
PCR. Isolates from the Rangipo, Otara and NZ_094 clusters all gave a band of the 
expected size for the DS6Quebec deletion and insertion-specific PCRs confirmed the 
deletion occurred at the exact same site as in the DS6Quebec strain family (Figure 
2.9). All Southern Cross and NZ_037 isolates and a single NZ_041 isolate failed to 
amplify in the multiplex PCR, despite repeated attempts. The remaining isolates 
from NZ_041 and all NZ_069 isolates gave the expected sized band for the absence 
of the deletion. The NZ_041 isolate that failed to amplify, one Southern Cross, and 
one NZ_037 isolate were also screened with the insertion-specific PCRs to ensure 
amplification failure was not the result of DNA degradation impairing amplification 
of long product. Neither the Southern Cross nor NZ_037 isolates amplified in either 
PCR reaction, confirming these clusters do not carry the DS6Quebec deletion. The 
NZ_041 isolate did not amplify for the 5¢ insertion-specific PCR, but gave a band 
of the correct size for the 3¢ insertion-specific PCR. This genomic region contains 
multiple mobile elements and is known to be highly variable and associated with 
frequent IS6110 insertion (Ho et al. 2000). The failure of these isolates to amplify 
in either a DS6Quebec or H37Rv-like manner suggests an alternative deletion or 
IS6110 insertion in this region.  
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Figure 2.9. DS6Quebec deletion PCR assay typing of New Zealand M. tuberculosis cluster 
isolates. MIRU-VNTR cluster ID is shown above the lane number. (A) DS6Quebec deletion 
multiplex PCR (lanes 1-3, NZ_041; 4-6, NZ_069; 7-12, Rangipo; 13-15, Otara; 16-18, 
Southern Cross; 19-21, NZ_037; 22-24, H, H37Rv; N, PCR negative control). (B,C) 
DS6Quebec-IS6110 insertion-specific PCR for the 5¢ (B) and 3¢ (C) ends of the deletion. Lane 
numbers correspond to isolates assayed in the multiplex PCR. 
 
 
2.2.5 Rangipo diagnostic  
Based on the reclassification of Rangipo SNPs (Section 2.2.1) and WGS of 
additional New Zealand cluster isolates (Chapter Four), a Rangipo specific 
SNP-based multiplex PCR-RFLP diagnostic assay previously developed in this 
laboratory (Ruthe 2015) was re-evaluated and updated. Reclassification of Rangipo 
SNPs identified the original diagnostic marker 1380G>A in Rv1821/secA2 
(Rv2067836GA) as specific to the Rangipo strain. Analysis of Illumina WGS data 
confirmed the presence of this SNP in a further 18 Rangipo genomes and its absence 
in 220 non-Rangipo L4.4 genomes (Section 4.3.2.2). An updated search in the 
GMTV database did not identify this SNP in 2501 global MTBC genomes 
(accessed August 2018).  
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2.2.5.1 Rangipo PCR-RFLP assay  
A revised RFLP-PCR diagnostic for the Rangipo specific Rv1821/secA2 SNP was 
developed to enable affordable and rapid identification of this strain. A 455 bp 
product PCR spanning the SNP was amplified and Sanger sequencing confirmed 
the correct fragment had been amplified. Digestion of this PCR product with the 
restriction enzyme MboI gave the expected fragments of 386 and 69 bp for Rangipo, 
and 215, 171 and 69 bp for non-Rangipo, allowing Rangipo and non-Rangipo 
isolates to be easily distinguished (Figure 2.10A,B).  
This assay was experimentally validated on 28 isolates sequenced on the ABI 
SOLiD and/or Illumina platforms and 39 additional M. tuberculosis isolates 
including New Zealand cluster isolates and isolates from various MTBC lineages 
and L4 sublineages (Figure 2.10C,D). One sample (Figure 2.10D, lane 12) 
classified as Rangipo by MIRU-VNTR typing produced the non-Rangipo banding 
pattern. This isolate was from a case that likely contracted tuberculosis overseas 
(Ruthe 2015), supporting the non-Rangipo diagnosis and highlighting the greater 
discriminatory power of SNP-based typing over conventional MIRU typing. All 
remaining isolates gave the expected fragments for Rangipo and non-Rangipo 
isolates. 
A total of 39 Rangipo isolates have been typed by WGS or PCR-RFLP for the 
Rv1821/secA2 SNP in this study and in previous work (Ruthe 2015) and all harbour 
the Rangipo specific variant. These isolates span a 26-year period (1991–2017) and 
include isolates from a range of geographic locations throughout New Zealand, and 
are expected to provide a good representative sample of this cluster. The 
phylogenetic analyses performed in Chapter Four show this SNP is a 
phylogenetically informative SNP specific to the Rangipo strain, further supporting 
its suitability for use as a diagnostic marker. 
A paper describing this diagnostic assay has been published in Diagnostic 
Microbiology and Infectious Disease (Mulholland et al. 2017) (Appendix D). 
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Figure 2.10. Rangipo strain specific PCR-RFLP diagnostic assay. (A) Schematic showing 
positions of the MboI recognition sequences (arrows) on the PCR product and the resulting 
fragment sizes for Rangipo and non-Rangipo samples. (B) PCR-RFLP assay showing uncut 
PCR products and digested fragments of non-Rangipo (Non-R) and Rangipo (R) PCR 
products. (C) Digested fragments from New Zealand clinical M. tuberculosis isolates 
sequenced on the Illumina and/or ABI SOLiD platform. Isolates with Rangipo 
MIRU-VNTR typing profiles are shown in red text. (Lanes 1-16, Rangipo; 17-21, Southern 
Cross; 22-28, Otara). (D) New Zealand clinical M. tuberculosis isolates and isolates from 
major MTBC lineages and other from lineage 4 sublineages. Isolates with Rangipo 
MIRU-VNTR typing profiles are shown in red text. (Lanes 1-3, NZ_041; 4-6, NZ_069; 7-
12 Rangipo; 13-15, Otara; 16-18 Southern Cross; 19-21, NZ_037; 22-25, NZ_094; 26, 
L1/EAI; 27-29, L2/Beijing; 30, L3/CAS; 31, Cameroon (L4); 32, Ural (L4); 33, Iran (L4); 
34, Uganda (L4); 35, PGG3 (L4); 36, X (L4); 37, LAM (L4); 38, Haarlem (L4); 39, H37Rv 
(L4)). 
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2.2.5.2 Evaluation of the Rangipo diagnostic in a clinical setting 
The Rangipo diagnostic was evaluated using culture independent DNA from heat 
inactivated sputum samples from a small local Rangipo strain outbreak in 
2017/2018. Four samples were provided by the Waikato Hospital (Hamilton, New 
Zealand), including two non-Rangipo control cases. The PCR-RFLP assay was 
performed as for extracted gDNA, with the exception that heat inactivated 
supernatant from sputum specimens was directly input into the PCR instead of 
gDNA (Section 2.1.8.2). Samples 1 and 2 were both diagnosed as Rangipo and 
samples 3 and 4 as non-Rangipo (Figure 2.11). Consistent with these results, 
MIRU-VNTR typing at LabPLUS confirmed Sample 1 and 2 as Rangipo 
(MIRU-VNTR 24-locus code, 233325153324–341444223362) and 3 and 4 as 
non-Rangipo (223325173533–445643423382). PCR-RFLP results were available 
within 24 hrs, however this could be further reduced for samples received early in 
the day. 
These results have been published in the New Zealand Medical Journal (Mulholland 
et al. 2018) (Appendix D). 
 
   
Figure 2.11. Rangipo PCR-RFLP diagnostic screening of clinical sputum samples. Lane 1, 
uncut Rangipo control; 2, uncut non-Rangipo control (H37Rv); 3 and 4, clinical sputum 
samples diagnosed as Rangipo by this assay (samples 1 and 2); 5 and 6, clinical sputum 
samples diagnosed as non-Rangipo (samples 3 and 4); 7, Rangipo control isolate after 
digestion; 8, Non-Rangipo control after digestion; 9, PCR negative control. 
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2.3  Discussion 
The Rangipo strain has been the source of several large outbreaks over the past 30 
years and anecdotal evidence suggests that it is highly transmissible (Colangeli et 
al. 2014; De Zoysa et al. 2001; McElnay et al. 2004). Analysis of contact tracing 
results of previous Rangipo strain outbreaks revealed a higher proportion of traced 
contacts with active disease and a lower proportion with latent infection compared 
to average contact tracing estimates (Section 2.2.1). The portion of infected cases 
with active disease also exceeded the 5–10% of infections typically expected to 
progress to active disease. The skew towards active disease and the relatively low 
proportion of contacts with latent infection suggests that the Rangipo strain might 
not necessarily be more infectious, but that a greater proportion of infected contacts 
progress to active disease.  
Bacterial, host and environmental factors can all influence the outcome of 
M. tuberculosis infection and as active pulmonary tuberculosis is required for 
transmission to occur, progression to active disease is relevant when considering 
tuberculosis transmission. De Jong et al. (2008) have reported strain specific 
differences in progression to active disease, demonstrating a role of bacterial 
genetic background in disease progression and the outcome of infection. While this 
preliminary analysis hints that Rangipo strain infections may be more likely to 
progress to active disease supporting the notion that this strain is highly virulent, it 
is limited by the absence of a control group/strain and heterogeneity among contact-
tracing methodologies, including those used to estimate average tuberculosis 
incidence among contacts (Fox et al. 2013). Latent infection could also potentially 
be underestimated due to limitations of methods for identifying latent infections 
(Al-Orainey 2009).  
Host factors also undoubtedly play an important role in the success of this strain. 
For example, prison incarceration is a common factor noted among Rangipo strain 
cases (De Zoysa et al. 2001) and is a known tuberculosis risk factor (Baussano et 
al. 2010). The Rangipo strain is predominantly found in Māori and inequalities 
facing this population such as household crowding, socioeconomic deprivation and 
cigarette smoking are also likely to influence transmission and outcome of 
infection. Further work should seek to examine transmission and rates of 
progression to active disease compared to other circulating strains to better 
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understand its epidemiology, along with laboratory testing to investigate its 
presumed high virulence. 
 
2.3.1 Rangipo SNPs 
To investigate potential bacterial genetic factors that may influence the 
pathogenicity of the Rangipo strain and to identify targets for further biochemical 
analysis, I sought to identify nsSNPs specific to this strain. Colangeli et al. (2014) 
identified 247 SNPs shared by ten Rangipo strain isolates collected from  
1991–2011 sequenced on the ABI SOLiD platform. All of these SNPs have 
previously been crosschecked against 38 MTBC genomes in publicly available 
databases to identify SNPs specific to the Rangipo strain (Ruthe 2015). Since that 
analysis was performed, the number of strains available for comparison has 
increased dramatically. In this work, reclassification against >1000 M. tuberculosis 
genomes decreased the total number of RS-SNPs from 99 to 22, and the number of 
RS-nsSNPs from 61 to 14. Having a large number of strains available for 
comparison is particularly important for the identification of diagnostic marker 
SNPs as it is essential SNPs are specific to the strain of interest to prevent 
misclassification. Of three putative RS-SNPs that have previously been proposed 
as diagnostic makers for the Rangipo strain (Ruthe 2015) only one, 1380G>A in 
Rv1821/secA, remained classified as a RS-SNP in this work and was validated as a 
suitable diagnostic marker for Rangipo. 
SNPs unique to the Rangipo strain, particularly those with in silico predicted 
functional effects, were predominantly located in genes involved in intermediary 
metabolism and respiration and lipid metabolism. A recent study by Gautam et al. 
(2017) sequenced nine Rangipo strain isolates on the Illumina platform and found 
nsSNPs common to Rangipo isolates were also predominantly located in genes with 
metabolic functions (Gautam et al. 2017). In the host granuloma, the bacterium 
experiences various stresses such as nutrient and oxygen depletion, requiring 
metabolic changes to circumvent nutritional shortages and to adapt to hypoxic 
conditions. The ability of M. tuberculosis to adapt to such hostile environmental 
changes during the course of infection underlies much of its success as a pathogen 
(Cook et al. 2009). Genes involved in basic cellular metabolism are generally not 
considered virulence factors, however other metabolic processes such as lipid 
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metabolism are important virulence determinants as during the course of infection 
the bacterium shifts from utilising carbon sources such as glucose, to fatty acids and 
host lipids (Schnappinger et al. 2003). Various lipids and glycolipids are also 
incorporated into the cell envelope where they are thought to be important for 
bacterial pathogenicity (Neyrolles and Guilhot 2011). 
Determining the functional consequences of SNPs is important in understanding 
how genetic variation in the MTBC impacts bacterial fitness and virulence. In vitro 
biochemical and in vivo characterisation of variants provide the ultimate 
experimental evidence of variant effects. However, these methods are laborious and 
the functions of many MTBC proteins remain unknown making such investigations 
challenging. Computational approaches can identify SNPs with putative molecular 
effects enabling large numbers SNPs to be examined in silico. Such approaches do 
not connect effect at the molecular level to “impact on organism”, but rather can be 
used to inform the selection of candidate variants for experimental analysis (Hecht 
et al. 2015).  
Eight SNPs unique to the Rangipo strain were predicted in silico to affect molecular 
function including two in the virulence factors narG and pks6. narG encodes the 
catalytic a-subunit NarG of the membrane bound multi-subunit nitrate reduction 
complex NarGHJI. This complex catalyses the respiratory reduction of nitrate 
(NO3-) to nitrite (NO2-), enabling nitrate to be used in place of oxygen as the final 
electron acceptor in the electron transport chain. M. tuberculosis is one of the 
strongest nitrate reducers amongst mycobacteria and the nitrate reductase system is 
implicated in M. tuberculosis virulence (reviewed in Khan and Sarkar 2012). pks6 
encodes a predicted polyketide synthase Pks6. Polyketide synthases are large 
multi-domain proteins that catalyse complex reactions for the synthesis of complex 
lipids and secondary metabolites, and Pks6 is suggested to be involved in the 
production of novel polar lipids (Waddell et al. 2005). pks6 gene inactivation 
attenuates M. tuberculosis in mouse (Camacho et al. 1999) and human macrophage 
models (Rosas-Magallanes et al. 2007), implicating pks6 in virulence, however its 
exact role in pathogenesis remains unclear. 
The Y363D SNP in coaE had the strongest prediction for a functional effect of all 
14 RS-SNPs. Further investigation showed this SNP is located in the GrpB domain 
and is part of highly conserved Y-K-Y-K motif. Currently the only assigned 
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function of this domain is for the correct folding of the full enzyme and the last 50 
residues at the C-terminus, including the Y363D SNP and all four conserved 
Y-K-Y-K residues, are dispensable for proper folding and catalytic activity (Walia 
et al. 2009). Therefore, if the sole role of the GrpB is for the folding of CoaE, the 
G72S SNP is unlikely to have an effect on enzyme activity. However, if this domain 
has an additional as yet unknown function, considering the chemical nature of the 
amino acid change and the highly conserved nature and structural confirmation of 
the Y-K-Y-K motif, this SNP could have a dramatic effect on activity. 
Rv2893 encodes a putative oxidoreductase and is predicted to utilise the unusual 
deazaflavin cofactor F420 (Selengut and Haft 2010). F420 is an unusual low-redox 
potential flavin derivative cofactor synthesised by methanogenic archaea and 
several aerobic bacterial phyla including the Actinobacteria (Daniels et al. 1985; 
Ney et al. 2017). F420 is thought to enhance the metabolic flexibility of 
mycobacteria and in M. tuberculosis plays an important role in survival under 
hypoxic conditions, and protection from oxidative, nitrosative and antibiotic stress 
(Gurumurthy et al. 2013; Hasan et al. 2010; Purwantini and Mukhopadhyay 2009). 
Rv2893 belongs to the LLHT family of F420-dependent enzymes. There are 14 
predicted F420-dependent LLHTs in M. tuberculosis (Selengut and Haft 2010), the 
most well characterised of which is F420-reducing glucose-6-phosphate 
dehydrogenase (FGD) (Bashiri et al. 2008; Oyugi et al. 2016; 2018). The functions 
of the majority of these, including Rv2893, remains unknown. 
One of the main aims of the SNP analysis presented in this chapter was to identify 
candidate SNPs for biochemical and structural investigation. While the pks6 and 
narG SNPs are of interest due to these being known virulence associated genes, for 
practical reasons these variants were not selected for further study in this work. 
Pks6 is a large multi-domain enzyme and NarG is part of a multi-subunit complex 
anchored to the membrane. These features make proteins very difficult to work with 
for in vitro biochemical studies and are expected to make them difficult to 
crystallise. Soluble M. tuberculosis CoaE has been recombinantly expressed in 
E. coli and enzyme activity assayed by spectrophotometry (Walia et al. 2009) 
making it a suitable candidate from a practical perspective. However, further 
investigation revealed the mutation is located in a region of the protein dispensable 
for CoaE catalytic activity in vitro (Walia et al. 2009).  
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Based on the role of cofactor F420 in M. tuberculosis, further in silico analysis and 
practical considerations, the Rv2893 G72S SNP was selected as a suitable candidate 
for further investigation in Chapter Three of this thesis. Rv2893 is a cytoplasmic 
protein and is not part of a multimeric complex, making it a more suitable candidate 
for protein crystallography than other genes of interest harbouring Rangipo SNPs. 
The intrinsic fluorescence of F420 and the differences in its absorbance spectrum 
between the reduced and oxidised states also provides a simple way to monitor 
enzyme activity for future assay development. Furthermore, little is known about 
the functions of most members of the F420-dependent LLHTs in M. tuberculosis, 
making this protein of general interest for further study.  
Since this SNP analysis was performed, additional Rangipo strains have been 
sequenced using Illumina technology (as part of this research and by Gautam et al. 
(2017)) leading to the identification of additional Rangipo specific SNPs (Section 
4.3.2.2). While these identify further candidates of interest, the selection of 
candidate SNPs was based on the analysis presented in this chapter as Illumina data 
was not available at the time.  
In addition to genomic variation in the form of SNPs, differential carriage of 
virulence-associated genes may also impact bacterial fitness and pathogenicity. 
This work shows that the Rangipo strain harbours the DS6Quebec deletion that results 
in the loss of several virulence-associated genes (discussed in Section 2.3.3). 
Gautam et al. (2017) have also recently identified several genes present in the 
Rangipo strain that are absent in H37Rv, including three virulence-associated 
genes. Although these large genomic variants are not restricted to the Rangipo 
strain, they potentially also affect strain virulence and further work is needed to 
determine the consequences of this genomic diversity in M. tuberculosis.  
 
2.3.2 The S lineage  
The Rangipo strain has previously been assigned to the L4/Euro-American lineage 
of the MTBC but the sublineage remained unclassified (Ruthe 2015). Here, 
Rangipo, and additionally the Otara and NZ_094 strains, are classified as belonging 
to the L4.4.1.1/S sublineage. The ‘S lineage’ was originally classified based on its 
spoligotyping signature, which is characterised by the absence of the direct repeat 
spacers 9–10 and 33–36 (Warren et al. 2002a). Sequence based phylogenetic 
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analyses show that S isolates group into the same SNP defined phylogenetic clade 
congruent with MIRU-VNTR and spoligotyping data (Coll et al. 2014; Homolka et 
al. 2012). A high-resolution WGS SNP phylogeny constructed from 1601 global 
MTBC genomes shows that the S lineage is equivalent to the L4.4.1.1 sublineage, 
which belongs to the larger L4.4 sublineage (Coll et al. 2014). Stucki et al. (2016b) 
have SNP-typed >3000 global L4 isolates from 100 countries and found L4.4 to be 
the fourth most frequent of the ten L4 sublineages globally accounting for 10% of 
isolates, and has an intermediate global distribution relative to other sublineages. In 
New Zealand, L4.4 is the most common L4 sublineage and accounts for 43% of L4 
isolates from New Zealand-born cases (Stucki et al. 2016b). 
Isolates belonging to the S lineage were first identified around the same time 
independently in Canada (‘DS6Quebec’) (Cheng et al. 2000), Italy (Sola et al. 2001) 
and South Africa (‘F28’) (Warren et al. 2002b). The DS6Quebec family is endemic 
in Canada and is the most prevalent lineage in French Canadians in Quebec (48% 
of isolates) and in Aboriginal populations in Ontario, Saskatchewan and Alberta  
(38–62% of isolates) (Pepperell et al. 2011). This lineage assumed to have been 
introduced to Quebec by a French migrant in the 17th century and was dispersed to 
indigenous populations in the 18–19th centuries via the Canadian fur trade 
(Pepperell et al. 2011). In New Zealand, the S lineage Rangipo and Otara strains 
are most prevalent in indigenous Māori and Pacific People and despite extensive 
social admixture of New Zealand Europeans and Māori, the Rangipo strain remains 
strongly associated with Māori. Different MTBC lineages are hypothesised to be 
adapted to specific human host populations (Gagneux 2012), raising the intriguing 
prospect that the S lineage may be locally adapted to these populations. 
Alternatively, the high prevalence of the Rangipo strain in Māori is also consistent 
with a founder effect or population bottle neck. 
A small number of SNPs were found to be shared between the New Zealand 
Rangipo strain and a subset of Canadian DS6Quebec family isolates, suggesting these 
strains might share a close phylogenetic relationship. This was further explored in 
a detailed phylogenetic analysis including Otara and other global L4.4 lineage 
isolates in Chapter Four of this thesis. 
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2.3.3 DS6Quebec deletion 
Nguyen et al. (2004) have previously postulated that the 11.4 kb DS6Quebec deletion 
that characterises the Canadian DS6Quebec family may be a marker of a more 
globally distributed lineage. We have confirmed that the Rangipo strain and other 
New Zealand S lineage isolates harbour the DS6Quebec deletion, corroborating this 
hypothesis. South African F28 strain isolates also have an IS6110 insertion in this 
region (Chihota 2011), which together with our results suggest the DS6Quebec 
deletion might be more widely characteristic of the S lineage. This was further 
investigated in Chapter Four (Section 4.3.3.3). 
The similar but evolutionarily independent RD152 deletion is characteristic of the 
highly successful Beijing/W strain (Tsolaki et al. 2005). Both the DS6Quebec and 
RD152 deletions remove or interrupt the seven genes from Rv1755c/plcD (which 
is truncated in H37Rv) to Rv1765c, and RD152 additionally interrupts Rv1754c 
(Figure 2.7). Some of these deleted genes have important roles in pathogenicity. 
Rv1759c/wag22 for example, is a PE-PGRS family fibronectin-binding protein that 
elicits an antibody response in human tuberculosis patients (Espitia et al. 1999) and 
is suggested to play a role in the immune response maintaining latent infection 
(Campuzano et al. 2007). Rv1760 is adjacent to Rv1759c/wag22 and encodes a 
possible triacylglycerol synthase. Triacylglycerol is an important energy source for 
sustaining M. tuberculosis during latent infection and this gene is highly 
upregulated in a hypoxic macrophage model mimicking the microenvironment 
within the granuloma (Daniel et al. 2011). It is interesting to note that this deletion 
removes genes that may play a role in latency. Increased progression from latent 
infection to active tuberculosis has been reported for contacts exposed to Beijing 
lineage strains compared to other M. tuberculosis strains (De Jong et al. 2008) and 
analysis of Rangipo outbreak contact tracing data performed here suggests 
relatively high rates of progression to active disease in Rangipo strain infections. 
While the genes deleted by the DS6Quebec- deletion are evidently not essential for 
virulence, the impact of this deletion on virulence and disease outcome remains 
unclear. Furthermore, additional deletions of variable lengths in this region have 
also been reported (Alonso et al. 2013; Kato-Maeda et al. 2001; Tsolaki et al. 2005). 
H37Rv also has two deletions in this region relative to M. bovis BCG and other 
MTBC strains (RvD2 and RvD3, both spanned by the DS6Quebec and RD152 
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deletions) (Brosch et al. 1999; Gordon et al. 1999). The highly variable nature of 
this region is associated with frequent IS6110 insertion, and homologous 
recombination between IS6110 elements provides a likely mechanism for frequent 
deletion events (Ho et al. 2000). 
 
2.3.4 Rangipo diagnostic 
WGS based M. tuberculosis strain-typing will likely become routine in the future 
but is not yet performed in New Zealand. WGS-directed SNP based assays such as 
the Rangipo PCR-RFLP diagnostic presented here, offers a rapid and affordable 
alternate approach for epidemiological typing in the interim. This diagnostic is able 
to distinguish between Rangipo and non-Rangipo isolates with higher 
discriminatory power than MIRU typing providing results within one day at little 
cost. Clinical isolates were able to be typed using culture-independent 
M. tuberculosis DNA directly from clinical sputum samples substantially faster 
than the standard turnaround time of 3-4 weeks for MIRU typing. Using a 
PCR-RFLP assay for strain typing offers the advantage of being cheap and easy to 
perform with basic lab equipment and requires little optimisation. As this is a 
SNP-based approach it could also be automated, for example by incorporation into 
the GeneXpert system. If the Rangipo strain is indeed more virulent, close 
supervision ensuring treatment adherence and broadening contact tracing networks 
may be beneficial to ensure secondary cases are completely and quickly detected to 
prevent potential later reactivation and further spread. The ability to rapidly identify 
Rangipo strain cases upon patient presentation will enable prompt intervention to 
help prevent further transmission of this strain. 
 
2.3.5 Conclusions 
The New Zealand Rangipo and Otara strains belong to the L4.4.1.1/S sublineage of 
the L4/Euro-American lineage of the MTBC. New Zealand S lineage strains 
harbour the DS6Quebec deletion and a putative relationship between the Rangipo 
strain and Canadian DS6Quebec family isolates was identified. Twenty-two SNPs 
were classified as specific to the Rangipo strain, including eight nsSNPs with 
predicted functional effects, providing interesting candidates for further 
investigation. In light of these results, a previously developed SNP-based Rangipo 
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diagnostic assay was re-optimised. This diagnostic enables rapid and affordable 
typing of Rangipo strain isolates directly from clinical sputum samples, offering 
higher resolution and faster results than conventional MIRU-VNTR typing.  
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3 Chapter Three 
Structure of the F420-dependent 
oxidoreductase Rv2893 
3.1 Introduction 
The New Zealand Mycobacterium tuberculosis Rangipo cluster harbours a strain 
specific single nucleotide polymorphism (SNP) encoding a G72S mutation in 
Rv2893 predicted in silico to affect protein function (Section 2.2.2). The Rv2893 
gene encodes a putative oxidoreductase that belongs to the luciferase-like hydride 
transferase family of flavin/deazaflavin proteins. Rv2893 is predicted to utilise the 
5¢-deazaflavin cofactor F420, a functionally versatile redox co-factor that is 
important for energy metabolism in M. tuberculosis and contributes to its ability to 
persist in challenging environments (Gurumurthy et al. 2013; Purwantini and 
Mukhopadhyay 2009). Bioinformatics analyses indicate the presence of at least 28 
F420-dependent proteins in M. tuberculosis (Selengut and Haft 2010). 
F420-dependent proteins have been implicated in a range of processes in 
mycobacteria, including synthesis of cell wall lipids (Purwantini et al. 2016; 
Purwantini and Mukhopadhyay 2013), fatty acid modification, and heme 
degradation (Ahmed et al. 2015), however, the biological function of most of these 
oxidoreductases remains unknown.  
There is no structure available for Rv2893 and its function is unknown. To 
investigate the consequences of the G72S mutation on protein structure and help 
elucidate the biological role of Rv2893, structures for both the wild-type protein 
(Rv2893H37Rv) and the Rangipo G72S variant (Rv2893G72S) in both the apo and 
F420-bound forms were solved using protein X-ray crystallography.  
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3.1.1 Cofactor F420 
F420 is a low redox potential 5´-deazaflavin cofactor named for the strong 
fluorescence of the oxidised cofactor upon excitation at 420 nm (emission at 
470 nm). It consists of an isoalloxazine tricyclic ring system with a side chain 
comprised of ribitol and phospholactate moieties and oligoglutamate tail of varying 
length (Figure 3.1). In archaea, two glutamate residues are present on the tail (Eirich 
et al. 1978), whereas up to nine are observed in mycobacteria (Bashiri et al. 2008). 
While its structure is similar to those of the universal flavin cofactors FAD and 
FMN, the N5 of the isoalloxazine ring is substituted for a carbon in F420 resulting 
in different electrochemical properties. Unlike the flavins, which can act as one or 
two electron carriers, F420 is an obligate two-electron hydride carrier and has a lower 
redox potential (−340 mV) (Jacobson and Walsh 1984) than FAD and FMN 
(−220 mV and 190 mV, respectively), and the nicotinamide cofactor NAD(P) 
(-320 mV) (Thauer et al. 1977). These properties make F420 useful for reducing a 
wide range of reactants, enhancing the metabolic flexibility of microorganisms that 
produce it. 
 
 
Figure 3.1. Molecular structure of cofactor F420. (A) Schematic representation of the 
chemical structure of F420. The length of the polyglutamate tail varies among 
microorganisms; in M. tuberculosis, the major species contain 5–6 residues (Bair et al. 
2001). (B) Oxidised and reduced forms of cofactor F420 (F420 and F420 H2, respectively). 
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F420 was formally identified and first isolated in the 1970s from methanogenic 
archaea (Cheeseman et al. 1972) and its chemical structure proposed six years later 
(Eirich et al. 1978). It was formally identified in bacteria in 1980 (Eker et al. 1980) 
and discovered in M. tuberculosis in 1985 (Daniels et al. 1985). F420 is considered 
to be taxonomically restricted to the Euryarchaeota and Actinobacteria, although 
recently it has been shown to be more widely distributed in aerobic soil bacteria 
than previously thought (Ney et al. 2017).  
F420 is synthesised universally amongst Mycobacteria (Greening et al. 2016). The 
ability to synthesize and reduce F420 is non-essential in mycobacteria under ideal 
conditions, however, loss of F420 biosynthesis and reduction results in impaired 
survival under oxidative and nitrosative stress and following exposure to 
antimicrobials, and impairs its ability to recover following hypoxia-induced 
dormancy (Gurumurthy et al. 2013; Hasan et al. 2010; Jirapanjawat et al. 2016; 
Purwantini and Mukhopadhyay 2009). Mechanisms that enable the bacterium to 
withstand these stresses are important for pathogenesis and persistence of 
M. tuberculosis (Ehrt and Schnappinger 2009), pointing to a likely role for F420 in 
the pathogenesis of M. tuberculosis. Furthermore, activation of the 
anti-tuberculosis drug PA-824 occurs via a F420-dependent mechanism (Manjunatha 
et al. 2006), a finding that has sparked additional interest in cofactor F420 and the 
enzymes which utilise it.  
 
3.1.2 F420-dependent enzymes  
The majority of F420-dependent enzymes fall into two major super families; the 
flavin/deazaflavin oxidoreductases (FDORs) and the luciferase-like hydride 
transferases (LLHTs). These have a diverse range of catalytic activities and vary in 
their co-factor preference for the different flavins (FMN, FAD and F420).  
The FDORs have a split β-barrel protein fold and can be divided into two major 
families (FDOR-A and FDOR-B) which share ~30% sequence identify (Ahmed et 
al. 2015; Taylor et al. 2010). FDOR-A family proteins are exclusively F420-binding 
and are taxonomically restricted to the Actinobacteria and Chloroflexi. Conversely, 
FDOR-B proteins variously utilise different cofactors (F420, FAD, FMN, and heme) 
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and are more widely distributed, including in non-F420 producing organisms. 
(Reviewed in Greening et al. 2016).  
Members of the LLHT protein super family have a TIM barrel fold. The LLHTs 
were previously known as luciferase-like monooxygenases (LLMs), however these 
are better defined as LLHTs as the reaction mechanisms of these enzymes is O2 
independent (Greening et al. 2016). The co-factor preference of these enzymes 
varies and they are found in both F420 and non-F420 producing organisms (Selengut 
and Haft 2010). A conserved glycine in the F420-binding site allows binding of the 
phosphate group without steric hindrance and distinguishes F420-dependent LLHTs 
from non-F420 dependent enzymes (Aufhammer et al. 2004). Fourteen of the 
seventeen LLHT family genes in M. tuberculosis have been predicted as being 
F420-dependent in silico (F420-LLHTs), including Rv2893 (Selengut and Haft 2010). 
F420-LLHTs are implicated in a range of processes in actinobacteria and most are 
thought to serve as reductases (reviewed in Greening et al. 2016). The most well 
characterised mycobacterial F420-LLHT is F420-dependent glucose-6-phosphate 
dehydrogenase (FGD, previously FGD1) from M. tuberculosis (mtbFGD) (Bashiri 
et al. 2007; Bashiri et al. 2008; Oyugi et al. 2016; 2018). FGD uses F420 as the 
hydride acceptor to catalyse the conversion of glucose-6-phosphate (G6P) to 
6-phosphogluconolactone, producing reduced F420 (F420H2) that is then used to 
reduce a diverse range of compounds by F420-dependent reductases. FGD is thought 
to be the main source of F420H2 in mycobacteria (Jirapanjawat et al. 2016). FGD 
and other characterised F420-LLHTs all have Si-face stereospecificity with respect 
to the C5 atom of the 5-deazaflavin group (Aufhammer et al. 2004; Aufhammer et 
al. 2005; Bashiri et al. 2008; Shima et al. 2000). Other F420-LLHTs in 
M. tuberculosis have been implicated in the cell wall lipid synthesis (Purwantini et 
al. 2016; Purwantini and Mukhopadhyay 2013), although the functional roles of 
most of these proteins in M. tuberculosis is unknown. 
 
3.1.2.1 Rv2893 
Rv2893 is an LLHT family protein that belongs to the likely F420-dependent 
F420_MSMEG_2516 family (TIGR03621), which includes three members from 
Mycobacterium smegmatis and only Rv2893 in M. tuberculosis (Selengut and Haft 
2010). Rv2893 belongs to the intermediary metabolism and respiration functional 
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category of genes (Tuberculist database assignment (Lew et al. 2011)) and is 
non-essential in M. tuberculosis for bacterial growth and for infection in a mouse 
model (Sassetti et al. 2003; Sassetti and Rubin 2003). The only phenotypic profiling 
data found for this protein shows that Rv2893 is repressed 1.5-fold during acid 
shock in vitro (Fisher et al. 2002).  
Rv2893 is a 325 amino acid protein with a molecular weight of 34.6 kDa. It shares 
65% identify with the M. smegmatis homologue MSMEG_2516 and 100% 
sequence identify with M. bovis Mb2917. The Rv2893 gene is located at position 
3202420–3203397 in the M. tuberculosis genome and is not part of an operon 
(Figure 3.2).  
 
 
Figure 3.2. Genomic context of Rv2893 in the M. tuberculosis H37Rv genome. Genes are 
coloured by functional category: information pathways (yellow), conserved hypotheticals 
(green), PE/PPE (pink), intermediary metabolism and respiration (blue), insertion 
sequences and phages (red). Rv2893 belongs to the intermediary metabolism and 
respiration functional category and is not part of an operon. 
 
 
3.1.3 Objectives 
SNP analyses in Chapter Two identified 22 SNPs specific to the New Zealand 
M. tuberculosis Rangipo strain. Eight of these were non-synonymous (nsSNPs) 
predicted in silico to effect on protein function, including a G72S mutation in the 
predicted F420-dependent LLHT Rv2893. Due to the role of F420 in M. tuberculosis 
and the relatively limited knowledge on F420-LLHTs, as well as for practical reasons 
(Section 2.3.1), the Rv2893 G72S mutation was chosen for further investigation. 
There is no structure available for this protein and its function is unknown. To 
investigate the impact of this SNP on protein structure and provide clues to the 
function of Rv2893, I sought to solve the structure of Rv2893 for both apo- and 
F420-bound Rv2893H37Rv and Rv2893G72S using protein X-ray crystallography.    
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3.2 Methods 
3.2.1 Molecular cloning of Rv2893 
Cloning primers were designed using Geneious R8 (Biomatters, N.Z.) for the 
ligation of Rv2893 variants into pYU28b (Bashiri et al. 2010) with an N-terminal 
His-tag (Appendix B.2). M. tuberculosis genomic DNA (gDNA) was kindly 
provided by LabPLUS (Auckland, New Zealand). Rv2893 was amplified from 
Rangipo strain gDNA (Rv2893G72S) using KAPA HiFiTM HotStart DNA 
polymerase (Kapa Biosystems, U.S.A.), and from H37Rv gDNA (Rv2893H37Rv) 
using HOT FIREPol® Blend Master Mix (Solis BioDyne, Estonia). PCR products 
were either gel extracted and purified using the QIAquick Gel Extraction Kit 
(Qiagen, Netherlands), or, purified from solution using the QIAquick PCR Product 
Purification Kit (Qiagen, Netherlands). Purified PCR products and plasmid DNA 
were double digested with NdeI and BamHI using the NEB CutSmart® buffer 
system (New England Biolabs, U.S.A.). Digestion products were purified from 
solution using the QIAquick PCR Product Purification Kit (Qiagen, Netherlands) 
and ligated with T4 DNA ligase (Invitrogen, U.S.A.). Ligation reactions were 
transformed into electrocompetent E. coli TOP10 cells by electroporation using 
standard laboratory protocols. For electroporation, single aliquots of freshly thawed 
cells were mixed with 10 µl ligation reaction and 40 µl 10% ice cold glycerol. 
Electroporation was performed in 2 mm cuvettes at 2.5 kV, 25 µF capacitance and 
200 Ω using a Bio-Rad Gene Pulser. Cells were immediately recovered in 1 ml of 
SOC media and incubated at 37 °C with shaking for 60 min before plating onto low 
salt LB agar plates with hygromycin B (50 µg.ml-1) for selection. Positive E. coli 
transformants were screened for Rv2893 insertion into pYU28b using PCR. 
Transformants testing positive for the insert were grown in 5 ml low salt LB broth 
with hygromycin B (50 µg.ml-1) overnight at 37 °C with shaking. Plasmid DNA 
was extracted from broth cultures using the QIAprep Spin Miniprep Kit (Qiagen, 
Netherlands) and sent to the Massey Genome Service (Palmerston North, N.Z.) for 
sequencing on an ABI3730 DNA Analyzer (Applied Biosystems Inc., U.S.A.) using 
T7 primers. 
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3.2.2 Protein expression in M. smegmatis 
Sequence verified plasmids were transformed into M. smegmatis mc2 4517 (Wang 
et al. 2010) by electroporation using established protocols (Cirillo et al. 1993). 
Single aliquots of freshly thawed cells were mixed with 1 µl plasmid DNA and 
260 µl of 10% ice cold glycerol. Electroporation was performed in 2 mm cuvettes 
at 2.5 kV, 25 µF capacitance and 1000 Ω using a Bio-Rad Gene Pulser. Cells were 
immediately recovered in 1 ml of Middlebrook 7H9 broth supplemented with ADC 
and 0.05% (v/v) Tween 80, and incubated at 37 °C with shaking for 3 hrs before 
plating onto low salt LB agar plates containing hygromycin B (50 µg.ml-1) and 
kanamycin (50 µg.ml-1) for selection. Plates were incubated in a humidity chamber 
at 37 °C for three days and then used to inoculate a 10 ml starter culture of PA-0.5G 
defined media (Appendix B.1) with 0.05% (v/v) Tween 80, hygromycin B 
(50 µg.ml-1) and kanamycin (50 µg.ml-1). This was grown for 48 hrs at 37 ºC with 
shaking, then used at a 1:100 dilution to inoculate expression cultures of ZYP-5052 
auto-induction media (Appendix B.1) with 0.05% (v/v) Tween 80, hygromycin B 
(50 µg.ml-1) and kanamycin (50 µg.ml-1). The optimal expression conditions for 
protein purification were determined to be growth for 24 hrs at 37 ºC and then for 
a further 4 days at 28 ºC (Section 3.3.1.1). Cells were harvested by centrifugation 
(4,500 x g 20 min, 4 °C), and either frozen at -80 °C or used immediately for protein 
purification (Section 3.2.3). 
 
3.2.2.1 Small scale protein expression trails 
Protein expression of Rv2893 was initially confirmed and optimised from small 
scale expression cultures using His-tag binding with Ni SepharoseTM High 
Performance beads (GE Healthcare, Sweden). Expression cultures (5 ml) were 
grown at either 37 ºC for 4 days; 28 °C for 5 days; or 37 °C for 24 hrs followed by 
28 °C for 4 days. Cells were harvested by centrifugation and resuspended in 500 µl 
sodium phosphate lysis buffer (50 mM sodium phosphate buffer, 200 mM NaCl, 
20 mM imidazole, pH 7.4). Cells were lysed on ice by sonication and the insoluble 
fraction separated by centrifugation. The soluble fraction was mixed with 25 µl Ni 
beads that had been pre-equilibrated with lysis buffer. Beads were incubated at 
room temperature for 15 min in a thermomixer at with shaking at 1,000 rpm, then 
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left to settle for 5 min, centrifuged (600 x g, 1 min), and the supernatant removed. 
Beads were washed twice with 1 ml of lysis buffer then analysed by SDS-PAGE. 
During the procedure, samples of whole cells, the soluble fraction, insoluble 
fraction and flow though were also set aside for analysis by SDS-PAGE. 
 
3.2.3 Protein purification 
Cell pellets from 500 ml expression cultures grown as in Section 3.2.2 were 
resuspended in 25 ml lysis buffer (50 mM HEPES, 200 mM NaCl, 20 mM 
imidazole, 10% glycerol, pH 7.4) and lysed on ice by sonication. Lysed cells were 
centrifuged (20,000 x g, 20 minutes, 4 °C) to separate the supernatant from 
insoluble cellular debris. Protein was isolated from the soluble fraction by 
immobilised metal affinity chromatography (IMAC) and anion exchange 
chromatography and excess salt removed either by dialysis or using a desalting 
column.  
 
3.2.3.1 Immobilised metal affinity chromatography purification 
IMAC was performed using a HisTrap HP column (GE Healthcare, Sweden) on a 
ÄKTA Basic or Purifier FPLC system (GE Healthcare, Sweden), or an NGC 
Quest™ 10 Plus Chromatography System (Bio-Rad, U.S.A.). The supernatant from 
lysed cells was successively filtered through 1.2 µm and 0.45 µm syringe filters and 
loaded onto the column. Weakly bound non-specific protein was removed by 
washing the column with 20 ml of 4% elution buffer (50 mM HEPES, 200 mM 
NaCl, 0.5 M imidazole, 10% glycerol, pH 7.4): 96% lysis buffer at a flow rate of 
1 ml.min-1. Rv2893 was eluted using a gradient of 0–100% elution buffer over 
75 ml at a flow rate of 1 ml.min-1 and collected in 2 ml aliquots. Rv2893 containing 
fractions were identified via the 280 nm absorbance trace and/or SDS-PAGE. 
 
3.2.3.2 Anion exchange chromatography 
Anion exchange was performed using a 5 ml HiTrap Q XL anion exchange column 
(GE Healthcare, Sweden) on a ÄKTA Basic or Purifier FPLC system (GE 
Healthcare, Sweden), or an NGC Quest™ 10 Plus Chromatography System 
(Bio-Rad, U.S.A.). IMAC purified Rv2893 fractions (Section 3.2.3.1) were pooled 
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and diluted with three volumes of anion dilution buffer (50 mM HEPES, 10% 
glycerol, pH 7.4), filtered through a 0.2 µm syringe filter and loaded onto the 
column. Unbound protein was removed by washing the column with 10 ml start 
buffer (50 mM HEPES, 50 mM NaCl, 10% glycerol, pH 7.4) at a 1 ml.min-1 flow 
rate. Rv2893 was eluted using a gradient of 0–100% elution buffer (50 mM HEPES, 
1 M NaCl, 10% glycerol, pH 7.4) over 40 ml at a flow rate of 1 ml.min-1 and 
collected in 2 ml aliquots. Fractions containing Rv2893 were identified via the 
280 nm absorbance trace and/or by SDS-PAGE. 
 
3.2.3.3 Buffer exchange  
For large scale dialysis, typically the most concentrated protein fraction from anion 
exchange (2 mL) was dialyzed against 500 ml target buffer (50 mM HEPES, 
200 mM NaCl, 10% glycerol, pH 7.4) overnight at 4 ºC using 6–8 kDa molecular 
weight cut off Spectra Por® dialysis tubing (Spectrum Laboratories, U.S.A.). 
Alternatively, a 5 ml HiTrap Desalting column (GE Healthcare, Sweden) was used 
to desalt protein samples into target buffer as per the manufacturer’s instructions.  
 
3.2.3.4 Size exclusion chromatography 
Prior to the establishment of anion and buffer exchange protocols, Rv2893 was 
purified by size exclusion chromatography for crystallography screens. Protein 
containing fractions from IMAC purification were pooled and concentrated by 
centrifugation in a 2 ml or 20 ml Vivaspin concentrator with a 10 kDa molecular 
weight cut off (Sartorius AG, Germany). Protein was filtered through a 0.2 µm 
Minisart syringe filter and 0.5 ml was loaded on to a SuperdexTM 200 10/300 GL 
column (GE Healthcare, Sweden) with size exclusion buffer (50 mM HEPES, 
200 mM NaCl, 10% glycerol, pH 7.4). Protein fractions were separated and eluted 
in size exclusion buffer at a flow rate of 0.35 ml.min-1 and collected in 0.5 ml 
aliquots. Fractions containing Rv2893 were identified from the 280 nm absorbance 
trace and/or SDS-PAGE. 
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3.2.3.5 Determination of protein concentration by A280  
Protein concentration was determined by measuring absorbance at 280 nm using a 
Nanodrop 2000 UV-vis spectrophotometer (Thermo Fisher scientific, U.S.A.) and 
correcting by the theoretical extinction coefficient (ε) as calculated using the 
ExPASy ProtParam tool (Gasteiger et al. 2005). 
 
3.2.4 Protein characterisation 
3.2.4.1 Molecular weight determination by size exclusion chromatography 
A SuperdexTM 200 Increase 10/300 GL analytical size exclusion column (GE 
Healthcare, Sweden) was calibrated using six protein standards from high & low 
molecular weight gel filtration calibration kits (GE Healthcare, Sweden), as per kit 
instructions. The column void volume (V0) was determined with 1 mg.ml-1 blue 
dextran dye. Standards and dye were eluted with size exclusion buffer (50 mM 
HEPES, 200 mM NaCl, 10% glycerol, pH 7.4) at a flow rate of 0.35 ml.min-1 using 
an NGC Quest™ 10 Plus Chromatography System (Bio-Rad, U.S.A.). A sample of 
Rv2893G72S purified by IMAC and anion exchange chromatography was separately 
eluted at a flow rate of 0.35 ml.min-1 and the retention volume determined from the 
280 nm absorbance trace. Retention volumes of protein standards were used to 
construct a calibration curve by plotting Kav (Equation 3.1) versus molecular weight 
and the molecular weight of Rv2893 was calculated using the standard curve. 
 Kav = (Ve - Vo) / (Vc –	Vo) (Equation 3.1) 
Where Kav = gel phase distribution coefficient, Ve = elution volume; Vo = column 
void volume; and Vc = geometric column volume 
 
3.2.4.2 Melt temperature determination by differential scanning fluorimetry 
Differential scanning fluorimetry (DSF) using the SYPRO method (Lo et al. 2004) 
was used to compare the melting temperature (Tm) of Rv2893G72S and Rv2893H37Rv. 
SYPRO dye (Life Technologies, U.S.A.) was diluted to 300X in buffer (50 mM 
HEPES, 200 mM NaCl, 10% glycerol, pH 7.4) and 7.5 µl of this was added to 
protein to a final volume of 25 µl with a protein concentration of 0.1 mg.ml-1. Melts 
were performed in a Rotor-GeneTM real time PCR machine (Corbett Life Science, 
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Australia) using a temperature gradient of 25-99 ºC with continuous fluorescence 
monitoring at excitation and emission wavelengths of 470 and 555 nm, respectively. 
Protein samples were assayed in triplicate alongside a blank containing no protein. 
Data was analysed in GraphPad Prism (www.graphpad.com). The Tm was taken as 
the inflection point of the raw data (d2F/dT2 = 0) and mean Tm values for triplicate 
samples were calculated.  
 
3.2.5 Protein Crystallography 
3.2.5.1 Crystallisation robot screens  
Initial determination of crystallisation conditions was performed using the sitting 
drop method. Screens were set up using a Mosquito® Crystal robotic system (TTP 
Labtech Ltd, UK), using the PEGRx HT and Index HT crystallisation screens 
(Hampton Research, U.S.A.). Conditions were set up with 200 nl drops of equal 
volumes of protein and reservoir solution, against a 100 µl reservoir in Intelli-Plates 
(Hampton Research, U.S.A.), and stored at 18 ºC.  
 
3.2.5.2 Crystallisation fine screens  
Crystallisation conditions were optimised by hanging-drop vapour diffusion in 
24-well plates (Hampton Research, U.S.A.). In general, fine screens varied the 
precipitant concentration and pH of conditions identified in robot screens. Drops of 
2–6 µl containing protein and reservoir solution in a 1:1 ratio were pipetted onto a 
siliconised coverslip which was then inverted and sealed over 0.5 ml reservoir 
solution. Plates were stored at either 18 °C, 21 °C, or 25 °C. Final crystallisation 
conditions used to grow crystals for data collection are shown in Table 3.1. 
 
3.2.5.3 Heavy atom derivatisation 
Electrophoretic mobility shift assays were employed to identify promising heavy 
atoms for experimental phasing, (Boggon and Shapiro 2000). Mixtures containing 
different heavy metal compounds at 2 mM and Rv2893G72S at 1 mg.ml-1 were 
prepared in protein buffer (50 mM HEPES, 200 mM NaCl, 10% glycerol, pH 7.4) 
to a final volume of 10 µl and incubated on ice for 15 minutes. The protein was then 
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analysed by Native PAGE on a 12% polyacrylamide gel to identify compounds that 
produced a band shift indicating heavy atom derivatisation. Promising compounds 
were soaked into crystals to create derivates for experimental phasing. A 2 µl drop 
of reservoir solution containing the heavy metal compound at 1–2 mM was pipetted 
onto a coverslip and a crystal was transferred to this drop. This was placed over the 
reservoir and left overnight before looping and freezing the crystal for testing.  
 
3.2.5.4 Ligand soaks 
A sample of F420 was kindly provided by Ghader Bashiri (University of Auckland, 
N.Z.). This had been purified from M. smegmatis mc24517 cells engineered to 
produce high levels of F420 (Bashiri et al. 2010) using solvent extraction and anion 
exchange as previously described (Bashiri et al. 2010; Isabelle et al. 2002), 
followed by high performance liquid chromatography. F420 concentration was 
calculated from an extinction coefficient of 25 mm-1.cm-1 at 400 nm (Jacobson and 
Walsh 1984) in 25 mM Sodium phosphate buffer, pH 7.0. A 2 µl drop of reservoir 
solution containing 1 mM F420 was pipetted onto a coverslip and a crystal was 
transferred to this drop. This was placed over the reservoir and left overnight before 
looping and freezing the crystal for testing. 
 
3.2.6 X-Ray diffraction data collection and structure determination 
3.2.6.1 Data collection 
Crystals were removed from crystallisation drops with a cryo-loop and then briefly 
submerged in cryo-protectant solution (crystallisation reservoir solution with either 
35% polyethylene glycol (PEG) 3350 or 10% PEG 3350 and 20% glycerol) before 
being flash frozen in liquid nitrogen. X-ray diffraction data were collected at the 
Australian Synchrotron (Melbourne, VIC). Data for apo crystals were collected at 
the macromolecular crystallography MX1 beamline using a Quantum 210r detector 
(ADSC, U.S.A.). Data from heavy metal and F420 soaked crystals were collected on 
the MX2 beamline using an EIGER x 16 M detector (Dectris, Switzerland). 
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3.2.6.2 Structure solution using single-wavelength anomalous dispersion  
Phase information was obtained experimentally using the anomalous dispersion of 
gold bound to a Rv2893H37Rv crystal derivatised in KAuCl4 as per Section 3.2.5.3. 
Multiple datasets were collected from the same crystal at 0.9537 Å as in Section 
3.2.6.1. Datasets were auto-processed at the Australian synchrotron in XDS 
(Kabsch 2010) then merged using phenix.scale_and_merge with optimisation for 
anomalous differences (Akey et al. 2016). Gold sites were identified and refined 
using the Auto-Rickshaw platform (Panjikar et al. 2005) and a solution was 
determined by single-wavelength anomalous diffraction (SAD) phasing in the 
AutoSol wizard in PHENIX (Terwilliger et al. 2009) using these sites and the 
merged KAuCl4 dataset as input. Automated model building with refinement was 
done using AutoBuild in PHENIX (Terwilliger et al. 2008), with the inclusion of a 
higher resolution isomorphous data set (obtained from a Hg acetate soaked crystal) 
to assist model building and refinement.  
 
3.2.6.3 Structure solution by molecular replacement  
The apo-Rv2893G72S structure was solved by molecular replacement in PHASER 
(McCoy et al. 2007) using the experimentally phased solution (Section 3.3.5) as the 
search model. Automated model building and refinement was done using the 
AutoBuild wizard in PHENIX (Terwilliger et al. 2008) and manual building 
performed in COOT (Emsley and Cowtan 2004; Emsley et al. 2010). The model 
was refined as in Section 3.2.6.4, and then used as the search model for molecular 
replacement for subsequent structures. 
Diffraction data for molecular replacement collected using a CCD detector (native 
crystals, Section 3.2.6.1) and were integrated in iMOSFLM (Battye et al. 2011) 
then scaled and merged in the CCP4 software suite (Winn et al. 2011) using the 
Data Reduction task. This sequentially runs POINTLESS to determine the Laue 
group and possible space group (Evans 2006), AIMLESS to scale and merge 
multiple observations of reflections (Evans and Murshudov 2013), and then 
CTRUNCATE to convert intensities to structure factor amplitudes, and provides 
merging and other data processing statistics. Diffraction data collected using an 
EIGER detector (F420 soaked crystals, Section 3.2.6.1) were indexed, integrated and 
scaled using XDS (Kabsch 2010) and then merged using AIMLESS (Evans and 
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Murshudov 2013). For all datasets, 5% of reflections were randomly marked for the 
Rfree set for validation during structural refinement.  
 
3.2.6.4 Model Refinement 
Models were initially refined using real-space and rigid body refinement and 
simulated annealing in phenix.refine (Afonine et al. 2012). Manual model building 
was performed in COOT (Emsley and Cowtan 2004; Emsley et al. 2010) with the 
electron density 2ǀFOǀ-ǀFCǀ and ǀFOǀ-ǀFCǀ maps contoured to 1 σ and 3 σ 
respectively. Ligands were manually added and fitted in COOT following 
identification of regions of unmodeled density. Model refinement using REFMAC5 
(Murshudov et al. 2011) and phenix.refine was performed regularly during manual 
building and ligand fitting to ensure alterations improved the model fit to the data. 
Waters were added in the final stages of refinement in phenix.refine.  
 
3.2.6.5 Structure Analysis 
Final refinement was performed in REFMAC5. Model statistics were generated 
using phenix.table_one and Ramachandran analysis performed using RAMPAGE 
(Lovell et al. 2003). Structure analysis and visualisation was performed in  
COOT and PyMOL (The PyMOL Molecular Graphics System, Version 2.2 
Schrödinger, LLC) and PyMOL used for image generation. Root mean square 
differences (RMSD) between protein molecules were calculated in PROsmart 
(Nicholls et al. 2014) in the CC4 suite. The dimer interface was analysed and 
surface area determined using PDBePISA (Krissinel and Henrick 2007). The 
Protein-Ligand Interaction Profiler (Salentin et al. 2015) and LigPlot+ (Laskowski 
and Swindells 2011) tools were used to assist the examination of the F420 binding 
mode. Hydrogen bonds were inferred where bond distances were within 2.5–3.2 Å 
for strong bonds and 3.2–4.0 Å for weak bonds (Jeffrey and Jeffrey 1997). 
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3.3 Results 
3.3.1 Heterologous expression and purification of Rv2893 
The Rv2893 genes from M. tuberculosis H37Rv (Rv2893H37Rv) and the Rangipo 
G72S variant (Rv2893G72S) were cloned into the mycobacterial expression vector 
pYUB28b (Bashiri et al. 2010) with an N-terminal His-tag (Section 3.2.1). Ligation 
reactions were first transformed into E. coli TOP10 cells for transformant selection, 
vector purification and sequence validation. Sequence validated plasmids were then 
transformed in M. smegmatis mc2 4517 cells (Wang et al. 2010) for heterologous 
protein expression and purification (Section 3.3.2). 
 
3.3.1.1 Small scale expression trails  
Small scale expression trails were first performed to evaluate Rv2893 protein 
expression in M. smegmatis mc2 4517 and his-tag binding affinity using Ni beads 
(Section 3.2.2.1). Small scale cultures expressing Rv2893G72S were grown at either 
37 °C for 4 days; 28 °C for 5 days; or at 28 °C for 4 days following an initial growth 
period at 37 °C for 24 hrs. Rv2893G72S predominantly expressed insolubly at 37 °C 
with a small amount of protein binding to the Ni beads (Figure 3.3A). A subtle 
improvement was seen at 28 °C with a stronger band of the correct size band in the 
soluble fraction, however, expression overall was lower (Figure 3.3B). Dropping 
the temperature to 28 °C after growing for 24 hrs at 37 °C had a marked effect on 
both soluble expression and overall yield (Figure 3.3C). Rv2893H37Rv expression 
was then trailed under the same conditions resulting in soluble expression with 
ample binding to the Ni beads (Figure 3.3D). Two bands of similar size and 
intensity were also observed on the Ni beads when Rv2893 was expressed at 28 °C 
and the same bands were also apparent at 37 ºC, although the smaller band was 
weaker. These two bands were both found to be Rv2893 and eluted as separate 
peaks in IMAC purification (Section 3.3.2). 
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Figure 3.3. Small scale protein expression trails and his-tag binding of Rv2893. (A–C) 
Rv2893G72S and (D) Rv2893H37Rv. Rv2893G72S cultures were grown at (A) 37 °C for 4 days; 
(B) 28 °C for 5 days; (C) 37 °C for 24 hrs then 28 °C for 4 days; and (D) Rv2893H37Rv 
grown at 37 °C for 24 hrs then 28 °C for 4 days. Samples were separated on 12% 
SDS-PAGE gels. Black boxes indicate expressed Rv2893. Labels: WC, whole cell sample; 
Sol, soluble fraction; Ins, insoluble fraction; FT, flow through; W1, wash one; and Ni, Ni 
beads with protein bound after wash steps.  
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3.3.2 Large scale expression and protein purification 
Having established soluble expression for Rv2893G72S and Rv2893H37Rv at small 
scale, M. smegmatis expression was scaled up to large volume (500 mL) cultures 
for protein purification. Soluble protein suitable for crystallography was 
successfully purified using a two-step protocol comprised of IMAC (Section 
3.2.3.1) followed by anion exchange (Section 3.2.3.2). Representative 
chromatograms are shown in Figure 3.4. Excess salt was removed either by dialysis 
or using a desalting column (Section 3.2.3.3). Anion purified and desalted protein 
was put directly into crystallisation screens. Using this protocol, protein suitable for 
crystallisation was purified at concentrations typically ~5–7 mg.ml-1, with 
concentrations as high as 8.7 mg.ml-1 obtained. 
Rv2839G72S eluted in two peaks by IMAC purification with a major peak at 
~220 mM imidazole and a second minor peak at ~400 mM imidazole (Figure 3.4A). 
SDS-PAGE bands from each peak were both similar in size to that expected for 
Rv2893 and corresponded to those observed during small-scale expression trails 
(Figure 3.3). Rv2839H37Rv also produced the same two bands, however these eluted 
in three peaks by IMAC purification; the first peak predominantly contained the 
lower weight band, the second peak was a mixed population of the two bands, and 
the third peak was predominantly the higher weight band (Figure 3.4B). Bands from 
Rv2893G72S were sent for analysis by mass spectroscopy at MS3 Solutions 
(Hamilton, N.Z.) and both were confirmed to be M. tuberculosis Rv2893 with no 
detectable differences between the two bands. Analysis by absorbance and 
fluorescence scans failed to detect cofactor F420 or any differences between the two 
peaks. The structures of Rv2893 also confirmed the absence of F420 in crystals 
grown from native purified protein. Because of the requirement for highly pure 
homogeneous samples for protein crystallisation, only the first peak from both 
Rv2839G72S and Rv2839H37Rv was carried through to further purification by anion 
exchange chromatography. Both Rv2893G72S and Rv2893H37Rv eluted in a single 
sharp peak at ~330 mM NaCl by anion exchange and the protein obtained was 
highly pure and of suitable concentration for crystallography (Figure 3.4C-D). 
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Figure 3.4. Rv2893 protein purification by immobilised metal affinity chromatography 
(IMAC) and anion exchange chromatography. (A–B) IMAC purification of (A) 
Rv2893G72S and (B) Rv2893H37Rv. Chromatograms depict 280 nm UV absorbance and 
elution profile over a 50 mM to 0.5 M imidazole elution gradient. Corresponding 12% 
SDS-PAGE gels show the soluble fraction loaded onto the column (Load), insoluble 
fraction (Ins), flow through (FT) and eluted fractions corresponding to each coloured bar. 
IMAC purifications shown contained 0.01% DDM in buffers. (C–D) Anion exchange 
chromatography purification of (C) Rv2893G72S and (D) Rv2893H37Rv. Chromatograms 
depict 280 nm UV absorbance and elution profile over a 50 mM to 1 M NaCl elution 
gradient. Corresponding 12% SDS-PAGE gels show the sample that was loaded onto the 
column (Load), the column flow through (FT) and eluted fractions. 
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One of the major challenges encountered establishing purification protocols for 
Rv2893 was that the protein was unstable and typically precipitated out of solution 
within 24 hours. Concentrating Rv2893 was also challenging as it precipitated on 
protein concentrator spin columns. Anion exchange provided a means to 
circumvent this problem and also removed the imidazole from IMAC purification. 
The most concentrated anion exchange fraction eluted was typically 150–200% 
more concentrated from that eluted by IMAC, resulting in concentrations sufficient 
for crystallisation without the need for additional concentration steps. 
Various approaches were trailed to improve the stability of Rv2893 including 
different additives, storage at different temperatures, and buffer screening using 
different lysis buffers, small scale dialysis and DSF thermal shift assays (Ericsson 
et al. 2006). The addition of glycerol had the most notable effect on stability and 
was included at 10% in all buffers. The inclusion of 1 mM dithiothreitol (DTT) in 
purification buffers also improved stability and this effect was retained when DTT 
was included only in lysis buffers and then re-added to purified protein for storage. 
This reduced the rate of protein aggregation by one or two days and was therefore 
included in all subsequent purifications. Earlier purifications included the addition 
of 0.01-0.03% n-Dodecyl β-D-maltoside (DDM). DDM is a non-ionic detergent 
that is effective for protein solubilisation and initially appeared promising at 
improving the stability of Rv2893. However, it still failed to retain protein in 
solution for >24 hrs, even at higher concentrations (1-2 %), and so was removed 
from purification buffers. Considering these challenges, the focus was made on 
laying down crystal screens using protein within 24 hrs of purification as freshly 
purified protein consistently produced the highest quality crystals.  
The oligomeric state of purified Rv2893 was determined using analytical size 
exclusion chromatography (Section 3.2.4.1). The elution volume corresponded to 
62.4 kDa, which is consistent with a dimer in solution when compared to the 
molecular weight of the monomer of 36.8 kDa (calculated using ProtParam, 
http://web.expasy.org/protparam). 
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3.3.3 Melt temperature of Rv2893G72S and Rv2893H37Rv 
The melt temperatures of Rv2893H37Rv and Rv2893G72S were estimated using DSF 
to determine if the Rangipo G72S mutation affects the thermal stability of the 
protein. The Tm was determined from the highest peak of the first derivative of the 
melting curve (the dF/dT maxima) as the second derivate was too noisy. This 
corresponds to the inflection point of the melting curve, which is the temperature at 
which half the protein is in the unfolded state. The Tm of Rv2893H37Rv was estimated 
to be 54.9 ºC and the Rv2893G72S variant had a 4 ºC higher Tm of 58.9 ºC (average 
of three replicates) (Figure 3.5). This indicates that that the Rangipo Rv2893G72S 
variant is more temperature stable than Rv2893H37Rv.  
 
 
Figure 3.5. Melting temperature (Tm) comparison of Rv2893H37Rv (blue) and Rv2893G72S 
(red). The first derivative of the fluorescence output is shown. Tm values were determined 
from the dF/dT maxima and are indicated by dashed lines.  
 
 
3.3.4 Crystallisation of Rv2893 
High throughput crystallisation trails were performed using the sitting-drop vapour 
diffusion method (Section 3.2.5.1) with Rv2893G72S at 2.6 mg.ml-1 and 2.2 mg.ml-1 
purified by IMAC and size exclusion chromatography (Section 3.2.3, with 0.01% 
DDM in buffers). The best condition (0.2 M ammonium acetate, 0.1 M Bis-tris pH 
5.5-6.5, 25% PEG 3350) was pursued using hanging-drop vapour diffusion fine 
screens (Section 3.2.5.2) using protein purified by IMAC and anion exchange 
chromatography directly eluted from anion exchange and/or following the removal 
of excess salt by dialysis or using a desalting column (Section 3.2.3). 
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Crystals appeared overnight and reached their maximum size within a few days. In 
addition to varying the precipitant concentration and pH of crystallisation 
conditions, a range of other approaches were trialled to improve crystal quality and 
diffraction. Additive screening and crystal seeding (batch and streak seeding) failed 
to improve crystal morphology and/or diffraction. Increasing the crystallisation 
temperature from 18 ºC to 25 ºC produced more single crystals and thicker crystals 
which diffracted well (Figure 3.6C, Table 3.1). Larger drop sizes (up to 6 µl) and 
the addition of glycerol or DTT inconsistently improved crystal quality. The final 
conditions used to grow crystals for data collection are reported in Table 3.1. 
 
 Table 3.1. Conditions used to grow Rv2893 crystals used for data collection. 
Dataset Protein Conc. Purification
1  Crystallisation conditions Temp. 
KAuCl4-
Rv2893H37Rv   2.8 mg.ml
-1 
IMAC + anion 
exchange + 
desalting 
0.1 M Bis-tris pH 6.0 
0.2 M Ammonium acetate 
16% PEG 3350 
25 ºC 
Hg acetate-
Rv2893H37Rv  2.7 mg.ml
-1 
IMAC + anion 
exchange + 
desalting 
0.1 M Bis-tris pH 6.2 
0.2 M Ammonium acetate 
25% PEG 3350 
25 ºC 
apo-
Rv2893G72S 5.0 mg.ml
-1 IMAC
2 + anion 
exchange + dialysis 
0.1 M Bis-tris pH 6.6 
0.2 M Ammonium acetate 
25% PEG 3350 
18 ºC 
apo-
Rv2893H37Rv  5.7 mg.ml
-1 IMAC
2 + anion 
exchange 
0.1 M Bis-tris pH 7.0 
0.2 M Ammonium acetate 
19% PEG 3350 
21 ºC 
F420-
Rv2893G72S  7.2 mg.ml
-1 IMAC + anion exchange + dialysis 
0.1 M Bis-tris pH 6.5 
0.2 M Ammonium acetate 
27% PEG 3350 
25 ºC 
F420-
Rv2893H37Rv  1.8 mg.ml
-1 IMAC
3 + anion 
exchange + dialysis 
0.1 M Bis-tris pH 6.3 
0.2 M Ammonium acetate 
18% PEG 3350, 1mM DTT 
25 ºC 
1  Protein purified as in Sections 3.2.3.1–3.2.3.3. 
2  1 mM DDM in lysis and IMAC buffers. 
3  1 mM DTT in lysis buffer. 
 
Figure 3.6. Typical morphology of Rv2893 crystals. (A) Rv2893G72S crystals grown at 
18 ºC. (B) Rv2893H37Rv crystals grown at 18 ºC. (C) Rv2893H37Rv crystals grown at 25 ºC. 
These crystals were used for KAuCl4 soaks to solve the structure by experimental phasing. 
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3.3.5 Experimental Phasing 
Initial attempts to solve the Rv2893 structure by molecular replacement using 
M. tuberculosis FGD (3C8N) as the search model were unsuccessful and so phases 
were determined experimentally. To identify potential heavy-atom derivatives to 
use for experimental phasing, native PAGE gel shift assays were performed 
(Boggon and Shapiro 2000). Rv2893G72S was incubated with various heavy-atom 
compounds and then analysed by native PAGE gel electrophoresis to identify heavy 
atoms that bind to the protein, as indicated by a band shift (Section 3.2.5.3). Shifts 
were detected for HgCl2, Hg acetate and K2PtCl4 (Figure 3.7). All gold compounds 
screened (KAu(CN)2, KAuCl4 and KAuBr4), visibly precipitated Rv2893 and the 
protein did not run on a Native-PAGE gel. While this indicated denaturation of the 
protein it also implied that gold was interacting with Rv2893, therefore gold was 
pursued in addition to mercury and platinum for experimental phasing.  
 
Figure 3.7. Heavy metal native PAGE gel shift assay to identify heavy atom derivatives for 
experimental phasing of Rv2893. 
 
Rv2893 crystals soaked overnight in HgCl2, Hg acetate, K2PtCl4, K2PtCl6 and 
KAuCl4 (Section 3.2.5.3) were taken to the Australian synchrotron for screening 
and data collection. Mercury, platinum and gold were all found to bind to the protein 
as indicated by excitation scans and/or the presence of an anomalous signal in the 
diffraction data. The anomalous signal from mercury and platinum however, was 
not adequate to solve the structure and the final solution was obtained using 
gold-soaked crystals and SAD phasing.  
Five datasets of 180 º/1800 frames were collected at 12.1 KeV (0.18 KeV above the 
LIII edge of gold, theoretical f² = 9.94 e- and f¢ = -10.39 e-) from various points and 
starting angles on a single KAuCl4 soaked crystal (Table 3.1). Data was processed 
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in the monoclinic space group P1211 and the maximum resolution of individual 
datasets ranged from 3.14–3.68 Å. Individual datasets were scaled and merged 
together to optimise anomalous differences (Table 3.2). The anomalous signal was 
predicted to extended to 3.8 Å, and the overall anomalous correlation was 0.542. 
Twenty gold sites were identified using SHELX and refined with BP3 in the 
Autorickshaw server (Panjikar et al. 2005). The PHENIX AutoSol wizard 
(Terwilliger et al. 2009) identified an additional nine gold sites and successfully 
calculated phases from the anomalous differences.  The calculated phases allowed 
model building and refinement and the inclusion of a higher resolution dataset 
collected from an isomorphous Hg acetate-soaked crystal (2.80 Å) was used to 
assist the model building (Table 3.2). The resultant model was not subject to further 
manual refinement as it was sufficient for molecular replacement with high 
resolution data. That we aware of, this was the first structure to be experimentally 
solved using the new EIGER detector on MX2 at the Australian Synchrotron.  
 
 
Figure 3.8. Diffraction of Rv2893 heavy metal derivatives. (A) Rv2893H37Rv derivatised 
with gold (KAuCl4) was used for SAD phasing. (B) Rv2893H37Rv derivatised with mercury 
(Hg acetate) was used as a higher resolution isomorphous dataset to improve model 
building. 
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Table 3.2. Data collection statistics for Rv2893 SAD-phasing and statistics for the 
experimentally phased model. Statistics for the highest-resolution shell are shown in 
parentheses. Hg acetate-Rv2893H37Rv data was used at the model building stage but not for 
phasing. 
Data collection1 KAuCl4-Rv2893H37Rv  Hg acetate-Rv2893H37Rv 
Wavelength (Å) 1.0247 0.9999 
Space group  P 1 21 1 P 1 21 1 
Unit cell dimensions  a/b/c (Å)   75.82/116.32/88.18    76.37/117.47/87.63    
                                  α/β/γ (°)  90.00/90.88/90.00 90.00/90.81/90.00 
Resolution range (Å) 3.13–48.55 (3.13–3.35) 2.80–48.79 (2.80–2.93) 
Rmerge 0.259 (0.608) 0.110 (0.628) 
Rpim 0.067 (0.381) 0.045 (0.254) 
Mean I/σ 6.2 (1.3) 11.8 (3.1) 
CC(1/2) 0.987 (0.783) 0.997 (0.857) 
Total number of observations 351907 (14044) 264418 (31420) 
Total number unique 26313 (4119) 37887 (4529) 
Completeness (%) 97.0 (84.3) 99.6 (97.2) 
Multiplicity  13.4 (3.4) 7.0 (6.9) 
Mosaicity  0.13 0.1 
Phasing statistics2   
Anomalous Completeness (%) 91.25  
Mean anomalous difference 0.0976  
Anomalous CC between  
half-datasets 0.524 (0.104)  
Model   
Rwork  
Rfree 
0.302 
0.363  
Protein residues 947  
 1  Data collection statistics calculated in Aimless. For Au-Rv2893H37Rv, data statistics are  
 for five merged datasets collected from the same crystal. 
 2  Phasing statistics calculated in phenix.scale_and_merge and phenix.xtriage 
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3.3.6 Structure determination by molecular replacement 
High resolution data obtained from native and F420 soaked crystals were used to 
solve apo- and F420-bound Rv2893G72S and Rv2893H37Rv structures by molecular 
replacement. The growth conditions of crystals used for final data collection are 
summarised in Table 3.1. To obtain structures complexed with F420, apo crystals 
were soaked overnight in 1 mM F420 (Section 3.2.5.4). Data for apo crystals were 
collected on the MX1 beamline at the Australian synchrotron using a CCD detector 
and data from F420 soaked crystals on the MX2 beamline at the Australian 
synchrotron using an EIGER detector. Datasets were all collected at 13.0 KeV and 
frames from 360 º oscillation were collected for each crystal. A delta of 0.5 º was 
used for collecting MX1 data, and MX2 data was collected using a delta of 0.1 º.  
All datasets were processed in space group P1211 to thresholds of CC(1/2) > 0.500 
and I/σ > 1.5 in the outer/high resolution shell (Table 3.3). The maximum resolution 
of all four datasets were in a similar range of 2.17-2.31 Å. Both the Rv2893G72S 
and Rv2893H37Rv native datasets contained eight molecules in the asymmetric unit 
(ASU) and had strong evidence of pseudo-translational symmetry (p = 1.48 x 10-4 
and p = 1.49 x 10-4, respectively). Datasets from F420 soaked crystals had four 
molecules in the asymmetric unit and no crystal pathologies were detected.   
The best dimer from the model obtained from the SAD solution (Section 3.3.5) was 
used as the search model for molecular replacement with the high resolution native 
Rv2893G72S dataset. Following refinement, the best monomer from this model was 
used as the search model to solve the remaining structures. Final statistics for 
refined models are given in Table 3.4. The higher R-factors for the apo structures 
are likely in part due to the translational pseudosymmetry in these datasets as this 
can lead to difficulties in refinement (Read et al. 2013). 
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Table 3.3. Data collection statistics for apo and F420 bound Rv2893G72S and Rv2893H37Rv. Statistics for the highest-resolution shell are shown in parentheses. 
Data Statistic apo-Rv2893H37Rv apo-Rv2893G72S F420-Rv2893H37Rv F420-Rv2893G72S 
Wavelength (Å) 0.9537 0.9537 0.9537 0.9537 
Space group  P 1 21 1 P 1 21 1 P 1 21 1 P 1 21 1 
Unit cell dimensions  a/b/c (Å)   114.75/117.17/116.40    114.82/116.94/116.35    80.63/118.81/85.61 81.12/118.23/86.50   
                                     α/β/γ (°)  90.00/96.16/90.00 90.00/96.21/90.00 90.00/91.23/90.00 90.00/91.59/90.00 
Resolution range (Å) 2.30–64.47 (2.30–2.34) 2.12–57.83 (2.12–2.16) 2.17–18.80 (2.17–2.21) 2.31–48.80 (2.31–2.36) 
Rmerge 0.240 (1.447) 0.212 (1.322) 0.078 (1.329) 0.078 (1.094) 
Rpim 0.093 (0.559) 0.082 (0.512) 0.032 (0.526) 0.032 (0.454) 
Mean I/σ 8.4 (1.5) 9.3 (1.7) 13.6 (1.5) 12.9 (1.5) 
CC(1/2) 0.992 (0.560) 0.994 (0.513) 0.999 (0.608) 0.999 (0.565) 
Total number of observations 1030086 (51414) 1306478 (64022) 593159 (32844) 494858 (30363) 
Total number unique 135812 (6760) 172401 (8481) 84901 (4491) 71447 (4548) 
Completeness (%) 100.0 (100.0) 99.7 (99.3) 99.7 (99.1) 100.0 (99.9) 
Multiplicity   7.6 (7.6) 7.6 (7.5) 7.0 (7.3) 6.9 (6.7) 
Mosaicity  0.56 0.59 0.15 0.11 
Monomers in the ASU  8 8 4 4 
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Table 3.4. Refinement and model statistics for native and F420 bound Rv2893G72S and Rv2893H37Rv. 
Model statistic apo-Rv2893H37Rv apo-Rv2893G72S F420-Rv2893H37Rv F420-Rv2893G72S   
Rwork 0.204 (0.296) 0.197 (0.293) 0.192 (0.293) 0.192 (0.303) 
Rfree 0.237 (0.312) 0.232 (0.315) 0.220 (0.312) 0.222 (0.334) 
Protein residues 2463 2458 1265 1264 
Total number of non-hydrogen atoms 19066 19576 9520 9415 
     Protein  17864 17853 9110 9132 
     Ligands 16 26 95 89 
     Solvent 1186 1697 315 194 
RMS  Bonds (Å) 0.014 0.014 0.015 0.014 
 Angles (°) 1.79 1.8 1.86 1.84 
Average B value (Å2) 28.78 28.26 51.30 57.85 
     Protein  28.87 27.87 51.36 57.93 
     Ligands 43.77 44.97 55.58 64.91 
     Solvent 27.2 32.07 48.24 50.75 
Ramachandran analysis1     
     Number of residues in favoured region (%)     2376 (97.9%) 2371 (98.1%) 1218 (97.8%) 1221 (98.2%) 
     Number of residues in allowed region (%) 51 (2.1%) 45 (1.9%) 27 (2.2%) 23 (1.8%) 
     Number of residues in outlier region (%)                                  0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
1  Ramachandran plots are presented in Appendix B.5. 
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3.3.6.1 Rv2893 structural models 
The crystal structures of apo-Rv2893H37Rv and apo-Rv2893G72S were solved at 
2.30 Å and 2.12 Å, respectively, and models refined to Rwork/Rfree values of 
0.204/0.237 and 0.197/0.232 (Table 3.4). Crystal structures of F420-Rv2893H37Rv 
and F420-Rv2893G72S were solved at 2.17 Å and 2.31 Å respectively, and models 
refined to Rwork/Rfree values of 0.192/0.220 and 0.192/0.222.  
Both apo structures were solved with four dimers in the ASU and F420 bound 
structures with two dimers in the ASU. The apo- and F420-bound structures for both 
Rv2893H37Rv and Rv2893G72S have very similar overall conformations, as evident 
from the low overall root mean square differences (RMSD) in the Ca atomic 
positions between monomers (RMSD 0.11-1.53 Å, mean 0.60 Å) (Table 3.5, 
Appendix B.6). In both apo structures, each of the eight chains had a similar overall 
conformation with RMSD values ranging from 0.11-1.20 Å (mean, 0.47 Å). For 
F420-Rv2893H37Rv and F420-Rv2893H37Rv structures, RMSD between chains ranged 
from 0.69–1.47 Å (mean, 1.3 Å).  
Up to three loops were missing in the electron density and were unable to  
be modelled in all chains. These loops are Gly197–Phe212 (the b6-a6 loop),  
Arg250–Ser272 (b7-a7 loop), and Glu304–Arg308 (b8-a8 loop) (Appendix B.7). In 
all chains, the first 25–26 residues from the N-terminus of the protein (including 
the His-tag) were not modelled, and 0–1 residue was missing from the C-terminus. 
In addition to these missing residues, various sidechains throughout the structures 
were missing electron density for the side chain atoms and so were pruned from the 
model. Non-protein electron density that accommodated PEG was present in both 
apo structures and glycerol was present in F420 bound structures.  
 
Table 3.5. RMSD in the Ca atomic positions between Rv2893 structures. Average RMSD 
for all combinations of chain comparisons are reported, and minimum and maximum 
shown in brackets. RMSD between chains belonging to the same structure are italicised. 
 apo-Rv2893H37Rv apo-Rv2893G72S F420-Rv2893H37Rv F420-Rv2893G72S 
apo-Rv2893H37Rv 0.47 (0.11-1.20) 0.44 (0.11-1.22) 0.69 (0.26-1.53) 0.67 (0.27-1.53) 
apo-Rv2893G72S  0.47 (0.18-1.16) 0.68 (0.22-1.53) 0.66 (0.29-1.53) 
F420-Rv2893H37Rv   1.04 (0.74-1.47) 0.81 (0.17-1.47) 
F420-Rv2893G72S    0.95 (0.69-1.25) 
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The electron density for F420 soaked crystals revealed F420 bound in two molecules 
of the same dimer for both F420-Rv2893G72S and F420-Rv2893H37Rv (chains A and B 
of the four chains in the ASU) (Figure 3.9A). A single monomer (chain D) in the 
other dimer had unexpected electron density that was neither protein, F420, nor 
water, in the active site region (Figure 3.9B). Considering the buffer and 
crystallisation conditions, it is not possible to guess the identity of the ligand that 
occupies this density. The arrangement of the sidechains of His48, His109 and 
Glu113 suggest a bound cation with tetrahedral coordination occupies part of this 
density. The N1 atoms of the imidazole sidechains of His48 and His109 and the 
carboxylate of Glu113 provide three of the required coordination partners and the 
fourth would be provided by a non-protein ligand. Mn2+ has the required 
coordination number and the binding site is occupied by amino acid residues that 
are among the three major ligands for Mn2+ in proteins (His, Asp, and Glu) (Zheng 
et al. 2008). Modelling Mn2+ into this site shows the expected tetrahedral binding 
geometry and Mn2+ fits the electron density well (Figure 3.9B). Modelling in other 
cations with a tetrahedral coordination (Co2+, Ni2+, Cu2+ and Zn2+) produced poorer 
electron density maps and a higher Rfree. Attempts were made to identify the 
unexpected ligand using phenix.ligand_identification, but failed to identify ligands 
that fit the density appropriately. This tool automates the fitting of the 200 most 
frequently observed ligands found in the Protein Data Bank (PDB) to a provided 
electron density map (Terwilliger et al. 2007). Model analysis was therefore 
performed using models with Mn2+ included and remainder of the density left 
unmodeled. 
 
Figure 3.9. COOT electron density maps for ligand binding in Rv2893. 2ǀFOǀ-ǀFCǀ (blue) 
and ǀFOǀ-ǀFCǀ (red/green) maps are shown contoured to 1 σ and 3 σ, respectively. (A) 
Electron density supporting the placement of F420. Density for the non-prolyl cis-peptide 
bond joining Leu74 and Val75 is also shown. (B) Non-protein electron density in the active 
site of chain D. The Mn2+ cation is shown as a grey cross. Density for the F420-Rv2893H37Rv 
is shown and the same unmodeled density was present in F420-Rv2893G72S.   
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3.4 Analysis of Rv2893 structures 
Each Rv2893 monomer is formed by a single (a/b)8 TIM barrel domain and has a 
surface area of ~13400 Å2 (Figure 3.10). Two monomers are arranged in an 
approximately 180 º rotation parallel to the central axis of the TIM-barrel to form 
the Rv2893 homodimer (Figure 3.11). The TIM barrel a-helixes a2 and a3 from 
each monomer pack closely at the dimer interface and the monomers also associate 
by interactions involving the a1 helix and additional loops. The dimer interface 
buries ~1900 Å2 (14% of each monomer) and involves four salt bridges and at least 
14 hydrogen bonds. The active site is located at the C-terminal end of the TIM 
barrel (C-terminal end of the b-strands) as in other LLHTs. The substrate binding 
region has a relatively open conformation and three main accessory loops of 18–34 
amino acids, loops b4-a4, b6-a6 and b7-a7, protrude upwards from the C-terminal 
end of the barrel. A fourth loop comprised of two b-strands (a4-b5, 28 amino acids) 
extends from the N-terminus of the TIM barrel and loops back around to sit adjacent 
to helix a4.  
A structural similarity search of the PDB using PDBeFold shows that Rv2893 
matches most closely with other bacterial LLHTs as expected. The closest structural 
homologue to Rv2893 is F420-dependent methylenetetrahydromethanopterin 
reductase (Mer) from the methanogenic archaea Methanosarcina barkeri (bMer) 
(Table 3.6). The top ten matches to Rv2893 included six different F420-dependent 
LLHTs (F420-LLHTs); three Mer enzymes from different methanogenic archaea 
(bMer, kMer and tMer); two actinobacterial FGD enzymes from M. tuberculosis 
(mtbFGD) and Rhodococcus jostii (rhFGD); and F420-dependent alcohol 
dehydrogenase (Adf) from the methanoarchaea Methanoculleus thermophilus. 
Superimposition of the three Mer structures show these are all structurally very 
similar (RMSD 1.1–2.5 Å), as are the two FGD structures (RMSD 1.5 Å). bMer 
(PDB code 1Z69) and mtbFGD (3B4Y) were therefore selected for comparison 
with Rv2893, along with Adf (1RHC), as these all have F420 bound (Figure 3.12). 
The four remaining top matches were to three different non-F420 dependent bacterial 
LLHTs (Table 3.6).  
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Figure 3.10. Structure of Rv2893. (A) Cartoon structure of Rv2893 with F420 bound 
(yellow). Colouring is based on secondary structure; red, TIM barrel b strands; blue, TIM 
barrel a helixes; pale yellow, short connecting loops (<18 aa); green, large accessory loops 
at the C-terminal end of the barrel; and cyan, large accessory loops at the N-terminal of the 
barrel. (B) Schematic depicting the topology of the Rv2893 structure. Colours correspond 
to the scheme in (A). 
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Figure 3.11. Dimeric arrangement of Rv2893. F420 (yellow) is bound to both chains in the 
dimer and is depicted as sticks. 
 
A sequence alignment of Rv2893, MSMEG_2516, bMer, mtbFGD, Adf and the top 
two non-F420-dependent LLHT hits (1M41 and 3RAO), was generated in STRAP 
using the Aligner3D method to consider both structural and sequence information 
(Gille and Frömmel 2001) (Figure 3.13). In Rv2893, His48 and His109 correspond 
to the mtbFGD active site residues His40 and Glu109 (Bashiri et al. 2008; Oyugi 
et al. 2016). Examination of the alignment and structures shows 1M41 and 3RAO 
lack the conserved non-prolyl cis-bond found in F420-LLHTs, as well as the catalytic 
histidine. Examination of the loops and substrate binding region in all four non-F420 
LLHTs structures showed no obvious commonalities with Rv2893, therefore 
further analyses focused on the three F420-LLHTs with F420 bound.  
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Table 3.6. Proteins in the PDB with structural similarity to Rv2893. The top ten matches identified using PDBeFold are shown. Structures used for main 
comparisons with Rv2893 are shown in bold and those used included in the alignment in Figure 3.13 are marked with asterisks.  
PDB ID RMSD (Å) %sseQ1 %sseT1 Protein Abbr.2 Organism F420-dependent 
F420 
bound 
1Z69* 2.35 88 81 Coenzyme F420-dependent N(5),N(10)-methylenetetrahydromethanopterin reductase bMer 
Methanosarcina 
barkeri  Yes Yes 
1M41* 2.15 79 83 FMNH2-dependent alkanesulfonate monooxygenase Ssud Escherichia coli  No N/A 
1F07 2.13 75 75 Coenzyme F420-dependent N(5),N(10)-methylenetetrahydromethanopterin reductase tMer 
Methanobacterium 
thermoautotrophicum Yes No 
3RAO* 2.34 79 83 Putative Luciferase-like Monooxygenase  Bacillus cereus No N/A 
1NQK 2.21 71 81 FMNH2-dependent alkanesulfonate monooxygenase Ssud Escherichia coli  No N/A 
1RHC* 2.24 83 87 F420-dependent alcohol dehydrogenase Adf Methanoculleus thermophilus Yes Yes 
3B4Y* 2.26 71 74 F420-dependent glucose-6-phosphate dehydrogenase 1 mtbFGD 
Mycobacterium 
tuberculosis  Yes Yes 
5LXE 2.34 71 74 F420-dependent glucose-6-phosphate dehydrogenase 1 rhFGD Rhodococcus jostii  Yes No 
1EZW 2.47 88 81 Coenzyme F420-dependent N(5),N(10)-methylenetetrahydromethanopterin reductase kMer 
Methanopyrus 
kandleri Yes No 
1LUC 2.44 71 81 Bacterial Luciferase  Vibrio harveyi No N/A 
1 %sse is percent of matched secondary structure of the query chain identified in the target protein (%sseQ) and of target chain matched in the query (%sseT) 
2 Abbr. = abbreviation used in this thesis  
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Comparison of the overall topology of Rv2893 with other F420-LLHT structures 
show all structures share the same TIM barrel fold and a similar a4-b5 loop at the 
N-terminal end of the barrel (Figure 3.12). The main differences are in the accessory 
loops at the C-terminal end of the barrel, particularly in the b6-a6 and b7-a7 loops. 
The b6-a6 loop is extended by 13–14 residues in Rv2893 compared to the other 
structures (discussed further in Section 3.4.1), whereas the b7-a7 loop is 20–36 
residues shorter and does not fold over F420 to cap the barrel. Substrate binding 
cavities were also very different among the F420-LLHTs. 
 
 
 
Figure 3.12. Overall topology of different F420-dependent LLHTs. Structures of 
M. tuberculosis Rv2893, M. tuberculosis FGD (3B4Y), M. barkeri Mer (1Z69) and 
M. thermophilus Adf (1RHC) with F420 bound are shown. The b7-a7 loop is coloured blue, 
the b6-a6 loop red, and F420 is shown as yellow sticks. Compared with mtbFGD, bMer and 
Adf, the Rv2893 b7 strand is interrupted and instead of forming a single extended strand, a 
short beta strand at the N-terminal end of the b7-a7 loop follows the b7 strand and is 
coloured as part of the b7-a7 loop in Rv2893. 
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Figure 3.13. Multiple sequence alignment of LLHT proteins. Sequences are shown for 
M. tuberculosis Rv2893, M. smegmatis MSMEG_2516, and five other LLHTs (Table 3.6). 
F420-dependent LLHTs are indicated. Secondary structure features for Rv2893 are shown 
above the sequences and labelled according to Figure 3.10. The non-prolyl cis-peptide bond 
is shown in red and labelled. The start of the b7-a7 loop in Rv2893 forms part of an extended 
b7 strand in other F420-dependent LLHTs (Figure 3.12) and is indicated by a dashed blue 
line. Putative active site residues, the Rangipo G72S SNP, and the conserved glycine for 
F420 binding, are indicated below the sequences with red, black and green asterisks, 
respectively. The alignment was generated in STRAP (Gille and Frömmel 2001) using 
Aligner3D and the figure drawn using ESPript (Robert and Gouet 2014). 
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3.4.1 b6–a6 loop  
Superimposition and sequence alignment of Rv2893 with other F420-LLHTs  
shows that the region connecting b6 and a6 of the TIM barrel – the b6-a6 loop, has 
a 13–14 aa insertion in Rv2893 (Figure 3.13, Figure 3.14A). This loop appears to 
be a flexible region of the protein and was only able to be fully modelled in three 
of four chains in the F420-bound structures and for one pair of chains related by 
pseudo-translational symmetry in apo structures. The Rv2893 b6-a6 loop extends 
from the C-terminal end of the barrel bridging over the tail of F420 to contact the 
b4-a4 loop. Three conformational states were modelled for this loop; an ‘open’ 
confirmation observed in both F420 bound and apo monomers; a more closed state 
only observed in F420 bound monomers (closed-1); and a different closed state in 
monomers with Mn2+ and the unexpected ligand (closed-2) (Figure 3.14B). A fourth 
conformation also appears to be present in the apo structures, however it was not 
able to be fully modelled. In the open conformation, the region of the loop between 
Asp201 and Phe209 extends outwards from the core of the TIM barrel, whereas in 
the closed-1 form this region is bent ~90 º towards to the core of barrel to sit above 
His200. This loop is exposed to the substrate binding cleft and is associated with 
differing positions of His200, which may be important for substrate binding 
(Section 3.4.3).  
 
 
Figure 3.14. The b6-a6 loop. (A) Structural overlay of the b6-a6 loop from Rv2893 (green), 
mtbFGD (gold), bMer (cyan) and Adf (pink). (B) A surface representation of Rv2893 is 
shown coloured by hydrophobicity (red, hydrophobic; white hydrophilic) and the 
underlying b6–a6 loop shown as a black cartoon with His200 as sticks. The b6–a6 loop was 
modelled in three different conformations in Rv2893 termed ‘open’, ‘closed-1’ and 
‘closed-2’. The open confirmation is observed in both apo and F420 -bound monomers, 
whereas the closed-1 confirmation was only observed in F420 bound monomers, and 
closed-2 only in monomers with the unknown ligand bound.  
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3.4.2 F420 binding  
The apo- and F420-bound Rv2893 structures are highly similar with only minor 
conformational changes in the main chain (average RMSD 0.72 Å) (Appendix B.4). 
The most notable difference was observed in the b6-a6 loop, as discussed in the 
previous section. As in other F420-LLHTs, F420 is bound at the C-terminal end of the 
TIM barrel with the isoalloxazine ring positioned innermost to the core of the barrel 
and the tail projecting outwards (Figure 3.15). The tail of F420 binds in a largely 
negatively charged cleft created between helix a4, a5, and the b4-a4 and b5-a5 loops 
(Figure 3.15A). The b6-a6 loop folds over the cleft but is not within bonding 
distance of F420. The isoalloxazine ring binds with the Re-face adjacent to the 
non-prolyl cis-peptide that connects Leu74 and Val75, as in other F420-LLHTs 
(Figure 3.15B) (Aufhammer et al. 2004; Aufhammer et al. 2005; Bashiri et al. 
2008). Rv2893 has the conserved aspartate on the b2–a2 loop (Asp47) found in 
other F420-LLHTs that is thought to stabilise the bulge of the cis-peptide bond 
(Aufhammer et al. 2004). However, unlike the other F420-LLHTs the F420 
isoalloxazine ring system lacks the pronounced butterfly bend in Rv2893 (Figure 
3.15C). In Rv2893, the F420 isoalloxazine ring adopts a planar conformation with a 
bend in the C5 about the pyrimidine and phenol rings of only 7 º. 
Rv2893 predominantly contacts F420 through hydrogen bonds involving main chain 
amide and carbonyl groups (Figure 3.15D). The pyrimidine ring of the isoalloxazine 
ring makes three hydrogen bonds to the peptide backbone, one to the side chain of 
Asn77, and one to an ordered water. The phenolic ring at the other end is held in a 
predominantly hydrophobic environment and makes only one weak hydrogen bond 
with the peptide backbone to a water molecule. The OH groups of the ribitol and 
phosphate moieties and the first glutamate residue of the tail make several hydrogen 
bonds to the backbone before the remainder of the tail the extends into the solvent. 
Upon F420 binding the Ca of Asn178 on the b5–a5 loop shifts ~2.4 Å away from 
the F420 tail and its side chain flips outwards to accommodate the phosphate group 
of F420, which then hydrogen bonds the backbone amide of Asn178 and Gly179 
(Figure 3.15E). 
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Figure 3.15. F420 binding to Rv2893 and other LLHTs. (A) Cartoon representation of 
Rv2893 with a surface charge representation of the F420 binding site (surface carve set to 
5 Å). Local regions of positive, negative and neutral electrostatic potential are coloured 
blue, red and white, respectively. (B) The bulge created by the non-prolyl cis-peptide bond 
packs against the Re-face of the F420 isoalloxazine ring. Hydrogen bonding interactions of 
the ring are indicated by dark grey (strong bonds) and light grey (weak bond) dashed lines. 
(C) F420 binding in different LLHTs; M. tuberculosis Rv2893, M. tuberculosis FGD 
(3B4Y), M. barkeri Mer (1Z69) and M. thermophilus Adf (1RHC). F420 bound to Rv2893 
lacks the pronounced butterfly bend apparent in the other structures. (D) Schematic 
showing hydrogen bonding contacts to F420 (bold, dark grey). Oxygen atoms are coloured 
red, nitrogen atoms blue, and phosphorous gold. Strong hydrogen bonds are shown as black 
dashed lines and weak bonds as light grey dashed lines. The non-prolyl cis-peptide bind 
between Leu74 and Val75 is indicated. (E) Conformational shift of Asn178 upon F420 
binding to accommodate the phosphate group. The F420 bound conformation is shown in 
green and non-F420 bound in light blue.  
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3.4.3 Substrate binding region and active site 
The substrate binding site is at the base of a deep solvent exposed cleft above the 
Si-face of the F420 isoalloxazine ring system and has a predominately hydrophobic 
character (Figure 3.16). The guanidine group of the Arg110 sidechain sits above 
the imidazole group of His48 and together with His48 and His109, and His200, 
form a hydrophilic region above the pyrimidine ring. In mtbFGD and Adf, hydride 
transfer is mediated by conserved histidine (His40 and His39, respectively) and 
glutamate residues (Glu109 and Glu108, respectively) (Aufhammer et al. 2004; 
Bashiri et al. 2008). Although His40 plays a crucial role in mtbFGD catalysis, it 
has recently been shown not act as a general base as previously proposed (Oyugi et 
al. 2016). Rv2893 retains the conserved histidine, His48, and this adopts the same 
confirmation at the Si-face of F420 as in other F420-LLHTs and is presumably 
positioned to bond with the substrate and partake in catalysis. His109 occupies the 
site of the catalytic glutamate that serves as the general acid donating a proton to 
N1 of F420 (Oyugi et al. 2016). Depending of its protonation state, His109 could act 
as either a general base or acid in catalysis. In apo-monomers, the His109 sidechain 
adopts either the same conformation as in F420 bound monomers above the O4 atom 
of F420, or, is rotated about 90 º in the N-terminal direction and hydrogen bonds with 
the peptide backbone. A third histidine in Rv2893, His200 on the b6-a6 loop, is also 
positioned in the substrate binding region with the imidazole ring ~5 Å above the 
F420 ribitol moiety in a slightly offset stacked confirmation with His109. In this 
conformation, the sidechains of His48, His109 and His200 all point into the 
substrate binding region above the Si-face of F420. In Adf and mtbFGD an essential 
tryptophan residue on the b2–a2 loop stabilises the transition state (Aufhammer et 
al. 2004; Bashiri et al. 2008; Oyugi et al. 2016). Rv2893 lacks this residue and 
Arg110 on the b4-a4 occupies the region of the tryptophan sidechain, however the 
Arg110 sidechain was not able to be modelled in all chains suggesting it is highly 
labile.  
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Figure 3.16. Rv2893 substrate binding cleft. (A) Surface view of Rv2893 showing F420 
bound at the base of the cleft. Local regions of positive, negative and neutral electrostatic 
potential are coloured blue, red and white, respectively. The b6-a6 loop is in the closed-1 
conformation. (B) Detailed view of the substrate binding region. Sidechain residues that 
make up the substrate binding region are shown as sticks and a surface representation shows 
protein surfaces within 6 Å of F420 coloured by hydrophobicity (red, hydrophobic; white 
hydrophilic). Residues for chain A (b6-a6 loop in the open conformation) are shown in light 
grey, and chain B (closed-1 conformation) in a darker grey. The closed-1 conformation 
brings Val207 into the substrate binding region. 
 
The other end of the substrate binding region above the F420 phenol ring is 
comprised predominately of hydrophobic resides and shares similar characteristics 
with that of Adf. In Adf, Val193, Leu227 and Trp229 are positioned to interact with 
both the phenolic end of the F420 ring as well as the hydrocarbon end of the 
substrate. These residue characteristics are conserved in Rv2893, whereby Ala196, 
Leu240 and Phe302 occupy the corresponding positions. However, in Adf, the 
b7-a7 loop closes over the active site and interacts with b2-a2 and b4-a4 creating a 
substrate binding pocket that is completely buried inside the enzyme. These loops 
adopt a very similar conformation in M. tuberculosis FGD, although the mtbFGD 
substrate binding pocket comprises fewer hydrophobic and more polar residues. In 
Rv2893, the b2-a2 loop is shortened and the b7-a7 loop does not close over the core 
of the barrel, leaving a cleft above the F420 Si-face exposed to the bulk solvent. This 
cleft is also lined by predominantly hydrophobic residues and in the b6-a6 loop 
closed-1 conformation found only in F420 bound monomers (Section 3.4.1), the 
hydrophobic sidechain of Val207 also faces into the upper region of the substrate 
cleft above the F420 C5 atom, further contributing to the hydrophobic environment 
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(Figure 3.16B). Mer also lacks an expanded b2-a2 loop and the Si-face of F420 and 
substrate binding site are open and largely exposed to the bulk solvent.  
Electron density that was neither protein, water, nor F420, was observed in the 
substrate binding region in a single apo-monomer in both F420 bound structures 
(Figure 3.17). An Mn2+ cation was modelled into part of this density, however, 
despite attempts to identify the ligand using automated modelling of a ligand library 
in PHENIX and manually modelling numerous different ligands, its identity 
currently remains unknown. Binding of this ligand disrupts the arrangement of 
His48, His109 and His200 (Figure 3.17A) and the b6-a6 loop adopts the closed-2 
conformation. The His48 sidechain is rotated ~25 º away from the F420 pyrimidine 
ring and the Mn2+ cation occupies the site between the imidazole rings of His48, 
His109 and the carboxylate of Glu113 on the b4-a4 loop. The imidazole ring of 
His109 is shifted into the region occupied by the O2 and N3 atoms of F420 and the 
other end of the ligand is positioned where the hydroxyl group of the F420 phenolic 
ring binds. This would prevent F420 binding, therefore the bound ligand is unlikely 
to be a substrate of Rv2893 but rather may represent a competitive inhibitor or 
regulator.   
The ‘head’ of the ligand is positioned adjacent to the cation and the shape of the 
electron density in this region is highly suggestive of a phosphate group. Library 
ligands modelled by PHENIX frequently placed a phosphate group adjacent to the 
cation and the shape of the density is appropriate for either a phosphate or sulphate 
group. Modelling PO4- in provides a good fit to the density and provides the 
appropriate tetrahedral geometry for the coordination of Mn2+, as well making 
hydrogen bonds to the His200 and Arg110 side chains (Figure 3.17B). The 
unmodeled density extends ~11 Å from the phosphorous atom into the core of TIM 
barrel. Both the central region and tail end of the ligand are planar and the two 
planes are offset by an approximately 120 º rotation. The shape of the density and 
modelling in various cyclic compounds suggests at these regions might be occupied 
by monocyclic rings.  
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Figure 3.17. The unidentified ligand bound in the Rv2893 active site. (A) Arrangement of 
active site residues His48 and His109, and His200, in the substrate binding region and 
binding of the unexpected ligand (semi-transparent white blob). F420 is not found in 
monomers with the ligand bound (light blue sticks). F420-bound monomers with the b6-a6 
loop in the open and closed-1 conformations are shown as green and dark green sticks, 
respectively. Binding of the unexpected ligand disrupts the confirmation of the active site 
residues and the tail of the ligand occupies the region in which the hydroxyl of the F420 ring 
binds. (B) Phosphate modelled into the head end of the density for the unidentified ligand. 
Coordination of Mn2+ to His48, His109 and Glu113 is indicated by dashed red lines.  
Hydrogen bonds made by the phosphate are indicated with dark grey dashed lines for strong 
bonds and light grey dashed lines for weak bonds. 
 
 
3.4.4 The Rangipo specific SNP encoding a G72S mutation 
The Rangipo specific G72S mutation site is positioned at the base of the bulge 
created by the non-prolyl cis-peptide bond (Figure 3.19). No major global or local 
topology changes were observed between the wild type Rv2893H37Rv and Rangipo 
variant Rv2893G72S structures (average RMSD between apo monomers 0.44 Å).  
 
Figure 3.18. Rangipo specific G72S SNP. Superimposition of F420-Rv2893H37Rv (green) and 
F420-Rv2893G72S (dark teal) with the SNP site and non-prolyl cis-peptide bond indicated. In 
F420-Rv2893H37Rv, an ordered water molecule (red sphere) occupies a similar position as the 
Ser72 hydroxyl group. No other local or global rearrangements were observed. 
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The non-prolyl cis-peptide bond is conserved in other F420-LLHTS and is important 
for F420 binding and catalysis as it creates a bulge that packs against the Re-face of 
F420, helping induce a butterfly bend in the F420 isoalloxazine ring system increasing 
its reactivity (Bashiri et al. 2008). Although the mutation is not in a position to 
directly interact with F420 or the substrate, its location at the base of this bulge is a 
prime position for having a functional effect via interaction with the bulge.  
Examination of the region and adjacent b-sheets shows that the G72S mutation 
creates two additional hydrogen bonds between the b3 and b4 strands (Figure 3.19B) 
which may explain the increased thermal stability observed for the G72S variant 
compared to the wild-type (Section 3.3.3). In Rv2893G72S, the OH group of Ser72 
makes hydrogen bonds to the backbone carbonyl groups of Thr73 on b3 and Glu102 
on b4, as well as with another ordered water that also hydrogen bonds to the 
carboxylate group of Glu102. In Rv2893H37Rv, these intramolecular hydrogen bonds 
are lost and an ordered water sits between the two b-strands in the site occupied by 
the Ser72 hydroxyl and makes hydrogen bonds to the carbonyl groups of Thr73 and 
Glu102, and to the other ordered water.  
 
 
 
Figure 3.19. Structural location of the Rangipo specific G72S SNP. Arrangement of the 
residues surrounding the SNP position and non-prolyl cis-peptide bond in (A) Rv2893H37Rv 
and (B) Rv2893G72S. Ordered water molecules are shown as red spheres and F420 as yellow 
sticks. Intra-molecular hydrogen bonds are indicated by yellow dashed lines, and hydrogen 
bonds to water molecules by light grey dashed lines. Hydrogen bond distances were all 
within 2.7-3.1 Å and the non-prolyl cis-peptide bond is indicated. 
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3.5 Discussion 
Members of the M. tuberculosis complex (MTBC) are genetically more diverse 
than traditionally assumed and increasing evidence suggests strain genetic 
background impacts virulence phenotypes and can have important clinical and 
epidemiological consequences (Section 1.4.1). Understanding the molecular 
mechanisms underlying this variation is an essential step towards understanding the 
complex relationship between bacterial genotype, virulence, and clinical outcomes. 
SNPs are one of the most common forms of genetic variation in the MTBC and 
have the potential to alter bacterial phenotype if they change the amino sequence of 
encoded proteins or alter transcriptional regulation. 
The Rangipo strain has been the source of numerous tuberculosis outbreaks in New 
Zealand over the past 30 years and has been suggested to be highly virulent relative 
to other circulating strains (Section 1.1.3). Characterising the consequences of 
genetic variation unique to this strain may help understand factors contributing to 
its success. Analysis of whole genome SNP data from the New Zealand Rangipo 
M. tuberculosis cluster identified several Rangipo specific nsSNPs predicted to 
affect protein function (Section 2.2.2.2) and thereby may affect bacterial phenotype. 
The putative F420-dependent oxidoreductase Rv2893 harbours a G72S mutation that 
I have identified as specific to the Rangipo strain (nsSNP) and is predicted to effect 
protein function in silico (Section 2.2.2.4). This SNP was selected for further 
investigation based on the biological roles of its predicted cofactor F420 in 
M. tuberculosis, as well as for practical considerations. F420 is an unusual low-redox 
potential cofactor that enhances the metabolic flexibility of mycobacteria and is 
important for survival in challenging environments (Gurumurthy et al. 2013; Hasan 
et al. 2010; Jirapanjawat et al. 2016; Purwantini and Mukhopadhyay 2009). 
However, the mechanisms by which F420 contributes to this and its roles in 
M. tuberculosis metabolism remain poorly understood.  
Crystal structures of Rv2893 were solved at 2.12–2.31 Å for the M. tuberculosis 
reference strain H37Rv protein and the Rangipo G72S variant in the apo-form and 
with F420 bound, confirming this protein is indeed an F420-dependent LLHT. Despite 
being expressed in M. smegmatis cells, which produce F420, Rv2893 purified 
without F420 bound and it had to be soaked into Rv2893 crystals to obtain the 
liganded structure. The same scenario was reported for mtbFGD expressed in 
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M. smegmatis and its F420-bound structure was also obtained by soaking crystals in 
F420 (Bashiri et al. 2008). Conversely, M. tuberculosis F420-reducing 
hydroxymycolic acid reductase (fHMAD, Rv0132c) (Purwantini and 
Mukhopadhyay 2013) (also an LLHT family protein), has also been expressed in 
M. smegmatis and was found to co-purify with F420 (Bashiri et al. 2012). These are 
the only other published M. tuberculosis F420-dependent LLHTs that have been 
purified and characterised, although the F420-dependency of an additional 
mycobacterial LLHT – phthiodiolone ketoreductase (fPKR) (Rv2951c), has also 
been experimentally validated (Purwantini et al. 2016). Rv2893 therefore increases 
the number of experientially confirmed F420-binding LLHTs in M. tuberculosis to 
four.  
There are only three other F420-dependent LLHT structures complexed with F420 
deposited in the PDB; mtbFGD (3B4Y), Adf (1RHC) and bMer (1Z69), and a 
further three without F420 bound; rhFGD (5LXE), kMer (1EZW) and tMer (1F07). 
The overall binding mode of F420 in Rv2893 is the same as in mtbFGD, bMer and 
Adf with the F420 isoalloxazine ring bound innermost and its Si-face exposed to the 
substrate binding region. However, in Rv2893 the F420 isoalloxazine ring lacks the 
pronounced butterfly bend apparent in the other structures, despite conservation of 
the non-prolyl cis-peptide bond. Non-prolyl cis-peptide bonds are energetically 
unfavourable features rarely found in protein structures and tend to occur in 
important regions, such as next to an active site (Jabs et al. 1999). In F420-LLHTs 
the non-prolyl cis-peptide bond is important for F420 binding and catalysis as it 
creates a bulge that packs against the Re-face of the isoalloxazine ring, inducing the 
formation and stabilisation of a butterfly bend confirmation about the C5 atom. This 
bent conformation is energetically unfavourable for oxidised F420 and is important 
for catalysis as in this conformation the C5 carbon adopts a more tetrahedral sp3-like 
geometry, increasing its reactivity (Aufhammer et al. 2004; Bashiri et al. 2008). 
This pronounced bend was not observed in Rv2893, and it is speculated that 
substrate binding may be required to induce this more reactive confirmation in 
Rv2893. In both Adf and bMer, protein residues pack against the phenol ring of 
F420 inducing the bent conformation, and in FGD1 rather than protein residues, the 
inhibitor citrate packs against F420 ring and promotes the bend (Bashiri et al. 2008). 
Rv2893 lacks packing above the phenol ring either from substrate or protein 
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residues and substrate binding may therefore be required to promote the butterfly 
bend and assist catalysis.  
The Rangipo G72S mutation is located adjacent to the non-prolyl cis-peptide and 
creates two additional hydrogen bonds between the b3 and b4 strands. Melting 
temperature analysis by DSF indicated that the Rangipo Rv2893G72S variant has 
higher thermal stability than the wild-type Rv2893H37Rv protein, which may be 
explained by these additional intra-molecular bonds. Although there is no simple 
relationship between changes in protein stability and protein functional changes, 
mutations that change stability frequently affect protein function (Bromberg and 
Rost 2009). Changes in stability alter the ratio of folded to unfolded molecules; high 
stability results in more folded molecules, whereas low stability results in a higher 
proportion of unfolded molecules and increases the propensity for aggregation. 
Changes in stability can have important phenotypic consequences, in humans for 
example, the majority of disease associated single nucleotide mutations affect 
protein stability, although typically these are destabilising mutations (Wang and 
Moult 2001). While the effects of destabilising mutations causing protein 
aggregation and decreasing the pool of active molecules are readily appreciated, 
changes that increase stability can also have marked effects. As well as increasing 
the ratio of folded to unfolded molecules, highly thermostable proteins are also 
more resistant to proteolysis (Daniel et al. 1982). Most notably, increasing stability 
can reduce flexibility, a critical feature of protein catalysis. There is a fine balance 
between protein stability and flexibility, whereby proteins must be rigid enough to 
retain confirmations required for function, but also still labile enough to allow 
structural changes required for substrate binding and catalysis. Thus, increased 
stability can adversely affect activity if it inhibits required conformational changes. 
No notable changes were apparent in F420 binding between Rv2893H37Rv and 
Rv2893G72S in the crystal structures, however, in biological reality proteins are not 
rigid molecules as portrayed in structural models. Thus, considering the location of 
the G72S mutation at the base of the cis-peptide bulge and the important role this 
feature plays in F420 binding and catalysis, concomitant with its effects on overall 
stability, it is speculated that this mutation will likely influence F420 binding affinity 
or catalysis in solution. Further work needs to be undertaken to characterize the 
binding kinetics of F420 to Rv2893H37Rv and Rv2893G72S to determine this. 
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Whether additional stability imposed by the G72S SNP impairs or enhances 
Rv2893 enzyme activity, its consequences on bacterial phenotype are likely to be 
largely dictated by its functional role in M. tuberculosis. Rv2893 retains the 
conserved catalytic histidine (His48) and another histidine (His109), occupies the 
site of catalytic acid found in other F420-LLHTs. Depending on its protonation state, 
His109 could act as either a general base or acid in acid-base catalysis and Rv2893 
therefore retains the necessary active site chemistry that would enable it to catalyse 
hydride transfer. It remains unclear whether Rv2893 is an F420-reducing 
dehydrogenase or an F420H2-reductase. FGD is the main source of F420H2 in 
M. tuberculosis. This apparent from the phenotypic effects produced by disrupting 
the gene encoding FGD, which reflect those produced by eliminating F420 
biosynthesis (Jirapanjawat et al. 2016; Purwantini and Mukhopadhyay 2009). 
fHMAD is also an LLHT family F420-reducing dehydrogenase (Purwantini and 
Mukhopadhyay 2013). The majority of other F420-dependent LLHTs however are 
expected to be reductases (Greening et al. 2016). It therefore seems more likely 
Rv2893 is a F420H2-reductase than a F420-reducing dehydrogenase. 
Rv2893 shares structural homology with other microbial F420-LLHTs; Mer, Adf 
and FGD, as well as non-F420-dependent LLHTs. These act on a diverse range of 
different substrates and have a broad range of roles in different organisms. FGD 
enzymes oxidise glucose-6-phosphate to 6-phospho-gluconolactone producing 
F420H2 which is then used by F420-dependent reductases. Mer is involved in CO2 
reduction in methanogenic archaea and catalyses the reduction of 
N5,N10-methylene-tetrahydromethanopterin to N5-methyl-tetrahydromethanopterin, 
with concomitant oxidation of F420H2 to F420. Adf is a secondary alcohol 
dehydrogenase also found in methanogenic archaea and enables isopropanol to be 
used a hydrogen donor for CO2 reduction, reducing F420 in the process (Widdel and 
Wolfe 1989). Rv2893 is well suited to bind a hydrophobic substrate and shares 
notable similarities with Adf in terms of the hydrophobic characteristics of the 
residues comprising the substrate binding site. However, unlike Adf, the Rv2893 
substrate binding region has a more open character which would allow for binding 
of a larger substrate. The Mer substrate, methylene-tetrahydromethanopterin, is also 
much bulkier than those of FGD and Adf, and accordingly Mer has a relatively open 
substrate binding cleft rather than a tight substrate binding pocket.  
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Interestingly, F420-bound structures were also found to be complexed with a 
currently unidentified ligand. This ligand represents a competitive inhibitor or 
regulator as the structural changes it induces would be inhibitory for F420 binding 
and catalysis. The head of the ligand is suggested to be a phosphate group and the 
remainder appears to comprised of one or more monocyclic rings, likely with a 
hydrophobic nature. As it was only bound in monomers unoccupied by F420 its 
binding is not dependent on F420 binding, so it is curious that it was not bound in 
the apo structures. Its presence could potentially be the result of an impurity in the 
F420 purification introduced during soaks. Alternatively, both apo, but not F420 
bound structures, were solved from crystallised protein that had been purified with 
DDM in lysis and IMAC buffers. This detergent may have stripped away the ligand 
early on the purification. Identification of this ligand will likely provide additional 
clues as to the function of Rv2893 and further work needs to be undertaken to 
determine its identity.  
 
3.5.1 Conclusions 
The structure of the M. tuberculosis putative F420-dependent oxidoreductase 
Rv2893 has been solved showing it shares the same overall TIM barrel fold as other 
bacterial LLHTs and validating it as an F420-binding protein. Only three other 
F420-LLHT structures complexed with cofactor F420 are currently available and this 
structure represents just the second F420-LLHT from M. tuberculosis. The Rv2893 
active site region and F420 binding mode share conserved features found in other 
F420-LLHTs important for F420 binding and enzyme catalysis. However, in Rv2893 
F420 lacks the pronounced butterfly bend and substrate binding may be required to 
induce this more reactive confirmation. The Rangipo specific G72S mutation is 
located at the base of the bulge created by the non-prolyl cis-bond important for 
F420 binding and catalysis. This SNP creates additional intramolecular hydrogen 
bonds and increases the thermal stability of Rv2893, which may have important 
consequences for F420 binding and/or enzyme activity. The biological consequences 
of this SNP will largely depend on the function of this protein in M. tuberculosis 
and further work will seek to elucidate its role. This will provide new insights 
regarding the role of F420 in M. tuberculosis and enable further investigation into 
the functional consequences of the Rangipo G72S SNP. 
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4 Chapter Four 
Evolutionary analysis of the Rangipo  
and Otara tuberculosis clusters 
4.1 Introduction 
Modern tuberculosis strain diversity in New Zealand Europeans, Māori and Pacific 
People is dominated by L4/Euro-American strains (Yen et al. 2013). Although the 
annual incidence rate of TB notifications in New Zealand is comparatively low at 
around 6.5 cases per 100,000 population, the disease disproportionally affects 
Māori and Pacific People (ESR 2018). Around three-quarters of Mycobacterium 
tuberculosis isolates from Māori and Pacific People have non-unique MIRU-VNTR 
molecular typing patterns and this is typically interpreted to indicate recent 
transmission of strains. The two largest M. tuberculosis clusters in New Zealand - 
the Rangipo and Southern Cross clusters, are most prevalent in Māori and Pacific 
People, respectively. The Otara cluster is another large cluster predominantly found 
in Pacific People. The Rangipo cluster is of particular public health concern due to 
it being a source of several outbreaks over the last thirty years and it has also been 
suggested to be highly virulent (Colangeli et al. 2014; De Zoysa et al. 2001; 
McElnay et al. 2004).  
One of the main objectives of this chapter was to trace the historical origins and 
dispersal of the Rangipo and Otara clusters. Both of these clusters belong to the 
L4.4 sublineage, which is the most prevalent L4/Euro-American sublineage in New 
Zealand born tuberculosis cases (43% of L4 cases) (Stucki et al. 2016b). Oceania 
was the last major global region to be reached by Europeans and it is generally 
assumed that tuberculosis was absent from New Zealand prior to European arrival 
(Durie 1998). When considering tuberculosis in New Zealand it is important to 
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understand the migratory and colonial history of New Zealand and the wider  
South Pacific.  
 
4.1.1 Historical and demographic context 
Oceania is geographic region in the Pacific Ocean comprised of Australia, 
Melanesia, Micronesia and Polynesia. The Polynesian sub-region is made up of 
over one thousand islands scattered across the central and southern Pacific Ocean, 
extending from Hawaii to the north to New Zealand and Easter Island to the south 
and east (Figure 4.1). New Zealand is home to both the indigenous Māori 
population and the largest diaspora communities of indigenous Polynesian people 
(Spickard et al. 2002), offering a unique setting for the investigation of 
M. tuberculosis dispersal and transmission in the South Pacific.  
 
 
Figure 4.1. Map of Oceania highlighting the Polynesian sub-region (blue). 
(Modified from https://commons.wikimedia.org/wiki/File:Oceania_UN_Geoscheme_ 
Regions_with_Zones_and_ISO3166_labels.svg) 
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Māori make up 15% of the New Zealand population and Pacific People account for 
7% (StatsNZ 2013). The majority of New Zealand’s Pacific island population 
identify with ethnic groups from Polynesia (excluding Hawaii), and Fiji is the only 
notable contributor from outside this region (4.9% of Pacific People identify as 
Fijian). The three major Pacific ethnic groups represented in New Zealand are 
Samoan, Cook Island Māori and Tongan, and 90% of Pacific People in New 
Zealand identify with one or more of these groups (StatsNZ 2013).  
 
4.1.1.1 Early European presence in Polynesia 
The islands of Polynesia have been inhabited by humans for around three thousand 
years, whereas Europeans have only been part of the history of this region for 
approximately the last five hundred years. The early-1500s to late-1700s were an 
era of great European exploration in the South Pacific, dominated by the Spanish 
in the 1500s, the Dutch in the 1600s, and then the British and French from the mid-
1700s. These early voyages commonly involved contact and trade with local 
communities, however, early contact between Europeans and indigenous Pacific 
peoples was both irregular and brief. The great European exploration and scientific 
voyages ceased from the late 1700s and the European presence in the Pacific began 
to be dominated by whalers, sealers and other traders. This led to the establishment 
of more regular and intensified contact between Pacific Islanders and Europeans 
and had much greater lasting impacts on Pacific societies than the previous passing 
visits of European explorers. The whaling industry had a particularly profound 
effect on indigenous Pacific Island populations and was a major driving force for 
European colonisation. From 1840, European colonies and protectorates were 
established, however with the exception of New Zealand (Section 4.1.1.2), the 
islands of Polynesia did not receive mass influxes of European migrants. The 
increasing volume of European ships passing through the Southern Pacific also 
promoted the growth of trading settlements and larger commerce hubs. Pacific 
societies changed significantly as people relocated to harbours for work and trade, 
and local economies shifted to provide goods for trade. (Campbell 2011; Fischer 
2013).  
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4.1.1.2 European discovery and early settlement of New Zealand 
The Polynesian ancestors of the Māori arrived in New Zealand around 
1230-1280 AD during an era of widespread Polynesian voyaging (King 2004; 
Wilmshurst et al. 2011). The era of long-distance Polynesian voyaging rapidly 
declined around 1450 AD (Rolett 2002) and Māori were isolated from island 
Polynesia and the rest of the world for several hundred years until the arrival of 
Europeans. The first European explorer to reach New Zealand was the Dutch 
explorer Abel Tasman in 1642, however it was not until 1769 that the first European 
set foot in New Zealand, Englishman Captain James Cook. Cook met with Māori 
on numerous occasions and the consequences of these encounters have been 
described as “far-reaching, although they did not change the cultural pattern or the 
quality of day-to-day Māori life” (King 2004). The French became interested in the 
Pacific around the same time as the English. French explorers were the only other 
Europeans who played significant role in mapping the New Zealand coastline, and 
they also interacted with local Māori during visits to New Zealand (Wilson 2016). 
The first Europeans to live in New Zealand were predominantly sealers, whalers, 
ship deserters or convicts, many of whom were of English or Irish descent (Phillips 
2015). European migration initially occurred at low levels, just over 300 Europeans 
had settled in New Zealand by 1830 and this increased to around 2,000 by 1840 
(King 2004). From 1840 the rate of immigration increased significantly and by the 
end of the 19th century the European population numbered nearly 800,000 (Orange 
2012) (Figure 4.2). The majority of Europeans who moved to New Zealand were 
from Britain and Ireland, with only minor contributions from other countries 
including a small number of French who settled in Akaroa (fewer than 100), and 
281 Germans who settled near Nelson (Phillips 2015). 
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Figure 4.2. Māori and European population in New Zealand, 1840–1901.  
Source: Orange (2012). 
 
 
4.1.1.3 New Zealand and the Pacific Islands 
From the early 1800s only very small numbers of Pacific people began to settle in 
New Zealand and by 1916 when the first census data counting Pacific ethnicities is 
available there were only 151 Pacific Island Polynesians in New Zealand (StatsNZ 
1916). The Pacific population began to slowly increase in the first half of the 20th 
century until a surge in migration in the 1950s to early 1970s with most migration 
coming from Samoa, the Cook Islands, Tonga, Niue, Tokelau and Fiji (Dunsford et 
al. 2011). Between 1951 and 1976 the Pacific Island Polynesian population 
increased from 3,624 to 61,354 (StatsNZ 1996) (Figure 4.3) and there are now 
approximately three hundred thousand Pacific people in New Zealand, comprising 
seven percent of the population (StatsNZ 2013).  
 
 
Figure 4.3. Pacific Island Polynesian population in New Zealand, 1916-1976.  
Source: (StatsNZ 1996). 
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4.1.1.4 A brief history of tuberculosis in New Zealand  
Tuberculosis is generally considered to have been absent from New Zealand prior 
to European arrival (Durie 1998). The disease may have been introduced as early 
as the arrival of English captain James Cook in 1769, as crew suffering from 
tuberculosis were present on the Endeavour (Gluckman 1976). Māori deaths from 
tuberculosis following voyages to England have been recorded as early as 1807 and 
by the 1830s high tuberculosis rates amongst Māori were becoming apparent 
(Gluckman 1976). In the first two decades of the 20th century public health efforts 
and discussion around tuberculosis in New Zealand focused on Europeans and the 
tuberculosis problem in Māori was largely ignored (Dow 1999; Durie 1998). By the 
1920s, the threat of tuberculosis to Māori was well known, however, the full extent 
of the problem was not acknowledged until the 1930s (Dow 1999). Although 
European tuberculosis morality rates have been recorded since the 1870s, the first 
reliable records for Māori mortality rates were not collected until the 1930s and 
show rates as high as 407.8 per 100,000 population (MacLean 1964). Following 
intensified public health efforts in the 1940-1950s, there was a marked decline in 
Māori tuberculosis notification rates (Figure 4.4) and by the 1970s tuberculosis was 
considered to have been bought under control (Durie 1998). Māori rates however, 
were still around five times higher than in Europeans, a trend that continues to 
persist today.  
 
 
Figure 4.4. New Zealand tuberculosis notification rates for European and Māori, 
1945-1978. Source: Appendices to the Journals of the House of Representatives (AJHR), 
H-31, 1951-97 in Dunsford (2008). 
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In 2015, the European and Other ethnic group had a tuberculosis notification rate 
of 0.6/100,000, whereas the rate in Māori was 3.2/100,000, and in Pacific People 
20.2/100,000 (ESR 2018). Furthermore, around three-quarters of M. tuberculosis 
isolates from Māori and Pacific People have non-unique molecular types (i.e. are 
clustered) compared to approximately one-third in the European or Other group 
(ESR 2018). Molecular clustering is typically interpreted to indicate recent 
transmission but can also represent the reactivation of latent infection of endemic 
strains (Nguyen et al. 2003). 
 
4.1.2 Phylodynamics and molecular dating  
Phylodynamic approaches combining molecular-dating with spatial and 
epidemiological data offer a powerful way to study pathogen evolution in space and 
time. Recent phylodynamic studies of M. tuberculosis have provided valuable new 
insights into the evolution of drug resistance (Eldholm et al. 2015; Eldholm et al. 
2016), the emergence and spread of outbreaks (Bjorn-Mortensen et al. 2016; 
Roetzer et al. 2013), and historic events associated with M. tuberculosis dispersal 
(Eldholm et al. 2016).  
Molecular dating methods estimate rates of genomic evolution in units of time, 
enabling absolute timescales to be placed on phylogenetic trees and evolutionary 
events such as lineage divergence or the appearance of mutations to be dated. 
Converting rates of sequence evolution and divergence events from relative to 
absolute time requires calibration of the molecular clock. Clock calibrations can be 
performed using information from the fossil record, geological or historical events, 
or from sample tip-dates. Tip-based calibration requires that samples are collected 
at different time points and that sequence data captures measurable levels of genetic 
change with time, providing a clock like signal that is used to calibrate the tree. 
Sequences that have these properties are termed ‘measurably evolving’ or 
‘heterochronous’ (Drummond et al. 2003). The ability to capture sufficient 
temporal signal in the data is dependent on the mutation rate, the number of variable 
sites in the sequences, and the temporal width of the sampling interval (Rieux and 
Balloux 2016). Whole genome sequencing of large datasets of bacterial pathogens, 
such as M. tuberculosis, shows the accumulation of genetic variation over 
epidemiological timescales, pushing M. tuberculosis into the realm of measurably 
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evolving populations and allowing tip-based calibration for fine-scaled molecular 
dating studies (Biek et al. 2015). The increased accessibility of whole genome 
sequencing (WGS) has also led to the sequencing of thousands of MTBC strains 
from throughout the globe and the deposition of this data into public repositories 
provides a rich archive of genomic data for studies of MTBC diversity and 
dispersal. 
 
4.1.3 Objectives 
Our collaborators Greg Cook and Htin Aung at the University of Otago, N.Z., have 
sequenced the genomes of thirteen Rangipo, seven Otara and five Southern Cross 
isolates on the Illumina MiSeq platform. This chapter presents genomic analyses I 
have undertaken using these data. The primary objectives of these analyses were; 
(1) to characterise the phylogenetic relationships and genetic diversity within and 
between these clusters, and (2) to trace the evolutionary history and identify the 
historical origin of the Rangipo strain. 
 
 
4.2 Methods 
4.2.1 Whole genome sequencing of New Zealand M. tuberculosis isolates 
4.2.1.1 Clinical M. tuberculosis isolates 
Clinical New Zealand M. tuberculosis isolates or genomic DNA (gDNA) for whole 
genome sequencing were kindly provided by the Waikato Hospital, Hamilton, New 
Zealand, and LabPLUS, Auckland, New Zealand.  
Thirteen isolates in the Waikato Hospital archive that had been identified as 
Rangipo strains on the basis of contact tracing and/or IS6110 molecular typing were 
available for WGS. Collection dates spanned an 18-year period (1991–2009). Four 
isolates; O, F, R/C2 and A, have previously been sequenced on the ABI SOLiD 
platform (Colangeli et al. 2014), and were re-sequenced under the IDs NZLK, 
NZLL, NZLM, NZLN, respectively. NZLK, NZLL and NZLN have previously 
been sent to LabPLUS for MIRU-VNTR 24-loci typing and share the ‘primary’ 
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Rangipo MIRU-VNTR 24-loci profile (233325153324-341444223362) (Ruthe 
2015).  
Seven Otara and five Southern Cross isolates were selected for WGS by 
collaborators at LabPLUS. These were chosen to encompass a range of collection 
dates and variant MIRU-VNTR 24-loci typing patterns among Otara cluster 
isolates. All Southern Cross isolates had identical MIRU-VNTR 24-locus profiles 
(123326153326-343224123253). Three Otara isolates (NZL01, NZL10, NZL13) 
shared the ‘primary’ Otara MIRU-VNTR 24-locus profile and the remaining four 
isolates represented three Otara variants (Appendix C.1). Collection dates of the 
Southern Cross strain isolates spanned a 13-year period (2002–2015) and Otara 
strain isolates spanned a seven-year period (2006–2013). 
 
4.2.1.2 Whole genome sequencing 
Rangipo isolates provided by the Waikato Hospital were sent to collaborators Greg 
Cook and Htin Aung at the University of Otago for culture and gDNA extraction as 
previously described (Aung et al. 2016). gDNA extracted from Otara and Southern 
Cross isolates was provided by collaborators Sally Roberts and James Bower at 
LabPLUS for sequencing. gDNA was sequenced at New Zealand Genomics 
Limited (Otago, New Zealand) using paired-end 250-bp reads on an Illumina 
MiSeq using the NexteraTM XT DNA Kit (Illumina Inc., Hayward, CA). For all 
isolates, raw paired-end sequencing data was supplied in fastq format for analysis.  
 
4.2.2 Lineage assignment 
Fastq files were analysed in the program KvarQ (Steiner et al. 2014) using the 
‘coll14’ test suite to determine MTBC lineage. This test suite contains the full set 
of MTBC barcode/marker single nucleotide polymorphisms (SNPs) described in 
Coll et al. (2014). The ‘resistance’ test suite was used to screen isolates for common 
drug resistance mutations. This test suite contains common drug 
resistance-associated SNPs and checks short gene regions known to harbour 
different drug resistance-associated mutations (Steiner et al. 2014). 
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4.2.3 Global M. tuberculosis L4.4 dataset  
4.2.3.1 Additional Rangipo M. tuberculosis genomes 
An additional nine Rangipo genomes from a recently published study (Gautam et 
al. 2017) were kindly provided by Ronan O’Toole and Sanjay Gautam (University 
of Tasmania, Australia) for inclusion in the analyses. These isolates came from 
multiple geographical locations and were collected over a two-year period  
(2010–2011). Eight isolates shared identical Rangipo strain MIRU-VNTR 24-loci 
profiles (233325153324 341444223362), and the ninth isolate (strain 356) differed 
at one locus (Gautam et al. 2017). The code ‘NZLR’ was added to the start of the 
published IDs of each of these isolates. 
 
4.2.3.2 Canadian DS6Quebec lineage M. tuberculosis genomes 
Unpublished WGS data for 25 Canadian clinical isolates belonging to the  
DS6Quebec lineage were kindly provided by Caitlin Pepperell (University of 
Madison-Wisconsin, Wisconsin, U.S.A.). These were selected to encompass a 
broad range of collection dates and molecular typing patterns. Libraries were 
prepared as previously described (Eldholm et al. 2016) and sequenced on the 
Illumina MiSeq platform.  
 
4.2.3.3 Publicly available L4.4 genomes 
A list of 401 L4.4 genomes in publicly available databases was kindly provided by 
Sebastien Gagneux and Daniela Brites (Swiss Tropical and Public Health Institute, 
Basel, Switzerland). This list had been generated by screening over 12,000 genomes 
using KvarQ (Steiner et al. 2014) and IDs of genomes identified as L4.4 extracted. 
From the provided list, I excluded genomes that were identified as having low 
(<10X) or mixed coverage. Metadata for the remaining genomes were obtained 
from the NCBI Short Read Archive (SRA) (https://www.ncbi.nlm.nih.gov/sra) and 
the European Nucleotide Archive (ENA) (https://www.ebi.ac.uk/ena), and relevant 
publications in which genomes were first described. Genomes were excluded if 
country data was not available. If multiple genomes were available for an isolate 
only the first was included. Literature searches together with KvarQ screening of 
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fastq files was performed to identify additional recent L4.4 isolates not deposited 
when the original list was compiled.  
Publicly available genomes included in the final L4.4 dataset (Section 4.2.3.4) 
included 188 genomes from 17 countries from recently published studies  
(Bjorn-Mortensen et al. 2016; Bryant et al. 2013a; Bryant et al. 2013b; Casali et al. 
2014; Casali et al. 2012; Clark et al. 2013; Guerra-Assunção et al. 2015; 
Guerra-Assunção et al. 2014; Holt et al. 2018; Walker et al. 2013a; Zhang et al. 
2013) and Broad Institute initiatives (broadinstitute.org) (Appendix C.4). Genomes 
were downloaded from the NCBI Short Read Archive (Leinonen et al. 2011) using 
fastq-dump (available in the NCBI SRA Toolkit). 
 
4.2.3.4 Datasets for phylogenetic analyses 
Two datasets were used for phylogenetic analyses: a global L4.4 dataset for 
maximum likelihood phylogenetic analysis (dataset 1, n = 236); and a subset 
comprised of all high quality L4.4.1.1/S isolates with known year of isolation for 
Bayesian phylogenetic analysis and molecular dating (dataset 2, n = 117) 
(Appendix C.4). Genomes were only included if they met the quality criteria 
described in Section 4.2.4. Datasets included New Zealand Rangipo and Otara 
cluster isolates sequenced on the Illumina platform as part of this project (Section 
4.2.1), previously published Rangipo isolates (Section 4.2.3.1), Canadian DS6Quebec 
lineage isolates (Section 4.2.3.2) and other global L4.4 genomes (Section 4.2.3.2).  
 
4.2.4 Reference guided assembly and variant calling 
FASTQ files were processed through the Reference Guided Assembly Pepperell 
Lab Pipeline (available at https://github.com/pepperell-lab/RGAPepPipe). Raw 
reads were trimmed using a quality threshold of 15 and reads less than 20 bp  
long were discarded using TrimGalore!, a wrapper script around Cutadapt (Martin 
2011) and FASTQC (Andrews 2010). Trimmed reads were mapped to the 
M. tuberculosis H37Rv reference genome (NC_000962.3) (Cole et al. 1998b) using 
BWA MEM (Li 2013). Duplicates were removed using Picard tools 
(http://broadinstitute.github.io/picard) and local realignment around indels was 
performed using GATK (DePristo et al. 2011). Variants were called with Pilon 
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(Walker et al. 2014) using a minimum depth threshold of 10, base quality of 20 and 
mapping quality of 40. VCF files generated by Pilon were converted to FASTA 
format using Pepperell lab in house scripts that treat ambiguous calls and deletions 
as missing data (‘?’ and ‘-’).  
Bases in or within 10 bp of repetitive regions, including genes annotated as 
PE/PPE/PGRS, REP13E12, transposable and phage elements were removed from 
FASTA sequences prior to alignment as these are prone to mapping errors. 
Geneious R8 (Biomatters, N.Z.) was used to search H37Rv reference annotations 
(NC_000962.3) to identify repetitive regions and these were curated into a bed file. 
Repetitive regions were masked in FASTA files using bedtools maskfasta and then 
removed.  
Mapping quality was assessed using Qualimap (Garcia-Alcalde et al. 2012). 
Genomes were excluded if the depth of coverage was <25X or if <75% of reads 
mapped to the reference genome. Genomes with missing data at >10% of sites were 
excluded from further analyses. 
 
4.2.5 Phylogenetic inference  
4.2.5.1 Nucleotide Alignments 
Variant sites were extracted from concatenated whole genome alignments using 
SNP-sites (Page et al. 2016). Only genomes with missing data at <10% of sites and 
sites where at least 90% of isolates had high quality base calls were included in 
phylogenetic and molecular dating analyses. The alignment-thin tool in the program 
BALi-Phy (Suchard and Redelings 2006) was used to remove positions from 
alignments with <90% high confidence base calls.  
 
4.2.5.2 Selection of nucleotide substitution model  
jModelTest2 (Darriba et al. 2012; Guindon and Gascuel 2003) was used to perform 
statistical selection of the best fitting nucleotide substitution model for phylogenetic 
analyses. SNP alignments were input into jModelTest2 (Darriba et al. 2012) and 
options were set to include models with different rate categories (x4) and unequal 
base frequencies. Models with invariant sites were not considered as by default SNP 
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alignments lack invariant sites. Model selection was based on the Bayesian 
information criterion. 
 
4.2.5.3 Maximum likelihood phylogenetic analysis 
Maximum likelihood phylogenetic trees were inferred from SNP alignments in 
PhyML (Guindon et al. 2010; Guindon and Gascuel 2003) using x1000 bootstrap 
replicates and the general time reversible (GTR) substitution model as this was the 
best fitting model jModelTest2 (Section 4.2.5.2). Trees were visualised in ggplot 
(Yu et al. 2017) and Figtree (tree.bio.ed.ac.uk/software/figtree/). Mesquite was 
used to infer SNP distances along branches by parsimony reconstruction of 
ancestral states using maximum likelihood trees and SNP alignments as input. 
 
4.2.6 Diversity and clustering analyses 
The R-package PopGenome (Pfeifer et al. 2014) was used to calculate fixation 
indices (FST), and genetic diversity (π, average nucleotide pairwise difference 
between sequences) from SNP alignments. Pairwise SNP distances were calculated 
using the poppr::bitwise.dist package in R using the ‘missing_match = T’ option to 
count sites with missing data as matching (Kamvar et al. 2014). WGS-defined 
clusters were identified based on SNP-distance using the criteria of Walker et al. 
(2013a), whereby recent transmission was ruled out if isolates were separated 
by >12 SNPs.  
 
4.2.7 Rangipo SNPs 
High quality SNPs (coverage depth ³10, base quality ³20, minimum mapping ³40, 
and excluding SNPs in repetitive regions) were extracted from VCF files and the 
vcf-isec tool in the VCFtools program package (Danecek et al. 2011) was used to 
identify Rangipo specific SNPs. SNPs shared by all Rangipo genomes were first 
identified and then compared against all other individual non-Rangipo genomes in 
the global L4.4 dataset (n = 220, Section 4.3.3.1) to identify SNPs unique to the 
Rangipo cluster. SNPs were annotated with snpEff v4.3 using the M. tuberculosis 
H37Rv database (Cingolani et al. 2012). 
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STRING network analysis was performed on proteins harbouring non-synonymous 
SNPs (nsSNPs) shared by all Rangipo strain isolates and Rangipo specific nsSNPs 
(RS-nsSNPs). Network analysis and clustering using the Markov Cluster Algorithm 
was performed using default settings to identify clusters of functionally connected 
proteins. Clusters containing ≥10 proteins were then analysed independently to 
identify functional enrichments by gene ontology (GO) biological processes. 
 
4.2.8 Bayesian evolutionary analysis 
4.2.8.1 Assessment of temporal signal in data 
Prior to BEAST2 analyses, datasets were assessed to determine if there was 
sufficient temporal signal in the data for accurate molecular dating. Maximum 
likelihood trees for all L4.4.1.1/S isolates with dates (dataset 2, n = 117) and for the 
DS6Q clade containing the New Zealand isolates (n = 47) were constructed in 
PhyML as in Section 4.2.5.3. Tempest (Rambaut et al. 2016) was used to determine 
the root-to-tip distance for regression analysis against tip date and regression 
analysis was performed in R. As further assessment of the strength of the temporal 
signal in the data, date randomisation was performed on the L4.4.1.1/S dataset used 
for molecular dating. Sampling dates of isolates were randomly shuffled 20 times 
and the randomised dates were then substituted for the real dates in XML files. Date 
randomised and original datasets were analysed in BEAST2 as described in Section 
4.2.8.2 using a strict clock and constant coalescent demographic model. 
 
4.2.8.2 BEAST analyses 
BEAST (Bayesian Evolutionary Analysis by Sampling Trees) is a software package 
for Bayesian phylogenetic analysis of molecular sequence data (Bouckaert et al. 
2014). It is focused towards inferring rooted, time-scaled phylogenies and provides 
a platform for parameter estimation and hypothesis testing of evolutionary models. 
Clock calibrations can be incorporated as priors on node-ages or using a tip-dating 
approach. BEAST uses Markov chain Monte Carlo (MCMC) sampling to estimate 
the posterior distribution (the probability distribution over parameter state space). 
Evolutionary parameters are sampled from their target distributions and the output 
provides an approximation of the posterior distribution from which statistics such 
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as the median and the 95% highest posterior density (HPD) interval are reported. 
The x% HPD is the smallest interval that encompasses x% of the probability 
distribution and is analogous to confidence intervals reported in classical statistics. 
Mutation rates and divergence times were estimated for the L4.4.1.1/S sublineage 
using MCMC sampling in BEAST2 (v2.4) (Bouckaert et al. 2014) with the 
BEAGLE library v2.1 (Ayres et al. 2012) to facilitate rapid likelihood calculations. 
XML input files were generated in BEAUTi using an input alignment of 3161 
variant sites from 117 L4.4.1.1/S genomes with known year of isolation (dataset 2). 
Only nucleotide positions where at least 90% of isolates had high quality data where 
included in molecular dating analyses (3,949,977 sites total). XML-input files were 
manually modified to specify the number of invariant sites, as calculated by scaling 
the number of non-SNP sites by the frequency of each base in the alignment. 
BEAST2 analyses were performed using the GTR substitution model with the strict 
and relaxed (uncorrelated log-normal distribution (UCLD)) clocks, and coalescent 
constant, exponential, or Bayesian skyline plot (BSP) demographic models. The 
performance of various clock and demographic models was assessed using path 
sampling (Section 4.2.8.3). Trees were calibrated using tip dates covering a 27-year 
period (1987 to 2013). Two monophyletic taxon sets were created to ensure the root 
was correctly placed as determined from the maximum likelihood tree. Uniform 
prior distributions were defined for the substitution rate (1 x 10-10–1 x 10-6 s/s/y). A 
uniform prior distribution was defined for population size in the constant and 
exponential demographic models (upper bound of 1 x 1010), and the Jeffrey’s (1/X) 
prior was unselected for the skyline model. The default Jeffrey’s (1/X) prior was 
not used for this parameter as it is an improper prior and therefore an unsuitable 
prior for path sampling as this requires sampling from the prior distribution (Baele 
et al. 2013). Default priors were used for the remaining parameters. 
To estimate posterior distributions for each model, three independent MCMC 
chains were run for 150–350 million states, sampling every 10,000 states. The first 
10% of states were discarded as burn-in and chains were assessed for convergence 
and sufficient mixing as indicated by effective sample sizes >200 for all parameters. 
The three chains less burn-in were then combined in LogCombiner and parameter 
estimation was based on the combined chain. Median parameter estimates are 
reported unless otherwise specified.  
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The maximum clade credibility tree was estimated from the combined tree samples 
in TreeAnnotator using median node heights. Trees were visualised and edited in 
Figtree (tree.bio.ed.ac.uk/software/figtree/) and ggplot (Yu et al. 2017). 
For all models, MCMC sampling was also used to sample from the prior in the 
absence of data to check there were no unexpected interactions between priors, and 
that the posterior estimate is not simply an artefact reflecting the prior. The effect 
of the prior selection on parameter estimation was examined by defining different 
upper bounds on the uniform distribution for the effective population size (1 x 108 
and 1 x 106) and using the default 1/X prior, in a strict clock and constant 
demographic model with all other parameter settings kept constant. 
 
4.2.8.3 Model selection 
In order to assess the performance of the various clock and demographic models 
used for molecular dating, marginal likelihood estimation (MLE) was performed 
using path sampling (Lartillot and Philippe 2006). Path sampling runs were set up 
and analysed using the BEAST Model Selection package (v1.3.4) and performed in 
BEAST2 (v2.5). For each model, 100 path steps were specified using the 
proportions of a b(0.3, 1.0) distribution to space out the steps. The pre-burn-in was 
specified as 10% of the total number of steps used in the standard MCMC run and 
for each step the default burn-in of 50% was used. Models were ranked based on 
average log MLE for two replicate runs. The log Bayes factor were calculated 
relative to the top ranked model. Log Bayes factors were interpreted according to 
the guidelines of Kass and Raftery (1995). 
 
 
4.3 Results 
4.3.1 New Zealand M. tuberculosis cluster isolates 
4.3.1.1 Illumina whole genome sequencing 
Thirteen Rangipo, seven Otara and five Southern Cross New Zealand clinical 
M. tuberculosis isolates were sequenced on the Illumina MiSeq platform (Section 
4.2.1) and I was provided with raw data in fastq format for analysis as part of this 
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thesis. The mean raw read depth was 158X (34–258X) and median read length was 
250 bp (32–251 bp). 
Trimmed reads were mapped to the M. tuberculosis H37Rv reference genome as 
described in Section 4.2.4. The mean depth of coverage across the reference 
genome was 105X (30–226X) and on average 98.8% of the genome had a depth of 
coverage of at least 10X (95.0–99.4%) (Table 4.1, Appendix C.2).  
 
Table 4.1. Summary of Illumina WGS data for New Zealand M. tuberculosis cluster 
isolates. 
Cluster n Year Mean raw read depth 
Mean coverage 
depth1 
Rangipo 13 1991–2009 64X (34–107) 50X (30–99) 
Southern Cross 5 2002–2015 234X (206–258) 190X (168–226) 
Otara 7 2003–2013 172X (77–237) 146X (72–207) 
All genomes 25 1991–2015 128X (34–258) 105X (30–226) 
1 Average mapped coverage across the H37Rv reference genome (NC_000962.3). 
 
4.3.1.2 Lineage assignment 
Lineage classification was performed using KvarQ (Steiner et al. 2014). This 
classified the Rangipo and Otara clusters as belonging the L4.4.1.1/S sublineage of 
the L4/Euro-American lineage and Southern Cross as L4.3.3/LAM, consistent with 
the classification in Section 2.2.3. No drug resistance mutations were identified.  
 
4.3.1.3 Phylogeny, clustering and genetic diversity of the New Zealand isolates 
Twenty-four of our New Zealand M. tuberculosis genomes and an additional four 
Rangipo strain M. tuberculosis genomes available from a previous study (Gautam 
et al. 2017) met the quality criteria for inclusion in downstream phylogenetic 
analyses. A maximum likelihood tree of these 28 genomes was inferred using a 
1735 bp SNP alignment as described in Section 4.2.5.3 and included an L2/Beijing 
strain isolate as an outgroup to root the tree (Figure 4.5). This SNP-based phylogeny 
shows that the Rangipo, Otara and Southern Cross MIRU-VNTR-defined clusters 
form three well-differentiated monophyletic clades with differing phylogenetic 
structures. The Rangipo and Otara clusters were separated from one another by 108 
SNPs and from the Southern Cross cluster by 554 and 524 SNPs, respectively.  
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Figure 4.5. Phylogeny of New Zealand M. tuberculosis cluster isolates. Maximum 
likelihood phylogeny of 28 clinical New Zealand M. tuberculosis genomes belonging to 
the Rangipo, Otara and Southern Cross clusters. The most recent common ancestor is 
shown as a black circle (rooted to L2/Beijing, not shown). Bootstrap values are shown for 
nodes with >50% support.  
 
 
WGS offers higher resolution to delineate recent transmission events and define 
clusters of infection compared with MIRU-VNTR (Bryant et al. 2013b; Roetzer et 
al. 2013; Walker et al. 2013a). A threshold of five or fewer SNPs has been 
suggested to define strains involved in recent transmission events and more than 12 
SNPs to rule out recent transmission (Walker et al. 2013a). Using these thresholds, 
SNP distances were used to identify WGS-defined clusters within each of the 
MIRU-VNTR clusters (Figure 4.6). As phylogenies were constructed using only 
high-quality sites with >90% confident base calls (which could potentially decrease 
the number of SNPs between isolates leading to an over estimation of clustering), 
pairwise differences calculated from all SNP positions were also examined (Table 
4.3) and all isolates still fell into the same WGS-defined clusters. 
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Table 4.2. Genetic variation in New Zealand M. tuberculosis cluster isolates. 
Cluster  n Total SNPs1 Pairwise SNPs2 π 
Rangipo  16 729 0–12 (4) 3.3 
Southern Cross  5 812 2–92 (6) 28.2 
Otara  7 886 2–107 (84) 66.3 
1  SNPs relative to H37Rv. 
2  Median SNP distance is shown in brackets. 
 
 
Figure 4.6. WGS-based clustering of New Zealand M. tuberculosis isolates. Maximum 
likelihood SNP phylogenies of MIRU-VNTR defined clusters showing WGS-defined 
clusters in grey. Individual isolates are indicated by numbers within white circles (prefixes 
NZL and NZLR removed from IDs) and unsampled internal nodes are shown in dark grey. 
Smaller black circles indicate nodes separated by more than one SNP, with each circle 
representing one additional SNP difference. Distances between nodes outside of clusters 
are shown with dashed lines and numbers represent SNP differences between nodes. Not 
to scale. 
 
Pairwise distances and nucleotide diversity (π) were calculated as measures of 
genetic variation within each MIRU-VNTR defined cluster (Table 4.2, Table 4.3). 
Rangipo isolates harboured the least genetic diversity of the three clusters (π = 3.3) 
with a maximum of 12 SNPs between any two isolates (0–12 SNPs; median, 4). 
Accordingly, all Rangipo isolates belong to a single WGS-defined cluster (Figure 
4.6) and the phylogeny is characterised by short terminal branches (0–5 SNPs, 
median 1 SNP), indicative of recent clonal expansion and temporally short 
transmission chains. A total of 729 SNPs relative to H37Rv were identified in the 
16 Rangipo strain genomes. This is comparable to previous reports of 747 and 727 
SNPs identified among ten and nine Rangipo strains, respectively (Colangeli et al. 
2014; Gautam et al. 2017).  
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The Otara phylogeny is characterised by long terminal branches (0–37 SNPs; 
median, 12 SNPs) and Otara isolates harboured the greatest genetic diversity of the 
three MIRU-VNTR clusters (π = 66.3) (2–107 pairwise SNPs; median, 94) 
indicating that this cluster represents an endemic strain in Pacific people. Unlike 
the Rangipo and Southern Cross isolates which shared identical MIRU-VNTR 
typing patterns (except for one Rangipo isolate), the Otara isolates represent four 
variant typing profiles, distinguishable by a single locus difference (Appendix C.1). 
Two isolates sharing the same variant MIRU-VNTR profile (NZL11 and NZ12) 
were separated by only two SNPs indicating recent transmission. All remaining 
pairwise comparisons differed by 28–107 SNPs and the three isolates sharing the 
‘primary’ Otara MIRU-VNTR type (NZL01, NZL10 and NZL13) were not 
monophyletic and differed by 40–103 SNPs. This indicates that the higher levels of 
SNP diversity observed for this cluster are not simply the result of the inclusion of 
isolates with more variant MIRU-VNTR profiles. 
The five Southern Cross isolates differed by 2–92 SNPs (median, 6 SNPs), although 
large SNP differences were attributable to just a single isolate, NZL04. The 
phylogeny shows NZL02, NZL07, NZL08 and NZL09 are closely related differing 
by only 2–6 SNPs and belong to a WGS-defined cluster, indicating relatively recent 
transmission. This strain caused a large tuberculosis outbreak in 1999 at an 
Auckland church attended by Pacific peoples, resulting in 27 cases of active TB and 
a further 57 cases of latent TB (Hill and Calder 2000). This cluster of isolates likely 
traces back to that outbreak. NZL04 however was separated by 89–92 SNPs from 
other Southern Cross isolates and does not belong to a WGS-defined cluster, despite 
sharing matching MIRU-VNTR profiles with the other Southern Cross isolates. 
This hints that the Southern Cross cluster might belong to a larger endemic Pacific 
strain, as for the Otara cluster, however more data is needed to investigate this. 
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Table 4.3. Pairwise SNP distances. Pairwise distance matrixes showing SNP variation 
between isolates within each of the three New Zealand M. tuberculosis clusters. 
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4.3.1.4 Phylogenetic analysis of additional Rangipo strain genomes 
Six of the 22 available Rangipo genomes failed to meet the strict quality criteria for 
inclusion in downstream phylogenetic analyses. This was predominantly due to low 
coverage (<25X) and/or a high proportion of missing base calls (>10%). To 
examine the phylogenetic relationship between these isolates and the included 
genomes, a phylogenetic analysis using more relaxed quality thresholds was 
performed. Genomes were re-processed as in Section 4.2.4 with the exception that 
variants were called using a minimum depth threshold of five instead of ten. One 
genome still had a high number of missing base calls and was excluded (NZLR547, 
31% missing sites). The remaining 21 genomes had <12% of missing sites and were 
all used for this analysis. Isolate collection dates covered a 21-year period (1991–
2011) and came from a range of geographical locations in New Zealand.  
The 21 Rangipo genomes were found to differ by 38 SNPs and a total of 742 SNPs 
relative to H37Rv were identified. Individual isolates were separated by 0–14 SNPs. 
A maximum likelihood phylogeny was constructed from a 710 bp alignment 
including H37Rv to root the tree as in Section 4.2.5.3 (Figure 4.7A). An unrooted 
maximum likelihood phylogeny was also constructed using a 38 bp alignment 
including all variant bases between the 21 Rangipo genomes (Figure 4.7B). The 
excluded isolates are dispersed throughout the phylogeny and none are more deeply 
rooted than those retained, indicating that the retained isolates provide a good 
representative sample of this cluster.  
 
Figure 4.7. Phylogeny of 21 M. tuberculosis Rangipo strain genomes. Genomes excluded 
from downstream phylogenetic analyses are shown in red. (A) Maximum likelihood 
phylogeny inferred from a 710 bp alignment rooted to H37Rv. (B) Unrooted maximum 
likelihood phylogeny inferred from a 38 bp alignment including all variant positions 
between Rangipo genomes. Distances between nodes are in number of SNPs.  
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4.3.2 Rangipo strain SNPs 
4.3.2.1 Common Rangipo SNPs 
A total of 513 high quality SNPs were identified in all 16 high quality Rangipo 
genomes (Appendix C.3). 438 of these were found in protein coding regions, 272 
of which were nsSNPs (62.1%), including four stop codon gains and one stop codon 
loss. 254 different genes harboured common Rangipo SNPs that altered protein 
coding sequence. Functional connections among the affected proteins were 
investigated using the STRING database (Szklarczyk et al. 2014). STRING 
identifies known and predicted protein-protein associations including direct 
(physical) interactions, as well as indirect (functional) interactions. The STRING 
network identified 424 functional interactions and an average of 3.3 interactions per 
protein (Table 4.4). No significant GO functional enrichments were detected. 
Cluster analysis identified 25 clusters of three or more functionally connected 
proteins three of which comprised ≥10 proteins. The largest was comprised of 13 
proteins, including eight polyketide synthases (Figure 4.8). GO functional 
enrichment analysis showed this cluster was enriched for proteins in lipid 
biosynthetic process, cellular lipid metabolic process and DIM/DIP cell wall layer 
assembly pathways (Table 4.5). The GO term “DIM/DIP cell wall layer assembly,” 
encompasses genes involved in the synthesis and export of surface glycolipid 
phthiocerol dimycocerosates (PDIM). The third largest cluster was enriched for GO 
pathways relating to DNA replication and repair and no significant enrichments 
were identified in the second largest cluster. 
 
Table 4.4. STRING network analysis of proteins harbouring common Rangipo strain 
nsSNPs. STRING network statistics for 254 proteins containing nsSNPs shared by all 
Rangipo genomes and for clusters of ≥10 proteins within the full network. 
 All  Cluster 1 Cluster 2 Cluster 3 
Number of nodes 254 13 11 10 
Number of edges 424 31 24 17 
Average node degree1 3.3 4.8 4.4 3.4 
Average local clustering coefficient2 0.345 0.404 0.721 0.796 
1  Average number of interactions for protein in the network 
2  How connected the nodes in the network are, high values = highly connected. 
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Table 4.5. Functional enrichment analysis for clusters of ≥10 proteins harbouring common 
Rangipo strain nsSNPs. Enrichment of GO terms in the first and third largest clusters of 
proteins harbouring nsSNPs common to all Rangipo genomes are shown. The second 
largest cluster did not have any function enrichments. 
Cluster Nodes Pathway description Genes 
False  
discovery 
rate 
1 13 lipid biosynthetic process 6 0.00331 
  cellular lipid metabolic process 6 0.00331 
  DIM/DIP cell wall layer assembly 3 0.0102 
3 10 DNA replication 5 1.3e-05 
  DNA ligation involved in DNA repair 2 0.00538 
  DNA metabolic process 4 0.012 
  cellular macromolecule biosynthetic process 6 0.012 
  cellular response to stress 4 0.0144 
  DNA repair 3 0.0366 
 
 
Figure 4.8. STRING protein-protein associations among the largest cluster of proteins 
harbouring common Rangipo SNPs. SNPs identified as specific to the Rangipo strain are 
shown in bold. (A) Network showing all types of interaction evidence among proteins. (B) 
predicted binding interactions. (C) strength of data supporting interactions, the thicker and 
darker the line the higher the confidence in the association.   
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4.3.2.2 Rangipo specific SNPs 
The 513 common Rangipo SNPs were compared against 220 non-Rangipo L4.4 
sublineage M. tuberculosis genomes in the global L4.4 dataset compiled for 
phylogenetic analyses (Section 4.3.3.1). 53 SNPs were found to be specific to the 
Rangipo strain (RS-SNPs), 29 of which were nsSNPs (54.7%) (Table 4.6, Appendix 
C.3). The positions of all 29 RS-nsSNPs and the Rv1821/secA2 diagnostic marker 
synonymous SNP (sSNP) were examined in the six Rangipo genomes excluded 
from phylogenetic analyses (Section 4.3.1.4) and all carried the Rangipo variant 
base. All 14 Rangipo specific nsSNPs and six of eight sSNPs identified based on 
SOLiD WGS data in Section 2.2.2 were confirmed as RS-SNPs in this analysis; 
including the Rv2893 G72S SNP further investigated in Chapter Three and the 
Rv1821/secA2 diagnostic maker SNP (Section 2.2.5).  
In silico functional effect prediction was performed for the additional 15 
RS-nsSNPs identified in this analysis the using the program SNAP2 (Section 
2.1.3.1). Three of these were predicted have functional effects, two of which are 
found in known virulence factors – Rv0022c/whiB5 and Rv2048c/pks12. Overall, 
11 of the 29 RS-nsSNPs (37.9%) were predicted to have functional effects, 
including four in known virulence factors: Rv0405/pks6 S1236L, Rv1161/narG 
Y802H, Rv0022c/whiB5 R43H and Rv2048c/pks12 R669P (Table 4.6).  
Functional category assignment of genes harbouring the 29 RS-nsSNPs shows 
genes involved in the lipid metabolism category accounted for 17.2% of 
RS-nsSNPs (5/29), a nearly 3-fold enrichment relative to the overall proportion in 
the M. tuberculosis genome (6%) (Camus et al. 2002) (Table 4.7). This is similar 
to the analysis of the 14 RS-nsSNPs in Section 2.2.2.1, in which a 3.6-fold 
enrichment of genes involved in lipid metabolism was observed (3/14, 21.4% of 
RS-nsSNPs). STRING network analysis was performed on all 29 proteins carrying 
RS-nsSNPs. This identified 16 predicted interactions and an average of 1.1 
interactions per protein (Figure 4.9). No significant GO functional enrichments 
were detected. Cluster analysis identified six different clusters, three comprised of 
three proteins and the remaining three of two proteins. The three proteins in one of 
these clusters (Pks12, FadD28 and Pks6) were also found in the largest cluster in 
the full network of 254 proteins (Figure 4.8). 
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Table 4.6. Rangipo specific nsSNPs identified from Illumina WGS data. Functional effect prediction output from SNAP2 is shown and virulence factors 
are indicated in bold type.  
SNP Locus/ Gene ID aa change Product SNAP2 Effect 
SNAP2 
Score 
Predicted 
Accuracy 
Rv3253CG Rv0002/dnaN P401R DNA polymerase III (beta chain) DnaN  N -26 61% 
Rv27315CT Rv0022c/whiB5 R43H Probable transcriptional regulatory protein WhiB-like WhiB5 Y 59 75% 
Rv45753TC Rv0041/leuS V731A Probable leucyl-tRNA synthetase LeuS  N -84 93% 
Rv129668GA Rv0107c/ctpI P292S Probable cation-transporter ATPase I CtpI N -61 82% 
Rv489437CT Rv0405/pks6 S1236L Membrane bound polyketide synthase Y 46 71% 
Rv550620GT Rv0458 D316Y Probable aldehyde dehydrogenase Y 14 59% 
Rv616877CT Rv0526 A11V Possible thioredoxin protein  N -18 57% 
Rv1032721CT Rv0926c A356T Conserved hypothetical protein N -96 97% 
Rv1289731TC Rv1161/narG Y802H Respiratory nitrate reductase (alpha chain) NarG Y 80 91% 
Rv1836099TG Rv1631/coaE Y363D Probable dephospho-CoA kinase CoaE  Y 87 91% 
Rv2304891CG Rv2048c/pks12 R699P Polyketide synthase Pks12 Y 24 63% 
Rv2402434GA Rv2142c/parE2 A26V Possible toxin ParE2 N -25 61% 
Rv2807374GC Rv2492 G33R hypothetical protein Y 79 85% 
Rv3202633GA Rv2893 G72S Possible oxidoreductase Y 28 63% 
Rv3219432CG Rv2912c G144R Probable transcriptional regulatory protein (probably TetR-family) N -55 78% 
Rv3283879TC Rv2941/fadD28 V182A Fatty-acid-AMP ligase FadD28  N -77 87% 
Rv3366098GA Rv3007c P118L Possible oxidoreductase Y 59 75% 
Rv3561770AG Rv3193c L468S Probable conserved transmembrane protein N -17 57% 
Rv3654060GA Rv3272 A205T Conserved hypothetical protein Y 68 80% 
Rv3858800GA Rv3439c A288V Conserved hypothetical alanine and proline rich protein N -54 78% 
Rv3895925GA Rv3479 A36T Possible transmembrane protein N -80 87% 
Rv3925115GT Rv3506/fadD17 A76S Fatty-acid-CoA synthetase FadD17  N -52 78% 
Rv3980075CA Rv3540c/ltp2 E195D Probable lipid transfer protein or keto acyl-CoA thiolase Ltp2 N -67 82% 
Rv3985279CG Rv3545c/cyp125 G56A Probable cytochrome P450 125 Cyp125 N -91 97% 
Rv4085870GA Rv3646c/ topA T463M DNA topoisomerase I TopA  N -5 53% 
Rv4150655GA Rv3707c A129V Conserved hypothetical protein N -62 82% 
Rv4163025GC Rv3719 Q240H Conserved protein N -89 93% 
Rv4177114CA Rv3728 P748T Probable conserved two-domain membrane protein N -46 72% 
Rv4377908CT Rv3894c/eccC2 G849S ESX-2 type VII secretion system protein EccC2 Y 20 63% 
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Table 4.7. Gene functional categories of Rangipo specific nsSNPs. The percentage of genes 
in H37Rv as reported in Camus et al. (2002) in each category is also shown. 
Gene Functional Category nsSNPs H37Rv 
Cell wall and cell processes 5 (17.2%) 18% 
Conserved hypotheticals 6 (20.7%) 26% 
Information pathways 3 (10.3%) 6% 
Intermediary metabolism and respiration 7 (24.1%) 22% 
Lipid metabolism 5 (17.2%) 6% 
Regulatory proteins 2 (6.9%) 5% 
Virulence, detoxification, adaptation 1 (3.4%) 2% 
Total 29  
   
 
 
 
Figure 4.9. STRING protein-protein associations among proteins harbouring Rangipo 
specific nsSNPs. Proteins harbouring SNPs with predicted functional effects are shown in 
bold type and known virulence factors are underlined. Nodes are coloured by clusters as 
identified by STRING. 
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4.3.3 Global phylogeny of L4.4  
To identify possible historical sources of the Rangipo and Otara clusters, a large 
genomic dataset comprising the New Zealand L4.4.1.1/S genomes and publicly 
available L4.4 genomes from around the world was compiled and used to infer a 
global L4.4 phylogeny. This was also used to determine the phylogenetic placement 
of the DS6Quebec deletion and provide new insights into the global population 
structure and phylogeographical distribution of L4.4. 
 
4.3.3.1 L4.4 dataset 
The final dataset used to construct the L4.4 global phylogeny was comprised of 236 
isolates (Appendix C.4, C.5). This included 23 high quality New Zealand Rangipo 
and Otara strain genomes (Section 4.3.1.3) and 213 global L4.4 genomes from 19 
different countries representing all five global regions (Figure 4.10). Collection 
dates were available for 72.4% of isolates (171/236) and spanned a 27-year period 
from 1987 to 2013. L4.4 is reported to occur at high proportions in parts of Africa 
and Asia (Stucki et al. 2016b). Reflective of this, Africa was the most highly 
represented region accounting for 41.4% of all isolates (97/236) followed by Asia 
with 22.9% of isolates coming from this region (54/236). The New Zealand strains 
accounted for 9.7% of all L4.4 isolates (23/236). 
 
 
Figure 4.10. Global distribution of 236 L4.4 sublineage genomes included in this study 
(dataset 1, n = 236).   
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4.3.3.2 Maximum likelihood phylogeny of L4.4 
A whole genome maximum likelihood phylogeny was constructed from a 9024 bp 
SNP alignment of 236 global L4.4 isolates and H37Rv to root the tree (Figure 4.11, 
Figure 4.12). This phylogeny splits L4.4 into three sublineages, L4.4.1.1/S, L4.4.1.2 
and L4.4.2, consistent with the classification system of Coll et al. (2014). Pairwise 
fixation indices (FST) were calculated to estimate population separation between 
sublineages. FST values provide a measure of the genetic differentiation between 
populations and range from zero (no separation) to one (complete separation). FST 
values between three L4.4 sublineages were between 0.50 and 0.57, indicating that 
the sublineages are well differentiated. 
 
 
Figure 4.11. Global phylogeny of the L4.4 sublineage. Maximum-likelihood phylogeny of 
236 global M. tuberculosis L4.4 sublineage genomes. Tips are coloured by global region 
and sublineages are labelled according to the nomenclature of Coll et al. (2014). A black 
circle indicates the node position of the most recent common ancestor of L4.4 (rooted to 
H37Rv, not shown). The DS6Q clade, the New Zealand Rangipo and Otara clusters, and 
country of other clades within the DS6Q are labelled. 
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Figure 4.12. Global phylogeny of the L4.4 sublineage and regional distribution of 
sublineages. Maximum-likelihood phylogeny of 236 global M. tuberculosis L4.4 genomes. 
Lineages are labelled according to the nomenclature of Coll et al. (2014). Tips labels are 
coloured by global region and pie charts show the regional distribution of isolates within 
sublineages. A black circle indicates node position of the most recent common ancestor of 
L4.4 (rooted to H37Rv, not shown). A grey box highlights the DS6Q. 
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The L4.4 phylogeny revealed differing global distributions and population 
structures of the three L4.4 sublineages, which presumably reflects different 
demographic histories of these sublineages. L4.4.2 was essentially restricted to 
Eastern Asia (45/46 isolates, 97.8%) indicating in-situ expansion of this sublineage. 
Conversely, L4.4.1.1/S and L4.4.1.2 have broader global distributions and show 
limited phylogeographical structure, indicative of high rates of migration and 
efficient dispersal.  
The New Zealand isolates accounted for 13.8% of L4.4.1.1/S sublineage genomes 
(23/168). The Rangipo and Otara clusters form two separate monophyletic clades 
within L4.4.1.1/S and are part of a larger clade consisting of 47 genomes from New 
Zealand, Canada and Russia (23, 21 and 3 genomes, respectively). The Canadian 
isolates belong to the DS6Quebec strain family discussed in Section 2.3.3, we 
therefore termed this clade the DS6Q clade. The Canadian isolates comprise three 
separate clades within the DS6Q. The polytomy at the root of the DS6Q clade and 
the polyphyletic nature of the New Zealand and Canadian isolates implies dispersal 
of multiple closely related strains from a common origin and is consistent with at 
least two separate introductions of the DS6Q clade into New Zealand. The 
DS6Quebec lineage is assumed to have been introduced to Canada from France 
(Pepperell et al. 2011) suggesting a similar European origin for the Rangipo and 
Otara clusters. This hypothesis was further explored using molecular dating 
(Section 4.3.4).   
 
4.3.3.3 DS6Quebec deletion 
The DS6Quebec deletion removes an ~11.4 kb region (positions 1987457 to 1998849 
in H37Rv), truncating the plcD gene and deleting a further six protein coding genes 
present in H37Rv (Figure 2.7). The Rangipo and Otara clusters were confirmed to 
harbour the DS6Quebec deletion by PCR (Section 2.2.4) and we hypothesised that 
this deletion might be more widely characteristic of the S lineage. All 236 genomes 
in the L4.4 dataset were examined for the presence of the DS6Quebec deletion. All 
L4.4.1.1/S and L4.4.1.2 genomes, but no L4.4.2 genomes, were found to harbour 
this deletion, showing that it is a characteristic deletion of L4.4.1 (Figure 4.13). One 
L4.4.1.1/S genome had an earlier start of the deletion (position 1987142) indicating 
a subsequent small deletion event.  
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Figure 4.13. Phylogenetic placement of the DS6Quebec deletion in the L4.4 sublineage. 
 
 
4.3.4 Molecular dating  
The temporal evolution of the L4.4.1.1/S sublineage was investigated using 
Bayesian evolutionary analysis in BEAST2. This enables inference of the time this 
sublineage emerged and allows a reconstruction of its demographic history. 
Molecular dating estimates for the DS6Q were able to be linked with historical trade 
and migrations, providing new insight into historical phenomena and social factors 
that have contributed to the dispersal and successful expansion of the Rangipo and 
Otara clusters. 
 
4.3.4.1 L4.4.1.1/S dataset  
The dataset used for molecular dating contained all L4.4.1.1/S genomes with known 
isolate collection dates (n = 117) (Appendix C.4, C.5). The range of collection dates 
was the same as for the full L4.4 dataset spanning a 27-year period from 1987 to 
2013. Genomes came from 14 different countries covering all five global regions 
and contained all 47 genomes identified as belonging to the DS6Q clade (23 from 
New Zealand, 21 from Canada and 3 from Russia). 
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Figure 4.14. Global distribution of L4.4.1.1/S sublineage genomes used for molecular 
dating analyses (dataset 2, n = 117). 
 
 
4.3.4.2 Assessment of temporal signal for tip-dating 
Molecular dating was performed using tip dates to calibrate the molecular clock 
(Section 4.3.4.3). Prior to molecular dating analysis using tip dating it is necessary 
to establish whether or not the data contains sufficient temporal signal for tip-based 
calibration (i.e. to determine if the population is ‘measurably evolving’) 
(Drummond et al. 2003). If the population is measurably evolving, the root-to-tip 
distance of isolates in the undated phylogeny should correlate with sampling time 
as more recently collected samples will have had more time to acquire additional 
mutations and diverge further from the ancestor at the root. Root-to-tip regression 
analysis showed a modest temporal signal in the L4.4.1.1/S dataset (adjusted 
R2 = 0.229) and a weaker signal in the DS6Q isolate subset (adjusted R2 = 0.139) 
(Figure 4.15A,B), the L4.4.1.1/S dataset was therefore used for further dating 
analyses. There was no significant difference between the two slopes (t-test, 
p = 0.0579) (this provides an estimate of the evolutionary rate).  
Date randomisation was performed as a further test of strength of the temporal 
signal in the L4.4.1.1/S dataset as this is a more robust method to test for temporal 
signal (Rieux and Balloux 2016). In this test, sample dates are permuted to create 
multiple date randomised datasets and parameters are estimated from the true and 
randomised dates then compared. At least 20 randomisation tests are recommended 
and under the strictest criterion and rate estimates obtained from the true dates 
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should not overlap with the 95% HPD intervals of estimates from the randomised 
dates (Duchêne et al. 2015). Twenty date randomisations were performed on the 
L4.4.1.1/S dataset. Estimates of the substitution rate and TMRCA for L4.4.1.1/S 
showed no overlap in the 95% HPD between the real and randomised dates (Figure 
4.15C,D), indicating that the data contains sufficient temporal signal for tip-based 
calibration. 
 
 
Figure 4.15. Assessment of temporal signal for tip-dating. (A,B) Root-to-tip regression 
analysis for (A) the L4.4.1.1/S dataset and (B) the DS6Q sample subset. (C,D) Tip date 
randomisation results for the L4.4.1.1/S dataset. Median and 95% HPD intervals for 
estimates of (C) substitution rate and (D) tree height (in years since 2013) after tip 
randomisation and for real dates. (GTR, strict clock, constant population demographic 
model).  
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4.3.4.3 Molecular dating in BEAST2 
Molecular dating analyses were performed in BEAST2 using a 3163 bp SNP 
alignment generated from 117 L4.4.1.1/S genomes. Analyses were performed using 
the GTR model of substitution using strict and relaxed molecular clocks, with 
coalescent constant, exponential and Bayesian Skyline demographic models. 
Triplicate MCMC chains were run for each model and showed sufficient mixing 
and ESS values >200 for all parameters for each chain. The different model 
combinations all produced very similar substitution rates and TMRCA estimates 
(6.15 x 10-8–6.64 x 10-8 s/s/y); outermost 95% HPD intervals over all models,  
4.23 x 10-8–9.08 x 10-8) (Table 4.8). Model comparison determined the strict clock 
with the Bayesian skyline demographic model best fit the data (Section 4.2.8.3). 
Under this model, the substitution rate was estimated as 6.28 x 10-8 s/s/y (95% HPD, 
4.54 x 10-8–8.10 x 10-8) resulting in a TMRCA estimate of 1492 for L4.4.1.1/S (95% 
HPD, 1325–1629) (Figure 4.16, Figure 4.17). All other parameter estimates 
reported in the main text are for this model. Trace outputs of key parameters 
showing convergence of the MCMC chain for replicate runs for this model are 
shown in Appendix C.6.  
 
 
 
Figure 4.16. Bayesian phylogeny of the L4.4.1.1/S sublineage. Maximum clade credibility 
tree inferred from 117 M. tuberculosis L4.4.1.1/S sublineage genomes. A black node marks 
the most recent common ancestor and the DS6Q is highlighted in grey. 
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Figure 4.17. Bayesian phylogeny and population dynamics of the L4.4.1.1/S sublineage. 
(A) Maximum clade credibility tree. Individual node heights are shown in years since 2013 
and posterior support for each node is indicated by colour. A grey box highlights the DS6Q. 
(B) Bayesian skyline plot showing change in effective population size (Ne) over time since 
1492. 95% HPD interval shown in grey. 
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Table 4.8. Substitution rate and TMRCA estimates for the L4.4.1.1/S sublineage. Estimates are reported for different clock and population demographic 
models. Median values are reported and the 95% HPD interval is shown in brackets. The GTR model of substitution was used for all analyses. Substitution 
rate is in substitutions per site per year (s/s/y). The best fitting model determined by path sampling is highlighted in bold type.  
Clock Demographic model Substitution rate (s/s/y) L4.4.1.1/S TMRCA DS6Q TMRCA Rangipo TMRCA Otara TMRCA 
Strict Constant 
6.63 x 10-8 1513 1671 1978 1827 
(4.34 x 10-8–9.06 x 10-8) (1301–1673) (1529–1777) (1965–1987) (1744–1886) 
Strict Exponential 
6.63 x 10-8 1513 1672 1978 1827 
(4.37 x 10-8–9.08 x 10-8) (1299–1672) (1530–1781) (1965–1986) (1745–1887) 
Strict Skyline 
6.28 x 10-8 1492 1652 1980 1813 
(4.54 x 10-8–8.10 x 10-8) (1325–1629) (1535–1741) (1969–1988) (1746–1868) 
UCLD Constant 
6.49 x 10-8 1500 1665 1977 1824 
(4.23 x 10-8 –8.93 x 10-8) (1277–1667) (1518–1774) 1964–1986) (1741–1887) 
UCLD Exponential 
6.64 x 10-8 1511 1673 1977 1828 
(4.37 x 10-8–8.98 x 10-8) (1294–1667) (1528–1772) (1965–1986) (1748–1888) 
UCLD Skyline 
6.15 x 10-8 1480 1645 1980 1809 
(4.39 x 10-8–7.98 x 10-8) (1300–1624) (1524–1743) (1968–1988) (1739–1867) 
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The population dynamics of the L4.4.1.1/S sublineage and the star-like structure 
near the root of the phylogeny suggest this sublineage underwent a swift population 
expansion following its emergence (Figure 4.17B). This was followed by a period 
where the population size remained consistent until another period of population 
growth in the 19th century followed by a sharp population decline in the last half of 
the 20th century. 
Our TMRCA estimate of the DS6Q clade was 1652 (95% HPD, 1535–1741) and 
1691 for Rangipo and the closest Canadian clade (95% HPD, 1588–1776) (Table 
4.8). This coincides with the French migration to Quebec (1608–1760) 
(Charbonneau et al. 1993) and is therefore consistent with a French/European origin 
of the DS6Q clade. The TMRCA estimate of the Rangipo cluster was 1980 (95% 
HPD, 1969–1988), indicating that Rangipo is either a relatively recent clonal 
expansion from a previously introduced DS6Q strain or a recent introduction. 
The Otara cluster has a much older TMRCA estimate of 1813 (95% HPD,  
1746–1868). As this cluster is most prevalent in Pacific people in New Zealand, the 
TMRCA and phylogenetic structure suggests this is an endemic strain in this 
population. Migration to New Zealand from the Pacific Islands occurred at low 
levels in the 1800s, such that there were only 151 Pacific Island Polynesians in New 
Zealand by 1916 (StatsNZ 1916). Migration from the Pacific Islands significantly 
increased in the 1950s–1970s (Dunsford et al. 2011) and between 1945 and 1976 
the Pacific population in New Zealand increased around 30-fold from 2,159 to 
~66,000 (StatsNZ 1996) (Figure 4.3). The phylogeny of the Otara cluster can be 
explained by initial dispersal to the Pacific Islands from Europe in the early 1800s, 
followed by several later introductions into New Zealand with more recent Pacific 
migrations. Long internal branches stretching >100 yrs back in time suggest at least 
four separate introductions of the Otara strain to New Zealand, while more recent 
nodes could represent transmission occurring either within New Zealand or the 
Pacific Islands.  
 
4.3.4.4 Model selection 
Path sampling in BEAST2 was used to compare the fit of the various clock and 
demographic models used in the molecular dating analyses. Based on path sampling 
MLE, the Bayesian skyline demographic model was found to fit the data best with 
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the strict clock fitting better than the relaxed clock (Table 4.9). Replicate MLEs for 
both models were highly congruent (Figure 4.18) and the relaxed clock with the 
skyline demographic model had a log Bayes factor of 3.4 relative to the strict clock, 
providing positive evidence in favour of the strict clock. The constant and 
exponential demographic models all had log Bayes factors >30 relative to the 
skyline model, providing very strong positive evidence against these models. These 
models all had very similar MLEs and the variability between MLEs for replicate 
path sampling runs was larger than the difference between models, reducing 
confidence in the ranking of the bottom four models. This however was not 
considered of major concern due to the high confidence and strong statistical 
support for selection of the top model. 
 
Table 4.9. Model evaluation using path sampling. Average marginal likelihood from two 
replicate runs are reported. Bayes factors are relative to the top ranked model. 
Rank Clock model Demographic model Log-marginal likelihood 
log Bayes 
factor  
1 Strict Skyline –5342225.5  
2 Relaxed Skyline –5342228.9 3.4 
3 Relaxed Constant –5342259.6 34.1 
4 Strict Constant –5342261.1 35.6 
5 Strict Exponential –5342262.4 37.0 
6 Relaxed Exponential –5342263.2 37.7 
  
 
 
Figure 4.18. Marginal likelihood estimates for replicate path sampling runs in BEAST2. 
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4.3.4.5 Validity of results 
To assess the validity and robustness of the results, date randomisation was 
performed and effects of prior distributions on parameter estimation were 
investigated. Date randomisation showed no overlap in the 95% HPD intervals 
between substitution rate estimates obtained from the true dates compared with 
those obtained from randomised dates demonstrating the sufficient temporal signal 
in the data (Section 4.2.8.1). MCMC was used to sample from the prior distribution 
in the absence of data and comparison of marginal posterior and prior distributions 
showed a strong signal from the data indicating these results are just not an artefact 
reflecting the prior. To assure unintentional biases were not being introduced into 
the results through the selection of priors, BEAST2 analyses were run using 
different prior distributions on the population size prior. Negligible effects on the 
substitution rate were observed using either the default Jeffreys (1/X prior) or 
differing upper bounds on uniform prior distributions (1 x 106–1 x 1010), 
demonstrating the robustness of the result to this prior specification.  
 
 
Figure 4.19. Comparison of parameter estimates using differing population size prior 
specifications. (GTR, strict clock, constant population demographic model). 
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4.4 Discussion 
4.4.1 The New Zealand M. tuberculosis clusters  
The three largest M. tuberculosis clusters in New Zealand defined by MIRU-VNTR 
24-locus typing are known as the Rangipo, Otara and Southern Cross clusters. High 
quality WGS sequencing data was available for 16 Rangipo, five Southern Cross 
and seven Otara clinical M. tuberculosis isolates. The Rangipo strain dataset 
provides a good representative sample of this cluster and shows it harbours little 
genetic diversity. All Rangipo isolates were all found to belong to a single cluster 
defined both by MIRU-VNTR typing and SNPs, consistent with relatively recent 
clonal expansion and transmission. SNP analyses revealed that the Otara strain 
isolates did not belong to a single WGS cluster and indicated recent transmission 
between only two of the seven sequenced isolates. Although a smaller number of 
isolates were sequenced from this cluster, it is apparent it harbours much higher 
levels of genetic diversity than the Rangipo cluster. Unlike the Rangipo and 
Southern Cross isolates, which had identical MIRU-VNTR profiles (except for one 
Rangipo isolate that differed at a single locus), the Otara strains sequenced included 
more variant MIRU-VNTR profiles. The higher level of genetic diversity among 
Otara strains however is not simply a result of this and these analyses indicate that 
the Otara cluster represents an endemic strain in Pacific People rather than a recent 
clonal expansion. Accordingly, molecular dating analysis of the Otara cluster show 
this strain was first introduced to the Pacific Islands from Europe in the early 1800s 
and has migrated to New Zealand several times (further discussed in Section 
4.4.2.1). These results also demonstrate the limitation of MIRU-VNTR typing to 
discriminate recent transmission events, consistent with other recent studies (Bryant 
et al. 2013b; Roetzer et al. 2013; Stucki et al. 2016a; Walker et al. 2013a). 
Recent transmission was evident among four of the five Southern Cross isolates and 
these are presumed to be related to the large outbreak caused by this strain in 1999 
(Hill and Calder 2000). A fifth more distantly related Southern Cross isolate hints 
that this MIRU-VNTR defined cluster might also belong a larger endemic Pacific 
strain, as for the Otara cluster. However, additional sequencing needs to be 
undertaken to better characterise the molecular epidemiology of this cluster.  
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The Rangipo strain is most commonly found in Māori and has been the source of 
numerous outbreaks over the last thirty years (Calder 2013; Colangeli et al. 2014; 
De Zoysa et al. 2001; McElnay et al. 2004). The Rangipo strain continues to cause 
outbreaks, the most recent involving six cases in the Waikato region in 2017/2018 
(R. Hoskins, Waikato Hospital, personal communication). Anecdotal evidence 
suggested that this strain may be highly virulent and contact tracing data from 
previous Rangipo outbreaks suggest high rates of progression to active disease in 
Rangipo strain infections (Section 2.2.1).  
Illumina sequencing data identified 29 SNPs specific to the Rangipo strain, 
including an additional 15 SNPs not identified from SOLiD data. The additional 
SNPs identified likely reflect differences in the sequencing technologies used as 
well as the bioinformatics processes used to analyse WGS data. Eight of the 29 
RS-nsSNPs were found in known virulence associated genes, four of which are 
predicted to have functional effects on the proteins they encode; Rv0405/pks6 
S1236L, Rv1161/narG Y802H, Rv0022c/whiB5 R43H and Rv2048c/pks12 R669P. 
A cluster of Rangipo SNPs was identified that was enriched for proteins, 
predominantly polyketide synthases, involved in lipid biosynthesis and metabolism 
and PDIM cell wall layer assembly. This cluster included two putative functional 
effect SNPs specific to the Rangipo strain; Rv0405/pks6 S1236L and 
Rv2048c/pks12 R669P. The M. tuberculosis cell wall is rich in unique lipids that 
are important for pathogenesis, including the glycolipid PDIM which is a major 
virulence factor in M. tuberculosis (Forrellad et al. 2013). Although the function of 
PDIM is not well understood, it is proposed to have roles in immune evasion and 
the modulation of host immune responses during the early steps of infection 
(reviewed in Arbues et al. 2014; Stanley and Cox 2013). Biosynthesis of PDIM and 
other important mycobacterial cell lipids involve polyketide synthases, therefore 
genetic variants affecting the function of these enzymes could have important 
phenotypic effects and consequences for strain virulence.  
In addition to potential functional effects, SNPs also provide valuable phylogenetic 
information that can be used to understand the evolution and dispersal of M. 
tuberculosis strains. The remainder of this work used SNP-based evolutionary 
analyses to gain new insight into historical and social drivers of success of the 
Rangipo and Otara clusters.  
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4.4.2 Origins and dispersal of the DS6Q clade in Polynesia 
I sought to investigate the origins and historical dispersal of the New Zealand 
Rangipo and Otara clusters using a phylodynamics approach and a large dataset of 
global M. tuberculosis genomes. A global phylogeny of the L4.4 sublineage 
identified that the Rangipo and Otara belong to a L4.4.1.1/S clade – the ‘DS6Q’ 
clade, that is commonly found in indigenous populations in Canada and New 
Zealand. Pepperell et al. (2011) have shown that this lineage was introduced to 
Western Canadian indigenous populations via the fur trade and later expanded 
concomitant with 19th century industrialisation (Pepperell et al. 2011). The 
DS6Quebec lineage accounts for 48% of M. tuberculosis isolates in Quebec and is 
assumed to have been introduced to Canada from France (Pepperell et al. 2011), 
implying a similar European origin for the New Zealand DS6Q clusters. Molecular 
dating analysis estimated the last common ancestor of the DS6Q clade existed in 
the mid-17th century which coincides with the French migration to Quebec  
(1608–1760) (Charbonneau et al. 1993), and is thus consistent with a French origin 
of the clade (Figure 4.20).  
Considering the history of early European activity in the South Pacific region and 
history of European migration to New Zealand, the introduction of DS6Q strains to 
Polynesia are hypothesised to represent trade-associated introductions resulting 
from contact with French whalers in the early 19th century (Figure 4.20). During 
the early 19th century, the only French economic activity of any scale in the South 
Pacific was the whaling trade (Maclellan 1998), of which the most significant years 
were 1832–1846 (Foucrier 2005). French whalers had a notable presence in New 
Zealand and were a significant factor in the British decision to annex New Zealand 
in 1840. The first French whalers arrived in New Zealand in 1836 and in the years 
1840-43 the majority of French whaling voyages included New Zealand (70/81) 
(Foucrier 2005). French protectorates were also established in the South Pacific 
starting with Tahiti/French Polynesia in 1842, however there was no large-scale 
overseas emigration from France to Polynesia.  
European whaling in the South Pacific began in the 1790s and was pursued mostly 
by American, British and French vessels. From 1820–60 the whaling industry was 
the backbone of Pacific commerce and was dominated by American whalers, 
although smaller numbers of British and French vessels continued to frequent the 
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region (Campbell 2011; Fischer 2013). These arrivals were coming from regions 
where tuberculosis rates were at epidemic proportions; Western Europe 
tuberculosis mortality rates approached 1000 per 100,000 people per year (Daniel 
2006), and the relationships established with local indigenous people during this 
era provide the necessary social context for transmission of the disease.  
 
 
Figure 4.20. Dated Bayesian phylogeny of the DS6Q clade and historical timeline. The 
DS6Q clade from the maximum clade credibility tree inferred from 117 L4.4.1.1/S 
M. tuberculosis genomes is shown. A black node marks the MRCA of the DS6Q clade, and 
node dates and 95% HPD intervals are shown for the DS6Q clade and the Rangipo and 
Otara clusters. The historical timeline shows the timing of the French migration to Quebec 
(1608–1760), South Pacific whaling era (late 1700s–1860s), the rapid urbanisation of 
Māori (1945–1980) and the surge in migration from the Pacific Islands to New Zealand in 
the 1950s–1970s. 
 
As with the Canadian fur trade, the formation of productive social and economic 
relationships with the local people was essential for the commercial success of the 
whaling industry (Stevens and Wanhalla 2017). The impacts of the southern New 
Zealand whaling trade on indigenous populations are described as being very 
similar to those in the fur trade. For example, intermarriage played a central role in 
industry establishment and success in both the Canadian fur trade and New Zealand 
whaling (Stevens and Wanhalla 2017). Polynesians were also frequently recruited 
onboard European and American whaling vessels accounting for up to one-fifth of 
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crews, and Māori and Tahitians were particularly popular amongst British and 
French whalers (Chappell 1997; Fischer 2013). These close interactions both on 
land and on-board would have established strong social ties conducive for the 
dispersal of M. tuberculosis. Accordingly contact with European trade vessels and 
ports have been implicated in the introduction of tuberculosis and other infectious 
diseases to the region (Chappell 1997; Lange 1984). In the Cook Islands for 
example, the locals themselves readily associated European ships as sources of 
disease, developing the phrase kua pai au, which translates to “I am shippy”, to 
pinpoint the source of their illness (Lange 1984).  
Limited data is available on M. tuberculosis diversity elsewhere in Polynesia. 
Molecular epidemiology studies using MIRU-VNTR and spoligotyping have found 
the S-type accounts for 11% of isolates on Kiribati (8/73) (Aleksic et al. 2013) and 
over one-third of M. tuberculosis isolates on Tahiti, French Polynesia (10/27) 
(Osman et al. 2017). Tahiti was an especially important commerce hub provisioning 
European whaling and trade vessels in the early 19th century and was made a French 
protectorate in 1842 and a colony in 1880. Although no WGS data was available 
for inclusion in phylogenetic analyses, we speculate whether the S lineage presence 
in Tahiti might also represent DS6Q clade strains introduced via the same historical 
trading activities.  
In addition to DS6Q strains in Canada and New Zealand, this clade is also 
represented by isolates from Russia. Unlike New Zealand and Canada where the 
DS6Q clade occurs at relatively high frequencies, the L4.4 sublineage is rare in 
Russia (Casali et al. 2014; Stucki et al. 2016b). Historically, Western Europe and 
Russia have been culturally and politically more connected and trade dates between 
them back to ancient times (Öhberg 1955). Thus, DS6Q dispersal to Russia has not 
been associated with any particular migrations or trade eras.  
 
4.4.2.1 History of the Otara cluster 
The early 19th century TMRCA estimate for the Otara cluster is consistent with an 
introduction to the South Pacific by French/European whalers (Figure 4.20). 
Although the median of TMRCA estimate slightly predates the peak of French 
whaling in the region, the 95% HPD falls well within this time period. Unlike New 
Zealand, which received a massive influx of European settlers from the 1840s, other 
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Polynesian islands did not experience the same en masse arrival of European 
emigrants, lending further support to this being a trade-associated introduction. The 
ancestor of the Otara strain was presumably introduced first to the Pacific Islands 
from Europe, and then later dispersed to New Zealand with more recent Pacific 
migrations. This highlights the importance of tuberculosis trends in the Pacific 
islands to those in New Zealand and the need for Pacific-wide TB control efforts.  
 
4.4.2.2 History of the Rangipo cluster 
These analyses show that the Rangipo cluster is a clonal expansion that emerged 
around forty years ago (Figure 4.20). Māori tuberculosis mortality rates declined 
sharply in the mid-20th century (MacLean 1964) and notification data also show a 
decline of 83% from 1954 to 1970 (AJHR H-31, 1951-97 in Dunsford 2008) (Figure 
4.4). Thus, it is expected modern strain diversity represents just a portion of that 
circulating prior to the mid-1900s and the observation that one single relatively 
recent clonal expansion accounts for 25% of tuberculosis in Māori further attests to 
this bottleneck. Along with falling tuberculosis rates, between 1945–1980 Māori 
also experienced one of the fastest rates of urbanisation of any population in the 
world (Pool 1991). This was accompanied by major host environment changes, 
including overcrowded housing and increased prison incarceration rates, both 
known tuberculosis risk factors (Baussano et al. 2010; Clark et al. 2002). The 
TMRCA of the Rangipo cluster fits with the urbanisation of Māori and the host 
social changes brought about by this are undoubtedly important factors contributing 
to the successful expansion and dispersal of this strain.  
Prisons represent reservoirs of tuberculosis disease for the general population and 
prison outbreaks have been linked to increased incidence of the strain in the 
surrounding community (Jones et al. 2003). The Rangipo strain was named for its 
association with a large outbreak in the 1990s that involved cases who had spent 
time in the Rangipo prison (De Zoysa et al. 2001; McElnay et al. 2004). The 
TMRCA estimate for the Rangipo cluster predates this outbreak, although its 
introduction into the prison environment has presumably promoted its further 
spread. Overall, the historic and social factors that have facilitated the success of 
this strain are themselves products of the colonial history of New Zealand and 
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therefore Rangipo strain cannot simply be considered a ‘prison strain’, as its name 
implies.  
French whaling in New Zealand presents a possible source for the introduction of 
DS6Q strains into New Zealand from which the Rangipo strain could have emerged. 
Alternatively, Rangipo could be a recent introduction into New Zealand coinciding 
with changes in host ecology facilitating its successful expansion. The TMRCA of 
Rangipo follows a period of mass migration to New Zealand from the Pacific 
Islands in the 1950s-1970s offering a conceivable route. Although it is evident that 
the Rangipo cluster has ultimately emerged from a strain of European origin, more 
in-depth sampling of L4.4.1.1/S isolates from both New Zealand and the Pacific 
may provide a clearer picture of the route this strain to New Zealand and will shed 
additional light into the dispersal of this sublineage in our region. 
 
4.4.3 Tuberculosis stigma  
The naming of the New Zealand clusters as ‘Rangipo’ and ‘Otara’ reflect the 
geographic locations where these strains were first identified. Naming diseases by 
place of origin can stigmatise the associated population and serves to emphasise the 
‘other’ aspect of disease (Perry and Donini-Lenhoff 2010). Tuberculosis stigma 
adversely affects health-seeking behaviours resulting in delays in diagnosis, 
influences treatment adherence and complicates contact tracing efforts, and thus has 
implications for tuberculosis control efforts (Craig et al. 2017). Stigma also 
increases emotional suffering of patients therefore alleviating the additional burden 
of stigma is also important for reducing the overall suffering of those affected by 
tuberculosis.  
Both Rangipo and Otara are Māori place names and Otara is home to large 
population of Pacific People, associating these tuberculosis strains with Māori and 
Pacific People more generally. Our results show that these strains do not represent 
Māori or Polynesian M. tuberculosis strains, but rather strains that have been 
introduced and expanded in these populations as a consequence of European contact 
and colonisation. This highlights the pejorative nature of these names and unfairly 
scapegoats the affected communities as sources of disease. These findings support 
the renaming of these clusters to refrain from further perpetuating stigmatisation of 
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communities where tuberculosis is present and further work will seek to rename 
these clusters in consultation with local Māori and communities of interest. 
 
4.4.4 The L4.4 sublineage  
In addition to defining the historic origins of the New Zealand clusters, these results 
also provide a characterisation of L4.4 and L4.4.1.1/S sublineage. Recent 
phylogeographic analyses show the evolutionary history of L4 was characterised 
by rapid diffusion and high rates of migration, identifying range expansion as a 
contributor to the growth of this lineage (O’Neill et al. 2017). Consistent with this, 
our results reveal efficient dispersal of L4.4 suggestive of high rates of migration.  
As this thesis was in the final stages of preparation, a new study was published by 
Brynildsrud et al. (2018) reconstructing the migratory history of the L4 lineage. 
This study included isolates from 15 countries in Europe, Africa, the Americas, and 
Southeast Asia, but none from the South Pacific. Global dispersal of L4 was found 
to be dominated by historical migrations out of Europe and dispersal of L4 to Africa 
and the Americas occurred concomitant with European colonial migrations 
(Brynildsrud et al. 2018). We observe the same scenario with the introduction of 
L4.4 to the South Pacific and the DS6Q clade provides a striking example of the 
role of European expansion in the global dispersal of M. tuberculosis. Our analyses 
reveal the migration of several closely related DS6Q strains out of Europe in the 
17th–19th centuries to remote and unconnected populations driven by expanding 
European trade networks and colonial migrations. The nearest branch neighbouring 
the DS6Q on our phylogeny splits into two nodes comprised of Vietnamese and 
South African descendants which share a MRCA in the mid-17th century (Figure 
4.17). This split coincides with the first planned migration of French Huguenots to 
South Africa in 1687 (van Ruymbeke et al. 2003) and the onset of French-
Vietnamese interactions starting in 1627 (Chapuis 1995). Additionally, the node 
age of the Vietnamese clade fits with the French Indochina war in the 20th century, 
suggesting these are also likely French introductions. 
The emergence and initial growth of L4.4.1.1/S in the 16th century is coincident 
with the European age of exploration (Arnold 2013) providing a plausible factor 
that may have contributed to the growth and dispersal of this sublineage. This era 
would have provided ample opportunity for dispersal from Europeans to other 
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populations and geographic range expansion followed by population expansion in 
the L4 lineage has recently been linked to this era (O’Neill et al. 2017). We also 
detect L4.4.1.1/S population growth in the 19th century. This could be attributable 
to various colonial activities around this time involving countries represented in our 
sample; the French-Canadian fur trade (1730-1870) (Innis 1999), the South Pacific 
whaling era (1790s-1860) (Campbell 2011), and the rapid occupation and 
colonisation of much of the African continent during the “Scramble for Africa” 
(1876-1912) (Pakenham 2015). A later population decline in the late 20th century 
coincides with the dramatic decline in tuberculosis incidence in the developed 
world over the last century. 
 
4.4.4.1 L4.4.1.1/S sublineage substitution rate  
Molecular dating analysis estimated a substitution rate for the L4.4.1.1/S lineage of 
6.3 x 10-8 s/s/y (95% HPD, 4.5 x 10-8 – 8.1 x 10-8). This is consistent with rates 
inferred by previous studies of modern L4 and mixed lineage MTBC genomes 
(median rates estimates, 7 x 10-8 – 1 x 10-7 s/s/y (Eldholm et al. 2015; Eldholm et 
al. 2016; Ford et al. 2011; Ford et al. 2013; Pepperell et al. 2013; Roetzer et al. 
2013; Walker et al. 2013a)); and slightly higher than long term mutation rates of ~5 
x 10-8 s/s/y estimated from ancient DNA studies (Bos et al. 2014; Kay et al. 2015) 
(Figure 4.21). Our rate is markedly higher than the long-term substitution rate 
inferred on the assumption of co-divergence of the MTBC and humans (the ‘out of 
Africa’ hypothesis; 2.6 x 10-9 s/s/y) (Comas et al. 2013).  
Colengali et al (2013) have previously estimated a substitution rate from Rangipo 
strain isolates using SNP differences between recently transmitted isolate pairs and 
reactivation cases. A rate of 5.5 x 10-10 substitutions/site/generation was estimated 
for recently transmitted tuberculosis (assuming a 20 hr generation time) and 
7.3 x 10-11 substitutions/site/generation for latent tuberculosis. This translates to a 
mean rate of ~1.4 x 10-7 s/s/y (my own calculation), which is slightly higher than 
our estimate for the L4.4.1.1/S lineage, but is still within range of other L4 rate 
estimates. This estimate however is limited, as the time from infection to active 
disease can vary markedly between cases, therefore the mean of the recent and 
latent rates does not necessarily provide a good comparison with ours or other 
substitution rates. 
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Figure 4.21. Comparison of substitution rate estimated in this study with previously 
published studies. Estimates of long-term substitution rate estimates are shown in the grey 
box. Short-term rate estimates from human M. tuberculosis isolates were calibrated using 
tip-dating (this study (L4.4.1.1/S), (Eldholm et al. 2015; Eldholm et al. 2016; Ford et al. 
2013; Roetzer et al. 2013), experimental infection of macaques (Ford et al. 2011), recent 
transmission events (Walker et al. 2013a), and historic events (Pepperell 2013). Long-term 
rate estimates were calibrated using aDNA (Bos et al. 2014; Kay et al. 2015) or human 
divergence events (Comas et al. 2013). 
 
While ours and other short-term substitution rate estimates for the reported MTBC 
are all highly similar, the long-term substitution rate and age of the MTBC remains 
debated and studies using different approaches have produced markedly different 
rate and date estimates. The out of Africa hypothesis postulates M. tuberculosis 
diversity and dispersal was shaped by human migrations out of Africa and suggest 
the last common ancestor of the MTBC existed around seventy thousand years ago 
(Comas et al. 2013). In contrast, two separate studies using ancient DNA from 
different time periods both produced 10-fold slower substitution rate estimates 
suggesting the last common ancestor of the MTBC existed less than six thousand 
years ago (Bos et al. 2014; Kay et al. 2015). Archaeological samples also indicate 
that tuberculosis is a much more ancient disease (Hershkovitz et al. 2008; 
Rothschild et al. 2001), although a more recent MRCA could be reconciled with a 
scenario of whole scale clonal replacement of ancient strains.  
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4.4.5 Study Limitations 
One limitation of this study is that the global isolates in our dataset were primarily 
compiled from isolates available in public repositories and not all countries where 
the L4.4 lineage is present are represented. The addition of further isolates from 
under-represented regions and within the Pacific would further strengthen the 
sample and provide a more detailed picture of L4.4 and DS6Q dispersal. Genomes 
were annotated with country of isolation, as recorded in databases and published 
sources. Isolates from countries where many cases occur in migrants could 
potentially reflect reactivation of infection contracted in the country of birth. 
However, this was kept in mind throughout the analyses and is not a concern for 
the clades/countries on which the conclusions of this work have been based.  
 
4.4.6 Conclusions 
Using a large, global WGS dataset and a phylodynamics approach I have 
investigated the origins and historical dispersal of the Rangipo and Otara clusters. 
Historical and social factors facilitating the expansion and dispersal of these strains 
have been identified, showing that they are a product of the colonial history of New 
Zealand and the South Pacific and highlight the importance of Pacific-wide 
tuberculosis control efforts. These results also demonstrate the power of 
phylodynamics approaches to study M. tuberculosis dispersal at both the global and 
local scale and provide valuable new insights into human social phenomena 
underlying the global dispersal of this globally successful bacterial pathogen. 
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5 Chapter Five 
Conclusions and future directions 
The overall aim of this research was to understand factors contributing to the 
success of prevalent Mycobacterium tuberculosis clusters in New Zealand, in 
particular the Rangipo cluster. Ultimately, this information could be used to better 
control the circulation of these strains. The Rangipo cluster has been circulating in 
New Zealand for around 30 years and continues to cause outbreaks, predominantly 
in the Māori population. This prompts the question – why is this strain so successful 
and seemingly highly transmissible in this population? And how can it be stopped? 
My research investigated evolutionary and functional aspects of genomic variation 
in the Rangipo cluster to address this question. 
This thesis identifies bacterial genetic variants that may contribute to the high 
transmissibility of the Rangipo strain and points to an important role for historical 
factors and host ecology changes in driving the success of this strain. The 
prevalence of this cluster is not solely due to this being a ‘hypervirulent strain’ but 
rather, likely the result of intersecting bacterial and host determinants, underpinned 
by the colonial history of New Zealand. Furthermore, this work demonstrates the 
use of whole genome sequencing (WGS) data in a multi-disciplinary approach to 
investigate different factors contributing to the success of prevalent M. tuberculosis 
strains, as well the practical applications of single nucleotide polymorphisms 
(SNPs) in a clinical setting. The SNP-based Rangipo strain specific diagnostic assay 
developed here enables accurate strain classification directly from sputum samples 
within 24 hours for minimal cost and with high discriminatory power. Being a  
SNP-based approach, typing for this Rangipo strain marker could be readily 
automated and incorporated into routine clinical practice. The rapid identification 
of this strain will enable clinicians and public health authorities to implement 
appropriate strategies to halt its further transmission.  
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Elucidating the functional consequences of genetic variation in the M. tuberculosis  
complex is important to understand how strain genetic background affects virulence 
and the outcome of infection. Several SNPs with putative functional effects specific 
to the Rangipo strain have been identified, providing several potential candidates 
for further investigation. An enrichment of non-synonymous SNPs in genes 
involved in lipid metabolism were identified. Lipid metabolism plays an important 
role in M. tuberculosis pathogenicity and presents a possible avenue for further 
investigation into molecular determinants of Rangipo virulence. However, in order 
to properly understand of the role of genetic background to the high transmissibility 
of the Rangipo strain, experimental virulence testing needs to be performed to 
validate its putative high virulence and to correlate genetic variants with phenotypic 
effects.  
The structures of the luciferase-like hydride transferase family protein Rv2893 
experimentally validate this as an F420-binding protein and identify additional 
intramolecular hydrogen bonds introduced by the Rangipo G72S mutation. The 
additional thermal stability produced by this mutation and its location at the base of 
the bulge induced by the conserved non-prolyl cis-peptide may influence F420 
binding and catalysis. The consequences of this mutation on enzyme activity and 
bacterial phenotype remain to be determined and will largely be dependent on the 
role of Rv2893 in M. tuberculosis. Further investigation is needed to elucidate the 
function of Rv2893 and for development of biochemical assays to determine the 
effect of the G72S mutation on catalysis. As a starting point, identifying the 
unexpected ligand found in Rv2893 structures will provide clues as to the function 
of this protein. Other approaches such as gene deletion of the Rv2893 homologue 
in Mycobacterium smegmatis and metabolomic profiling, will provide possible 
routes to further probe the function of this protein. Binding assays also need to be 
undertaken to determine the kinetics of F420 binding and how the G72S mutation 
affects this. 
The New Zealand Rangipo and Otara strains are predominantly found in Māori and 
Pacific People, respectively. My research shows these are unequivocally of 
European origin and are linked to European trade expansion and colonisation. 
These clusters have differing demographic histories and highlight the relevance to 
New Zealand of tuberculosis in the Pacific islands. Understanding Pacific wide 
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transmission dynamics will be vital for the improvement of strategies seeking to 
reduce the tuberculosis burden in the region. 
WGS is now sufficiently fast and affordable that it is possible to sequence large 
collections of M. tuberculosis isolates. Further sequencing of clinical isolates will 
provide a wealth of additional information about tuberculosis transmission in New 
Zealand. Clinical isolate collections held at Waikato Hospital and LabPLUS will be 
valuable resources for such further work. Sequencing these collections would 
provide the opportunity to perform a detailed characterisation of strain diversity and 
transmission of tuberculosis in New Zealand at high resolution. Understanding local 
tuberculosis trends and transmission dynamics has important implications for 
public health and is essential for improvement of strategies seeking to arrest the 
transmission of local strains. Additional L4.4.1.1/S sublineage genomes will also 
further enhance our understanding of how this sublineage dispersed and expanded 
in New Zealand and the South Pacific.  
Importantly, this work demonstrates that these strains are products of the colonial 
history of New Zealand, highlighting the inappropriate and pejorative naming of 
these strains with Māori names. Addressing the transmission of these and other 
tuberculosis strains in New Zealand, requires a multi-disciplinary approach and 
necessitates consultation with affected communities. Further work will seek to 
rename these strains in consultation with Māori and other groups of interest. This 
will be important for community engagement and a step towards addressing the 
stigma that can hamper tuberculosis control efforts and exacerbates the suffering of 
those affected by the disease. 
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7 Appendices 
Appendix A: Appendices relating to Chapter Two 
Appendix A.1. MIRU-VNTR typing patterns of New Zealand M. tuberculosis 
cluster isolates provided by LabPLUS. 
Cluster MIRU ID MIRU-12 MIRU-24 
Rangipo NZ_040          233325153324 341344223362 
  NZ_040_001 233325153324 341444223352 
  NZ_040_002 233325153324 341434223362 
  NZ_040_003 233325153324 341544223362 
Southern Cross NZ_061_001 123326153326 343224123253 
  NZ_061_002 123326153326 342224123253 
  NZ_061_005 123326153326 342125123253 
Otara NZ_062_001 233325143322 341544223382 
  NZ_062_002 233325143322 341534223392 
  NZ_062_004 233325143322 2415442233C2 
NZ_037 NZ_037          124326153224 323124123262 
NZ_041 NZ_041_001 223125153324 242334223552 
  NZ_041_002 223125153324 222334223552 
NZ_069 NZ_069          223326153321 242234223552 
  NZ_069_006 223326153321 242334223552 
NZ_094 NZ_094_001 233325143325 3415442213B2 
  
 
Appendix A.2. Rangipo SNPs identified from SOLiD whole genome sequencing 
data. Spreadsheets detailing these are provided in a separate file 
(Appendix_A2_Rangipo-SOLiD-SNPs.xlxs) 
Common Rangipo SNPs: Classification of SNPs common to the Rangipo strain 
identified by Colangeli et al. (2014) (n = 247) 
Rangipo Specific SNPs: SNPs classified as specific to the Rangipo strain (n = 22) 
and Rangipo and SUMu/Canadian DS6Quebec shared SNPs (n = 4) 
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Appendix A.3. Rangipo SNP validation primers. Primer sequences and expected 
PCR product sizes for validation of Rangipo specific SNPs by Sanger sequencing. 
SNP Locus Primer name Primer sequence (5' to 3') Product size (bp) 
Rv3253CG Rv0002  Rv0002(P401R)_fwd GATTGCGTTTAACCCAACCTATCT 297 
  /dnaN Rv0002(P401R)_rev GCAATTCCAGATCTACACATGCC  
Rv550620GT Rv0458 Rv0458(D316Y)_fwd ACGACGACTTCTGCGACAA 227 
    Rv0458(D316Y)_rev GGACAACACCTTTTCCAGC   
Rv1289731TC Rv1161   Rv1161(Y802H)_fwd ACATTCCAGAGGGCAAGCTC 249 
   /narG Rv1161(Y802H)_rev CCAGATGACGTTTCGCCAG   
Rv1836099TG Rv1631   Rv1631(Y363D)_fwd CTACGACCACACCGACAGT 253 
  /coaE Rv1631(Y363D)_rev ATCCAGGAACCACGGCTC  
Rv2807374GC Rv2492 Rv2492(G33R)_fwd AATCTTTGGGGTCGCCTTTC 295 
   Rv2492(G33R)_rev GGATAATTCTGCACCGAAGACT  
Rv3202633GA Rv2893 Rv2893(G72S)_fwd ACTCCATGACCGTTGCCAG 387 
    Rv2893(G72S)_rev CCCGTGTTGCCCCGGAATC   
Rv3283879TC Rv2941   Rv2941(V182A)_fwd ATCGAAGTTGATTTGCTCGA 246 
  /fadD28 Rv2941(V182A)_rev CATGTCGTGGTAGAAGGGT  
Rv3366098GA Rv3007c RV3007c(P118L)_fwd AAGCCACATAATCCCCGACA 290 
    RV3007c(P118L)_rev CTTCGCTACCCAAACGAGC   
Rv3561770AG Rv3193c Rv3193c(L468S)_fwd GCGGACGTGTTAGAGATCACC 293 
   Rv3193c(L468S)_rev AACGGTAACCTGCGCGACTA   
Rv3895925GA Rv3479 Rv3479(A36T)_fwd CGGTGTTACGCGGGAGAT 288 
    Rv3479(A36T)_rev CGGAGAAGCTCGGTCAAGG   
Rv3980075CA Rv3540c  Rv3540c(E195D)_fwd GTCTCCTGGCAGCAGTCC 296 
  /ltp2 Rv3540c(E195D)_rev GGTCAGGTGCAAACTCGTTT  
Rv4085870GA Rv3646c   Rv3646c(T463M)_fwd TCGACGATGTCCAACCGTT 274 
  /topA Rv3646c(T463M)_rev CCAACATTGATGATTTCCGGC   
Rv4377908CT Rv3894c   Rv3894c(G849S)_fwd CACGATGATGTTGCTGCGTAG 291 
  /eccC2 Rv3894c(G849S_rev CCCGACGAATTCCTCTATTACGA   
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Appendix B: Appendices relating to Chapter Three 
Appendix B.1. Bacterial strains, vectors and media used in this study. 
Bacterial Strain Description 
E. coli TOP10 (electrocompetent)  
F-mcrA Δ(mrr-hsdRMS-mcrBC) Φ80 dlacZ ΔM15 
Δ lacX74 deoR recA1 araD139 Δ(ara leu)7697 
galU galK rpsL endA1 nupG 
M. smegmatis mc24517 M. smegmatis expression strain with T7 RNA polymerase; Kmr (Wang et al. 2010) 
 
Vector Description 
pYUB28b E. coli mycobacterium shuttle vector. 4921 bp, T7 
promoter, MCS pET28b, C- and N-terminal 
His-tags, N-terminal thrombin cleavage site, Hygr 
(Bashiri et al. 2010) 
 
Solid media Description 
LB agar 1% (w/v) bactotryptone, 0.5% (w/v) yeast extract, 1% (w/v) NaCl,  
15 g/L agar 
Low salt LB 
agar 
1% (w/v) bactotryptone, 0.5% (w/v) yeast extract, 0.5% (w/v) NaCl, 
15 g/L agar 
7H10/ADC/T80 
agar 
1.9 g 7H10 powder, 0.5% (v/v) glycerol in 90 ml H2O, autoclaved 
then 10 ml ADC enrichment and 0.05% (v/v) Tween 80 added at 
50 °C 
 
Liquid media Description 
LB broth 1% (w/v) bactotryptone, 0.5% (w/v) yeast extract, 1% (w/v) NaCl,  
Low salt LB 
broth 
1% (w/v) bactotryptone, 0.5% (w/v) yeast extract, 0.5% (w/v) NaCl,  
7H9/ADC/T80 
broth 
0.47 g 7H9 powder, 0.2% (v/v) glycerol in 90 ml H2O, autoclaved 
then 10 ml ADC enrichment medium and 0.05% (v/v) Tween-80 
added at 50 °C  
SOC recovery 
media 
2% (w/v) bactotryptone, 0.55%(w/v) yeast extract, 10 mM NaCl, 
2.5 mM KCl, 10 mM MgCl2, 10 mM MgSO4, autoclaved and then 
added 20 mM glucose before use. 
PA-0.5G 
defined media 
50 mM Na2HPO4, 50 mM KH2PO4, 25 mM (NH4)2SO4, 1 mM 
MgSO4, 0.5% (w/v) glucose, 0.1X metals mix1, 100 μg.ml-1 each of 
17 amino acids (no Cys, Tyr or Met). Individual components 
autoclaved or sterile filtered before adding to sterile H2O 
ZYP-5052 auto-
induction media 
1% (w/v) bactotryptone, 0.5% (w/v) yeast extract autoclaved and 
then added sterile 50 mM Na2HPO4, 50 mM KH2PO4, 25 mM 
(NH4)2SO4, 1 mM MgSO4, 0.5% (w/v) glycerol, 0.05% (w/v) 
glucose, 0.2% (w/v) a-lactose, 1X metals mix1 
1 1000X Metals mix made up from the sterile stock solutions of separate components to 
give the following concentrations: 50 μM FeCl3 in 0.12 M HCl (filter sterile), 20 μM 
CaCl2, 10 μM MnCl2, 10 μM ZnSO4, 2 μM CoCl2, 2 μM CuCl2, 2 μM NiCl2, 2 μM 
Na2MoO4, 2 μM Na2SeO3, 2 μM H3BO3.  
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Appendix B.2. Cloning primers. Primers used to clone Rv2893 into pYUB28b and 
T7 primers used for screening and sequence confirmation of the insert. 
Primer name Primer sequence (5' to 3') RE site Product size (bp) 
Rv2893 cloning_fwd GGAATTCCATATGACCGTTGCCAGCACCGCTCA NdeI 996 Rv2893 cloning_rev CGGGATCCCTAGCCGTAGCGCAGGAG BamHI 
T7_fwd (promoter) TAATACGACTCACTATAGGG  1260/3171 T7_rev (terminator) GCTAGTTATTGCTCAGCGG  
11260 bp if the correct insert is ligated, 317 bp for empty vector 
 
 
 
Appendix B.3. Gene and protein information. The position of the Rangipo G72S 
mutation is in bold and highlighted by a grey box.  
 
Rv2893H327Rv (978 bp) 
ATGACCGTTGCCAGCACCGCTCACCATACACGTCGGCTACGTTTCGGGTTGGCGGCACCGTTGCCC
CGCGCGGGCACCCAGATGCGCGCCTTCGCGCAGGCTGTCGAGGCCGCCGGGTTCGACGTGCTGGCC
TTCCCGGACCACCTGGTGCCTTCGGTTTCGCCGTTCGCAGGCGCGACCGCCGCGGCGATGGCCACG
CAACGACTGCACACCGGCACATTGGTGCTCAACAACGACTTTCGCCATCCCGTGGACACCGCTCGA
GAGGCGGCCGGTGTGGCAACCCTCGCCGAAGGCCGCTTCGAACTGGGACTGGGCGCCGGACACCGG
AGGTCCGAATACGACGCCGCCGGCATTACCTTCGATTCCGGGGCAACACGGGTGGCGCGGCTCATC
GAATCGGCGCACCTGATCCGTGCGCTGCTGGACGCGGAGCCCGTCGACTTCGACGGGCAGCATTAC
CGGGTGCACGCCGAAGCGGGCTCACTGGTGGCACCGCCGAAGGTCCGGGTCCCCCTGCTAGTGGGC
GGCAACGGGACCGAGGTGCTGCGGCTGGGCGGACGCATCGCCGACATTGTCGGCCTGGCCGGGATC
AGCCACAACCGCGACGCCACCCAGGTCCGGTTCACCCACTTCGACGCCGACGGCCTGGCCGACCGG
ATCGCCGTGGTACGTCACGCGGCCGGCGATCGCTTCGAAGCCATTGAGCTCAACGCGCTGATCCAG
GCGGTGGTCTGCACCAACGACCGAAACGCGGCGGCCGCCGAACTGGCCGCCACCTTGGGCGGGATC
ACGCCCGAGCAGGTCCTCGAGTCGCCGTTTCTGCTGCTCGGTACCCACGAGCAGATGGCCGAGGCT
CTCGCCGCGCGGCAGCGGCGGTTCGGTGTCAGCTATTGGACGGTGTTCGACGAGTGGGCTGGCCGC
GCGTCGGCAATGCGCGACATCGCCGAGGTCATCGCGCTCCTGCGCTACGGCTAG 
 
Rv2893H327Rv (325 aa)  
MW 34617.24 Da, pI 6.22 
MTVASTAHHTRRLRFGLAAPLPRAGTQMRAFAQAVEAAGFDVLAFPDHLVPSVSPFAGATAAAMAT
QRLHTGTLVLNNDFRHPVDTAREAAGVATLAEGRFELGLGAGHRRSEYDAAGITFDSGATRVARLI
ESAHLIRALLDAEPVDFDGQHYRVHAEAGSLVAPPKVRVPLLVGGNGTEVLRLGGRIADIVGLAGI
SHNRDATQVRFTHFDADGLADRIAVVRHAAGDRFEAIELNALIQAVVCTNDRNAAAAELAATLGGI
TPEQVLESPFLLLGTHEQMAEALAARQRRFGVSYWTVFDEWAGRASAMRDIAEVIALLRYG 
 
Rv2893H327Rv pYUB28b N-terminal His-tag (345 aa) 
MW 36780.57 Da, pI 6.57 
MGSSHHHHHHSSGLVPRGSHMTVASTAHHTRRLRFGLAAPLPRAGTQMRAFAQAVEAAGFDVLAFP
DHLVPSVSPFAGATAAAMATQRLHTGTLVLNNDFRHPVDTAREAAGVATLAEGRFELGLGAGHRRS
EYDAAGITFDSGATRVARLIESAHLIRALLDAEPVDFDGQHYRVHAEAGSLVAPPKVRVPLLVGGN
GTEVLRLGGRIADIVGLAGISHNRDATQVRFTHFDADGLADRIAVVRHAAGDRFEAIELNALIQAV
VCTNDRNAAAAELAATLGGITPEQVLESPFLLLGTHEQMAEALAARQRRFGVSYWTVFDEWAGRAS
AMRDIAEVIALLRYG 
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Rv2893G72S (978 bp) 
ATGACCGTTGCCAGCACCGCTCACCATACACGTCGGCTACGTTTCGGGTTGGCGGCACCGTTGCCC
CGCGCGGGCACCCAGATGCGCGCCTTCGCGCAGGCTGTCGAGGCCGCCGGGTTCGACGTGCTGGCC
TTCCCGGACCACCTGGTGCCTTCGGTTTCGCCGTTCGCAGGCGCGACCGCCGCGGCGATGGCCACG
CAACGACTGCACACCAGCACATTGGTGCTCAACAACGACTTTCGCCATCCCGTGGACACCGCTCGA
GAGGCGGCCGGTGTGGCAACCCTCGCCGAAGGCCGCTTCGAACTGGGACTGGGCGCCGGACACCGG
AGGTCCGAATACGACGCCGCCGGCATTACCTTCGATTCCGGGGCAACACGGGTGGCGCGGCTCATC
GAATCGGCGCACCTGATCCGTGCGCTGCTGGACGCGGAGCCCGTCGACTTCGACGGGCAGCATTAC
CGGGTGCACGCCGAAGCGGGCTCACTGGTGGCACCGCCGAAGGTCCGGGTCCCCCTGCTAGTGGGC
GGCAACGGGACCGAGGTGCTGCGGCTGGGCGGACGCATCGCCGACATTGTCGGCCTGGCCGGGATC
AGCCACAACCGCGACGCCACCCAGGTCCGGTTCACCCACTTCGACGCCGACGGCCTGGCCGACCGG
ATCGCCGTGGTACGTCACGCGGCCGGCGATCGCTTCGAAGCCATTGAGCTCAACGCGCTGATCCAG
GCGGTGGTCTGCACCAACGACCGAAACGCGGCGGCCGCCGAACTGGCCGCCACCTTGGGCGGGATC
ACGCCCGAGCAGGTCCTCGAGTCGCCGTTTCTGCTGCTCGGTACCCACGAGCAGATGGCCGAGGCT
CTCGCCGCGCGGCAGCGGCGGTTCGGTGTCAGCTATTGGACGGTGTTCGACGAGTGGGCTGGCCGC
GCGTCGGCAATGCGCGACATCGCCGAGGTCATCGCGCTCCTGCGCTACGGCTAG 
 
Rv2893G72S (325 aa)  
MW 34647.27 Da, pI 6.22 
MTVASTAHHTRRLRFGLAAPLPRAGTQMRAFAQAVEAAGFDVLAFPDHLVPSVSPFAGATAAAMAT
QRLHTSTLVLNNDFRHPVDTAREAAGVATLAEGRFELGLGAGHRRSEYDAAGITFDSGATRVARLI
ESAHLIRALLDAEPVDFDGQHYRVHAEAGSLVAPPKVRVPLLVGGNGTEVLRLGGRIADIVGLAGI
SHNRDATQVRFTHFDADGLADRIAVVRHAAGDRFEAIELNALIQAVVCTNDRNAAAAELAATLGGI
TPEQVLESPFLLLGTHEQMAEALAARQRRFGVSYWTVFDEWAGRASAMRDIAEVIALLRYG 
 
Rv2893G72S pYUB28b N-terminal His-tag (345 aa)  
MW 36810.59 Da, pI 6.57 
MGSSHHHHHHSSGLVPRGSHMTVASTAHHTRRLRFGLAAPLPRAGTQMRAFAQAVEAAGFDVLAFP
DHLVPSVSPFAGATAAAMATQRLHTSTLVLNNDFRHPVDTAREAAGVATLAEGRFELGLGAGHRRS
EYDAAGITFDSGATRVARLIESAHLIRALLDAEPVDFDGQHYRVHAEAGSLVAPPKVRVPLLVGGN
GTEVLRLGGRIADIVGLAGISHNRDATQVRFTHFDADGLADRIAVVRHAAGDRFEAIELNALIQAV
VCTNDRNAAAAELAATLGGITPEQVLESPFLLLGTHEQMAEALAARQRRFGVSYWTVFDEWAGRAS
AMRDIAEVIALLRYG 
 
 
Appendix B.4. Rv2893 protein structures. MTZ and PDB files are provided 
separately in folder Appendix_B3_structures. Note that in PDB files numbering 
starts at the methionine before the His-tag and therefore add 20 amino acids on to 
the position, e.g. G72 is G92. 
Structure Files (.mtz and .pdb) 
Rv2893H37Rv SAD solution Rv2893_solution 
apo-Rv2893H37Rv apo-Rv2893H37Rv 
apo-Rv2893G72S  apo-Rv2893G72S 
F420-Rv2893H37Rv F420-Rv2893H37Rv 
F420-Rv2893G72S  F420-Rv2893G72S 
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Appendix B.5. Ramachandran analysis for Rv2893 structures.   
 
apo-Rv2893H37Rv apo-Rv2893G72S 
   
Number of residues in favoured region     Number of residues in favoured region     
(~98.0% expected)  : 2376 (97.9%) (~98.0% expected)  : 2371 (98.1%) 
Number of residues in allowed region Number of residues in allowed region      
(~2.0% expected)  :   51 (2.1%) (~2.0% expected)  :   45 (1.9%) 
Number of residues in outlier region Number of residues in outlier region                                       
0 (0.0%) 0 (0.0%) 
 
  
F420-Rv2893H37Rv F420-Rv2893G72S 
  
Number of residues in favoured region     Number of residues in favoured region     
 (~98.0% expected)  : 1218 (97.8%) (~98.0% expected)  : 1221 (98.2%) 
Number of residues in allowed region Number of residues in allowed region      
(~2.0% expected)  :   27 (2.2%) (~2.0% expected)  :   23 (1.8%) 
Number of residues in outlier region Number of residues in outlier region                                       
0 (0.0%) 0 (0.0%) 
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Appendix B.6. Root mean square differences (RMSD) in the Ca atomic positions between protein chains for Rv2893 structures.  
Chains with F420 bound are shaded grey. 
 
  apo-Rv2893H37Rv apo-Rv2893G72S F420-Rv2893H37Rv F420-Rv2893G72S 
   A B C D E F G H A B C D E F G H A B C D A B C D 
ap
o-
Rv
28
93
H
37
R
v  
A  0.30 0.16 0.45 0.48 1.20 0.56 0.73 0.17 0.29 0.23 0.43 0.50 0.70 0.46 1.15 0.30 1.37 0.99 1.53 0.31 1.35 0.96 1.53 
B   0.34 0.11 0.32 0.40 0.35 0.33 0.30 0.15 0.34 0.12 0.34 0.34 0.33 0.42 0.40 0.37 0.49 0.51 0.40 0.36 0.43 0.51 
C    0.50 0.46 1.20 0.54 0.73 0.24 0.34 0.18 0.48 0.48 0.70 0.44 1.15 0.31 1.40 0.97 1.52 0.31 1.37 0.95 1.52 
D     0.42 0.43 0.36 0.34 0.47 0.18 0.50 0.12 0.36 0.35 0.42 0.45 0.54 0.39 0.51 0.56 0.55 0.39 0.46 0.56 
E      0.61 0.24 0.51 0.51 0.36 0.48 0.39 0.25 0.50 0.17 0.62 0.49 0.53 0.65 0.42 0.48 0.51 0.64 0.39 
F       0.45 0.26 1.22 0.43 1.20 0.45 0.49 0.28 0.62 0.15 1.21 1.05 0.26 0.84 1.20 1.03 0.27 0.84 
G        0.36 0.60 0.38 0.56 0.35 0.15 0.36 0.32 0.48 0.57 0.50 0.51 0.43 0.56 0.48 0.51 0.39 
H         0.75 0.37 0.73 0.38 0.40 0.11 0.53 0.30 0.78 0.66 0.35 0.61 0.77 0.63 0.30 0.60 
ap
o-
Rv
28
93
G
72
S 
A          0.27 0.19 0.43 0.52 0.71 0.46 1.16 0.33 1.37 1.01 1.53 0.34 1.35 0.97 1.53 
B           0.32 0.18 0.35 0.36 0.35 0.44 0.38 0.32 0.53 0.52 0.38 0.32 0.46 0.52 
C            0.47 0.48 0.69 0.43 1.14 0.33 1.38 0.97 1.51 0.34 1.35 0.95 1.50 
D             0.34 0.38 0.38 0.47 0.51 0.38 0.54 0.55 0.52 0.39 0.48 0.55 
E              0.39 0.27 0.49 0.54 0.48 0.55 0.41 0.52 0.45 0.54 0.36 
F               0.51 0.29 0.78 0.73 0.35 0.60 0.76 0.63 0.32 0.58 
G                0.62 0.45 0.50 0.67 0.41 0.43 0.49 0.66 0.40 
H                 1.17 1.05 0.22 0.78 1.15 0.98 0.29 0.78 
F 4
20
-
Rv
28
93
H
37
R
v  
A                  1.31 1.03 1.47 0.18 1.30 1.01 1.47 
B                   0.96 0.76 1.14 0.17 0.98 0.73 
C                    0.74 1.04 0.94 0.23 0.75 
D                     1.27 0.73 0.77 0.24 
F 4
20
-
Rv
28
93
G
72
S  A                      1.12 1.01 1.25 
B                       0.89 0.69 
C                        0.75 
D                         
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Appendix B.7. Unmodeled regions in Rv2893 structures.  
Structure Chain From  To  
apo-Rv2893H37Rv B GLY 197 PHE 212 
 B ARG 250 SER 272 
 B TRP 305 ARG 308 
 D ILE 198 PHE 212 
 D TRP 305 ARG 308 
 E ILE 198 PHE 209 
 E TRP 305 GLY 307 
 F HIS 200 VAL 207 
 G ILE 198 THR 210 
 H ILE 198 PHE 209 
apo-Rv2893G72S B ALA 196 PHE 212 
 B ASN 251 SER 272 
 B GLU 304 ARG 308 
 D GLY 197 HIS 211 
 D TRP 305 ARG 308 
 E ILE 198 THR 210 
 E TRP 305 GLY 307 
 F ILE 198 PHE 209 
 F TRP 305 GLY 307 
 G ILE 198 THR 210 
 G ALA 258 ILE 264 
 G TRP 305 GLY 307 
 H SER 199 VAL 207 
F420-Rv2893H37Rv A TRP 305 GLY 307 
 B TRP 305 GLY 307 
 C SER 199 ARG 208 
 C TRP 305 GLY 307 
 D THR 260 GLY 263 
 D TRP 305 ARG 308 
F420-Rv2893G72S A ALA 204 GLN 206 
 A TRP 305 ARG 308 
 B TRP 305 ARG 308 
 C SER 199 ARG 208 
 C TRP 305 GLY 307 
 D TRP 305 ARG 308 
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Appendix C: Appendices relating to Chapter Four 
Appendix C.1. New Zealand M. tuberculosis isolates sequenced on the Illumina 
MiSeq platform (n = 25). 
Rangipo cluster isolates (n = 13) 
ID1 Year MIRU ID MIRU-12 MIRU-24 IS6110-RFLP 
NZLA 1992         
NZLB 1992      
NZLC 1999      
NZLE 2001      
NZLF 2002    13/008RP 
NZLG 2004    13/008RP 
NZLH 2006    13/008 
NZLI 2006    13/008RP 
NZLJ 2008    13/008RP 
NZLK (O) 2008 NZL_040_001 233325153324 341444223362 13/008RP 
NZLL (F) 1996 NZL_040_001 233325153324 341444223362   
NZLM (R)  2009    13/008RP 
NZLN (A) 1991 NZL_040_001 233325153324 341444223362   
1 The ID isolates were sequenced under on the ABI SOLiD platform (Colangeli et al. 
2014) are shown in brackets. 
      
Otara cluster isolates (n = 7) 
ID Year MIRU ID MIRU-12 MIRU-24  
NZL01 2008 NZL_062-001 233325143322 341544223392   
NZL03 2011 NZL_062-004 233325143322 2415442233C2  
NZL05 2008 NZL_062-002 233325143322 341534223392   
NZL10 2013 NZL_062-001 233325143322 341544223392   
NZL11 2003 NZL_127-001 233325141322 341544223392   
NZL12 2013 NZL_127-001 233325141322 341544223392   
NZL13 2006 NZL_062-001 233325143322 341544223392   
     
Southern Cross cluster isolates (n = 5) 
ID Year MIRU ID MIRU-12 MIRU-24  
NZL02 2010 NZL_061-001 123326153326 343224123253   
NZL04 2007 NZL_061-001 123326153326 343224123253   
NZL07 2015 NZL_061-001 123326153326 343224123253   
NZL08 2002 NZL_061-001 123326153326 343224123253   
NZL09 2002 NZL_061-001 123326153326 343224123253   
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Appendix C.2. Sequencing and mapping statistics for 25 New Zealand M. tuberculosis genomes sequenced on the Illumina MiSeq platform. 
Isolate ID Total read count 
Mean read 
length 
Median 
read length 
Raw read 
depth 
Mean 
Coverage1 Mean MQ 
% Reads 
Mapped %10X
2 %20X2 %30X2 
NZLA 1781828 214.6 250 86.7 66.9 58.1 88.9 99.2 98.3 93.4 
NZLB 1181092 213.1 250 57.1 43.8 57.9 87.5 98.7 90.1 66.2 
NZLC 1211718 229.6 250 63.1 49.4 58.2 90.2 98.9 94.2 77.0 
NZLE 1270322 224.6 250 64.7 49.8 58.0 88.3 99.0 94.5 77.2 
NZLF 902728 224.7 250 46.0 35.8 57.9 88.1 98.2 84.1 51.3 
NZLG 779518 193.3 222 34.2 30.4 57.7 96.8 95.0 68.3 35.8 
NZLH 1497248 225.9 250 76.7 57.6 58.1 88.3 99.1 97.8 89.9 
NZLI 1341768 198.1 249 60.3 46.2 57.8 89.6 98.2 89.8 68.6 
NZLJ 1465386 226.7 250 75.3 50.3 58.0 82.5 98.9 94.2 76.6 
NZLK  2472612 190.2 214 106.6 99.3 58.2 98.7 99.0 98.3 97.4 
NZLL  1280644 221.5 250 64.3 47.1 57.9 85.3 98.8 91.0 69.8 
NZLM  1161542 219.5 250 57.8 42.8 58.1 87.2 98.7 90.5 65.4 
NZLN  913298 206.6 241 42.8 34.0 58.1 88.5 97.8 81.6 48.7 
NZL01 4018730 203.5 248 185.3 147.9 58.9 83.8 99.3 99.0 98.7 
NZL03 4915778 212.7 250 237.0 206.9 58.8 94.0 99.3 99.1 98.8 
NZL05 4978762 195.7 233 220.8 173.5 58.9 80.9 99.2 99.0 98.7 
NZL10 3783886 209.3 249 179.5 152.6 58.7 91.6 99.3 99.0 98.7 
NZL11 4382194 212.3 250 210.9 185.8 58.8 93.2 99.4 99.2 99.0 
NZL12 1703674 199.5 232 77.0 71.8 58.7 97.4 98.7 97.7 96.1 
NZL13 1929004 206.6 250 90.3 85.4 58.9 98.9 98.7 97.9 96.9 
NZL02 5147200 218.5 250 254.9 226.0 59.1 95.9 99.2 98.9 98.6 
NZL04 5178286 190.4 214 223.5 182.0 58.9 84.8 99.2 99.0 98.7 
NZL07 5542744 205.1 249 257.7 204.2 59.1 83.7 99.1 98.9 98.6 
NZL08 4652740 195.2 231 205.8 168.4 59.0 84.6 99.3 99.1 98.8 
NZL09 5069446 198.0 241 227.6 170.8 59.0 78.3 99.2 98.9 98.6 
1  Average mapped coverage across the H37Rv reference genome (NC_000962.3). 
2  Fraction of the reference sequenced with at least a given coverage rate 
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Appendix C.3. Rangipo SNPs identified by analysis of Illumina whole genome 
sequencing data. Spreadsheets detailing these are provided in a separate file 
(Appendix_C3_Rangipo-Illumina-SNPs.xlxs). 
Common Rangipo SNPs: SNPs shared by all Rangipo isolates (n = 513)  
Rangipo Specific SNPs: Rangipo specific SNPs identified from Illumina WGS data 
by comparison with 220 global L4.4 M. tuberculosis genomes (n = 53) 
 
Appendix C.4. Isolates used in phylogenetic analyses. Spreadsheets detailing these 
are provided in a separate file (Appendix_C4_L44-dataset.xlxs). 
Dataset 1: Complete L4.4 sublineage global dataset (n = 236) 
Dataset 2: L4.4.1.1/S sublineage molecular dating dataset (n = 117) 
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Appendix C.5. Frequency of M. tuberculosis L4.4 sublineage genomes included in 
phylogenetic analyses by country. 
Dataset 1. Complete L4.4 sublineage global dataset  
Country L4.4.1.1 L4.4.1.2 L4.4.2 All L4.4 
Canada 21 12.6% 4 17.4% 0 – 25 10.6% 
China 0 – 0 – 7 15.2% 7 3.0% 
Colombia 1 0.6% 0 – 0 – 1 0.4% 
Greenland 18 10.8% 0 – 0 – 18 7.6% 
India 1 0.6% 0 – 0 – 1 0.4% 
Kenya 2 1.2% 0 – 0 – 2 0.8% 
Malawi 22 13.1% 7 31.8% 0 – 29 12.3% 
Malaysia 0  – 0 – 1 2.2% 1 0.4% 
Netherlands 1 0.6% 4 17.4% 0 – 5 2.1% 
New Zealand 23 13.8% 0 – 0 – 23 9.7% 
Romania 1 0.6% 0 – 0 – 1 0.4% 
Russia 4 2.4% 0 – 0 – 4 1.7% 
South Africa 59 35.3% 0 – 0 – 59 25.0% 
South Korea 0 – 0 – 1 2.2% 1 0.4% 
Sweden 2 1.2% 0 – 0 – 2 0.8% 
Thailand 0 – 0 – 1 2.2% 1 0.4% 
Uganda 7 4.2% 0 – 0 – 7 3.0% 
United Kingdom 2 1.2% 3 13.0% 1 2.2% 6 2.5% 
Vietnam 4 2.4% 4 17.4% 35 76.1% 43 18.2% 
Total 168 100% 22 100% 46 100% 236 100% 
 
Dataset 2. L4.4.1.1/S sublineage molecular dating dataset 
Country   
Canada 21 17.9%  
Colombia 1 0.9%  
India 1 0.9%  
Kenya 2 1.7%  
Malawi 22 18.8%  
Netherlands 1 0.9%  
New Zealand 23 19.7%  
Romania 1 0.9%  
Russia 4 3.4%  
South Africa 31 26.5%  
Sweden 2 1.7%  
Uganda 2 1.7%  
United Kingdom 2 1.7%  
Vietnam 4 3.4%  
Total 117 100%  
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Appendix C.6. Assessment of MCMC chain convergence. Trace outputs are shown 
for key parameters from three independent chains for the best fitting model as 
determined by path sampling (GTR, strict clock, Bayesian skyline demographic). 
(A) Posterior probability. (B) substitution rate in substitutions/site/year (s/s/y). (C) 
tree height (years since 2013); and (D-F) time to most recent common ancestor 
(TMRCA) for the DS6Q clade, and Rangipo and Otara clusters.  
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Appendix C.7. Bayesian MCC tree of 117 M. tuberculosis L4.4.1.1/S genomes 
showing individual node ages. Median node ages in years since 2013 are shown. A 
grey box highlights the DS6Q.  
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Appendix C.8. Bayesian MCC tree of 117 M. tuberculosis L4.4.1.1/S genomes 
showing posterior probabilities of individual nodes. A grey box highlights the 
DS6Q. 
 
  
